Benzothiophene, thienopyridine and thienopyrimidine derivatives for modulation of STING

By using benzothiophene, thienopyridine and thienopyrimidine compounds of specific groups to regulate the STING signal pathway, the problem of insufficient STING signal regulation in the prior art is solved, and effective regulation of type I interferon production is achieved. for the treatment of a variety of diseases.

CN114206880BActive Publication Date: 2024-12-06CTXT PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080051984.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-18
Filing Date
2020-07-17
Publication Date
2024-12-06
Estimated Expiration
2040-07-17

AI Technical Summary

Technical Problem

Existing treatments are difficult to effectively regulate the STING signaling pathway, resulting in insufficient treatment of infectious diseases and autoimmune diseases, especially in the regulation of the production of type I interferon.

Method used

A compound with a specific structure of benzothiophene, thienopyridine and thienopyrimidine compounds containing specific groups is provided for regulating the activity of STING and thus affecting the production of type I interferons for the treatment or prevention of related diseases. .

Benefits of technology

By regulating the STING signaling pathway, compounds can effectively regulate the production of type I interferons and are used to treat inflammation, allergic diseases, autoimmune diseases, infectious diseases and cancer, providing potential treatment and prevention methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114206880B_ABST
    Figure CN114206880B_ABST
Patent Text Reader

Abstract

The compound of formula I, wherein W is O or NH; A 1 Yes CR A or N; A 2 Yes CR B or N; A 3 Yes CR C or N; A 4 Yes CR D or N; where A 1 , A 2 , A 3 , and A 4 No more than two of them can be N; R A , R B , R C and R D One or two (if present) are selected from H, F, Cl, Br, Me, CF 3 , cyclopropyl, cyano, OMe, OEt, CH 2 OH, CH 2 OMe and OH; the rest of R A , R B , R C and R D (if present) is H; R N1 is H or Me; R C2 and R C3 One of them is C(=O)NH 2 ; another is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF 3 , CH 2 OH, CH 2 OMe, C 2‑4 Alkenyl and C 5 Heterocyclic group; R C1 and R C4 independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF 3 , CH 2 OH, CH 2 OMe, C 2‑4 Alkenyl and C 5 Heterocyclic group. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to substituted benzothiophenes, thienopyridines and thienopyrimidines and their use as medicaments, and in particular in the treatment of diseases ameliorated by modulation of STING. Background of the Invention

[0003] Vertebrates are constantly threatened by microbial invasion and have evolved immune defense mechanisms to eliminate infectious pathogens. In mammals, this immune system consists of two branches: innate immunity and adaptive immunity. The innate immune system is the first line of defense initiated by pattern recognition receptors (PRRs) that detect ligands from pathogens and associated molecular patterns (Takeuchi 2010). An increasing number of these receptors have been identified, including Toll-like receptors (TLRs), C-type lectin receptors, retinoic acid-inducible gene I (RIG-I)-like receptors, and NOD-like receptors (NLRs), as well as double-stranded DNA sensors. Activation of PRRs leads to upregulation of genes involved in inflammatory responses, including type 1 interferons, proinflammatory cytokines, and chemokines that inhibit pathogen replication and promote adaptive immunity.

[0004] The adaptor protein STING (stimulator of interferon genes), also known as TMEM 173, MPYS, MITA, and ERIS, has been identified as a central signaling molecule in the innate immune response to cytoplasmic nucleic acids (Ishikawa 2008; WO 2013 / 166000). Activation of STING leads to the activation of IRF3 and NF K STING is critical for responses to pathogen- or host-derived cytosolic DNA and to aberrant nucleic acids known as cyclic dinucleotides (CDNs).

[0005] CDNs were originally identified as bacterial secondary messengers responsible for controlling many reactions in prokaryotic cells. Bacterial CDNs, such as c-di-GMP, are symmetrical molecules characterized by two 3',5' phosphodiester bonds.

[0006]

[0007] Direct activation of STING by bacterial CDN has recently been demonstrated by X-ray crystallography (Burdette 2013). Therefore, bacterial CDN and its analogs have attracted attention as potential vaccine adjuvants (Libanova 2012; WO2007 / 054279; WO2005 / 087238).

[0008] Recently, the response to cytosolic DNA has been elucidated and shown to involve the production of a novel mammalian CDN signaling molecule identified as cGAMP by an enzyme called cyclic GMP-AMP synthase (cGAS, formerly known as C6orfl50 or MB21D1), which then activates STING. Unlike bacterial CDNs, cGAMP is an asymmetric molecule characterized by its mixed 2',5' and 3',5' phosphodiester bonds (Gao 2013A). The interaction of cGAMP(II) with STING has also been demonstrated by X-ray crystallography (Cai 2014).

[0009] Interferon was originally described as a substance that can protect cells from viral infection (Isaacs 1957). In humans, type I interferons are a family of related proteins encoded by genes on chromosome 9 and encode at least 13 subtypes of interferon alpha (IFNα) and one subtype of interferon beta (IFNβ). Recombinant IFNα was the first approved biotherapeutic and has become an important therapy in viral infections and cancer. In addition to its direct antiviral activity on cells, interferons are known to be potent modulators of immune responses, acting on cells of the immune system.

[0010] Administration of small molecule compounds that can modulate the innate immune response, including activation or inhibition of the production of type I interferons and other cytokines, could become an important strategy for treating or preventing human diseases, including viral infections and autoimmune diseases. This type of immunomodulatory strategy has the potential to identify compounds that are useful not only for infectious diseases, but also for cancer (Zitvogel 2015), allergic diseases (Moisan 2006), neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis (Lemos 2014; Cirulli 2015; Freischmidt 2015), other inflammatory conditions such as irritable bowel disease (Rakoff-Nahoum 2004), and as vaccine adjuvants (Persing 2002; Dubensky 2013).

[0011] STING is essential for antimicrobial host defense, including protection against a range of DNA and RNA viruses and bacteria (reviewed in McNab 2015; Ma 2016). The families Herpesviridae, Flaviviridae, Coronaviridae, Papillomaviridae, Adenoviridae, Hepadnaviridae, Orthomyxoviridae and Paramyxoviridae, and Rhabdoviridae have evolved mechanisms to inhibit STING-mediated type I interferon production and evade host immune control (Holm 2016; Ma 2015; Wu 2015; Liu 2016; Chen 2014; Lau 2013; Ding 2013; Nitta 2013; Sun 2012; Aguirre 2012; Ishikawa 2009). Therefore, small-molecule activation of STING could be beneficial for the treatment of these infectious diseases.

[0012] In contrast, increased and prolonged type I IFN production has been associated with a variety of chronic infections, including mycobacteria (Collins 2015; Wassermann 2015; Watson 2015), Francisella (Storek 2015; Jin 2011A), Chlamydia (Prantner 2010), Plasmodium (Sharma 2011), and HIV (Herzner 2015; Gao 2013B). Similarly, excess type I interferon production has been found in patients with complex forms of autoimmune diseases. Genetic evidence in humans and corroboration from studies in animal models support the hypothesis that inhibition of STING results in reduced type I interferon that drives autoimmune diseases (Crow 2006; Stetson 2008). Thus, inhibitors of STING offer a treatment for patients with chronic type I interferon and proinflammatory cytokine production associated with infection or complex autoimmune diseases. Allergic diseases are associated with a Th2-biased immune response to allergens. Th2 responses are associated with elevated levels of IgE, which, through its effects on mast cells, promotes hypersensitivity to allergens, leading to symptoms such as those observed in allergic rhinitis and asthma. In healthy individuals, the immune response to allergens is more balanced with a mixed Th2 / Th1 and regulatory T cell response. Induction of type 1 interferons has been shown to result in a reduction in Th2-type cytokines in the local environment and promote Th1 / Treg responses. In this context, induction of type 1 interferons, for example by activating STING, may provide benefit in the treatment of allergic diseases such as asthma and allergic rhinitis (Huber 2010).

[0013] Compounds that bind to STING and act as agonists have been shown to induce type 1 interferons and other cytokines when incubated with human PBMCs. Compounds that induce human interferons can be used to treat a variety of disorders, such as allergic diseases and other inflammatory conditions, such as allergic rhinitis and asthma, infectious diseases, neurodegenerative diseases, precancerous syndromes and cancers, and can also be used as immunogenic compositions or vaccine adjuvants. Compounds that bind to STING can act as antagonists and can be used to treat, for example, autoimmune diseases. It is expected that targeting STING with an activator or inhibitor may be a promising method for preventing and treating diseases and conditions in which regulation of the type 1 IFN pathway is beneficial, as well as for immunogenic compositions or vaccine adjuvants, including inflammation, allergic and autoimmune diseases, infectious diseases, cancer, precancerous syndromes.

[0014] Skin cancer and a variety of cutaneous viral infections involve an immunoprivileged environment, and activation of a local immune response to the lesions may be a topical therapeutic approach. STING agonists may be used to treat viral warts, superficial skin cancers, and precancerous actinic keratoses. Through a dual mechanism of action, STING activation (e.g., delivered by microneedle patches or topical formulations) may be used to control HPV directly through the production of antiviral type I interferons, and indirectly by enhancing the adaptive immune response downstream of innate immune activation. STING agonists may activate innate immune responses in lesions and drive T cell responses against HPV.

[0015] Recent evidence has shown that spontaneous activation of the STING pathway within tumor-resident dendritic cells leads to the production of type I IFNs and adaptive immune responses against tumors. Furthermore, activation of this pathway in antigen presenting cells (APCs) in the tumor microenvironment drives subsequent T cell priming against tumor-associated antigens (Corrales 2015). International patent applications WO2014 / 093936, WO2014 / 189805, WO2013 / 185052, WO2015 / 077354 and WO2015 / 185565 disclose certain cyclic dinucleotides and their use in inducing immune responses by activating STING.

[0016] Furthermore, non-CDN compounds have been described as active agonists of STING.

[0017] Applications WO2019 / 069269, WO2019 / 069270, WO2017 / 175156 and WO2017 / 175147 as well as Ramanjulu 2018 describe certain amidobenzimidazole-based and diamidobenzimidazole-based compounds and their use in modulating STING.

[0018] Applications WO2019 / 027858 and US2018 / 0093964 describe certain benzo[b]thiophene compounds and their use as antagonists of STING. WO2019 / 195063 describes azabenzothiophene compounds, and WO2019 / 195124 describes benzothiophenes and related compounds and their use as STING agonists. WO 2019 / 219820 describes benzothiophenes, thienopyridines and thienopyrimidines as STING modulators.

[0019] Applications WO2018 / 234808, WO2018 / 234807, GB2563642A, WO2018 / 234805 describe certain aromatic amide compounds and their use as modulators of STING.

[0020] STING has known polymorphisms, including an allele encoding histidine at position 232 that is refractory to bi-3',5' (classic) CDNs but responsive to 2',5'-3',5' (atypical, mixed-linked) CDNs (Diner 2013; Jin 2011B). Single nucleotide polymorphisms in the STING gene have been reported to affect responsiveness to typical CDNs of bacterial origin (Diner 2013; Gao 2013C; Conlon 2013). Five major STING haplotypes have been reported (WT, R232H, HAQ, AQ, and Q alleles), which vary at amino acid positions 71, 230, 232, and 293 (Jin 2011B; Yi 2013).

[0021] The compounds of the present invention modulate the activity of STING and, therefore, may provide beneficial therapeutic effects in the prevention and treatment of diseases, disorders and / or conditions in which modulation of STING (stimulator of interferon genes) is beneficial, such as inflammation, allergic and autoimmune diseases, infectious diseases, cancer, precancerous syndromes, and as vaccine adjuvants. Summary of the invention

[0022] The first aspect of the present invention provides a compound of formula I:

[0023]

[0024] in:

[0025] W is O or NH;

[0026] R 1 Selected from:

[0027] (i) H;

[0028] (ii)C 3-6 Cycloalkyl;

[0029] (iii)C 3-7 A heterocyclic group, which is optionally substituted by a group selected from:

[0030] Methyl; and

[0031] Esters; and

[0032] (iv) Straight or branched chain C 1-4 Alkyl, which is optionally substituted by a group selected from:

[0033] Alkoxy;

[0034] Amino;

[0035] Acylamino;

[0036] acylamido;

[0037] acyloxy;

[0038] Alkyl carboxyl esters;

[0039] Alkylcarbamoyl;

[0040] Alkylcarbamoyl esters;

[0041] Phenyl;

[0042] Phosphonates;

[0043] C optionally substituted by a group selected from methyl and oxo 3-7 heterocyclyl; and

[0044] a naturally occurring amino acid, which is optionally N-substituted with a group selected from methyl, acetyl and boc;

[0045] A 1 Yes CR A or N;

[0046] A 2 Yes CR B or N;

[0047] A 3 Yes CR C or N;

[0048] A 4 Yes CR D or N;

[0049] Among them A 1 , A 2 , A 3 , and A 4 No more than two of them can be N;

[0050] R A , R B , R C and R D One or two of (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH;

[0051] The rest of R A , R B , R C and R D (if any) is H;

[0052] R N1 is H or Me;

[0053] R C2 and R C3 one of which is C(=O)NH2; the other is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C 2-4 Alkenyl and C5 heterocyclic group;

[0054] R C1 , and R C4 independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C 2-4 alkenyl and C5 heterocyclic group.

[0055] The second aspect of the present invention provides a compound of the first aspect for use in a method of treatment. The second aspect also provides a pharmaceutical composition comprising the compound of the first aspect and a pharmaceutically acceptable excipient.

[0056] The third aspect of the present invention provides a method for treating or preventing a disease improved by regulating STING, comprising administering the compound of the first aspect of the present invention or the pharmaceutical composition of the second aspect of the present invention to a patient in need of treatment. The third aspect of the present invention also provides the use of the compound of the first aspect of the present invention in the manufacture of a medicament for treating or preventing a disease improved by regulating STING, and the compound of the first aspect of the present invention or its pharmaceutical composition, which is used to treat or prevent a disease improved by regulating STING.

[0057] definition

[0058] C 3-6 Cycloalkyl: As used herein, the term "C 3-6 The term "cycloalkyl" refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a saturated cyclic hydrocarbon compound having from 3 to 6 carbon atoms. 3-6 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), and cyclohexyl (C6).

[0059] C 3-7 Heterocyclyl: As used herein, the term "C 3-7 The term "heterocyclyl" refers to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a monocyclic heterocyclic compound, the moiety having 3 to 7 ring atoms; wherein 1-2 atoms are heteroatoms selected from oxygen or nitrogen.

[0060] In this context, a prefix (such as C 3-7 ) represents the number of ring atoms or a range of numbers of ring atoms, whether carbon atoms or heteroatoms.

[0061] C3-7 Examples of heterocyclyl groups include, but are not limited to, those derived from:

[0062] N1: aziridine (C3), azetidine (C4), pyrrolidine (tetrahydropyrrole) (C5), pyrroline (e.g. 3-pyrroline, 2,5-dihydropyrrole) (C5), 2 H-pyrrole or 3 H-pyrrole (isopyrrole, isoazole) (C5), pyrrole (C5), piperidine (C6), dihydropyridine (C6), tetrahydropyridine (C6), pyridine (C6), azepine (C7), azepane (C7);

[0063] N2: diaziridine (C3), diazetidine (C4), imidazolidine (C5), pyrazolidine (diazacyclopentane) (C5), imidazoline (C5), pyrazoline (dihydropyrazole) (C5), imidazole (C5), pyrazole (C5), piperazine (C6), pyrazine (C6), pyrimidine (C6), pyridazine (C6), diazepine (C7), diazepane (C7);

[0064] O1: oxetane (C4), tetrahydrofuran (C5); oxane (C6);

[0065] O2: dioxetane (C4), dioxolane (C5); dioxane (C6), dioxole (C5);

[0066] N1O1: tetrahydrooxazole (C5), dihydrooxazole (C5), tetrahydroisoxazole (C5), dihydroisoxazole (C5), isoxazole (C5), oxazole (C5), morpholine (C6), tetrahydrooxazine (C6), dihydrooxazine (C6), oxazine (C6).

[0067] C 1-4 Alkyl: As used herein, the term "C 1-4 The "alkyl group" belongs to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a saturated hydrocarbon compound having 1 to 4 carbon atoms.

[0068] Examples of saturated alkyl groups include, but are not limited to, Me: methyl (C1), Et: ethyl (C2), Pr: propyl (C3), and Bu: butyl (C4).

[0069] Examples of saturated straight chain alkyl groups include, but are not limited to, methyl (C1), ethyl (C2), nPr: n-propyl (C3), and nBu: n-butyl (C4).

[0070] Examples of saturated branched alkyl groups include, but are not limited to, iPr: isopropyl (C3, -C(CH3)2), Bu: isobutyl (C4), sBu: sec-butyl (C4) and tBu: tert-butyl (C4).

[0071] C 2-4 Alkenyl: As used herein, the term "C 2-4 "Alkenyl" refers to an alkyl group having 2 to 4 carbon atoms and having one or more carbon-carbon double bonds.

[0072] Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH2), 1-propenyl (-CH=CH-CH3), 2-propenyl (allyl, -CH-CH=CH2), isopropenyl (1-methylvinyl, -C(CH3)=CH2) and butenyl (C4).

[0073] C 1-4 Fluoroalkyl: As used herein, the term "C 1-4 "Fluoroalkyl" refers to a C 1-4 Alkyl group.

[0074] Alkoxy: -OR, wherein R is C as defined above 1-4 Alkyl group. It can be represented by -O - C 1-4 Examples of alkoxy groups include, but are not limited to, methoxy (OMe, C1), ethoxy (OEt, C2), propoxy (C3), and butoxy (C4).

[0075] Alkylcarbamoyl: -NHC(=O)OR, wherein R is C as defined above. 1-4 Alkyl Groups. Examples of alkylcarbamoyl groups include, but are not limited to, -N(H)C(=O)OCH3, -N(H)C(=O)OCH2CH3, and -N(H)C(=O)OC(CH3)3.

[0076] Alkylcarbamoyl ester: -OC(=O)NRR', wherein R and R' are independently selected from H and C as defined above. 1-4 Examples of alkylcarbamoyl ester groups include, but are not limited to, -OC(=O)N(CH3)2 and -OC(=O)N(H)CH3.

[0077] Alkyl carboxyl ester: -OC(=O)OR, wherein R is C as defined above. 1-4Alkyl Groups. Examples of alkyl carboxyl ester groups include, but are not limited to, -OC(=O)OCH3, -OC(=O)OCH2CH3, -OC(=O)OC(CH3)3, and -OC(=O)OCH(CH3)2.

[0078] Amino: -N(R)R', wherein R and R' are independently selected from H and C as defined above 1-4 Alkyl. Examples of amino groups include, but are not limited to, -NH2, -N(H)CH3, -N(H)C(CH3)2, -N(CH3)2, -N(CH2CH3)2.

[0079] Amido (carbamoyl, carbamoyl, aminocarbonyl, amide, aminoacyl): -C(=O)N(R)R', wherein R and R' are independently selected from H and C as defined above. 1-4 Examples of acylamino groups include, but are not limited to, C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(CH3)2, -C(=O)N(H)CH2CH3, and -C(=O)N(CH2CH3)2.

[0080] Acylamido: -N(R)C(=O)R', wherein R and R' are independently selected from H and C as defined above. 1-4 Alkyl. Examples of acylamido groups include, but are not limited to, -N(H)C(=O)CH2CH3, -N(H)C(=O)CH3, and -N(CH3)C(=O)CH3.

[0081] Phenyl: -C6H5, where the phenyl group itself may be optionally replaced by one or more C 1-4 An alkyl group, one or more C 1-4 A fluoroalkyl group, one or more C 1-4 The alkoxy group, one or more halogen substituents and one or more cyano substituents are substituted.

[0082] Benzyl: -CH2-phenyl, wherein phenyl is as defined above.

[0083] Ester (carboxylate, carboxylic acid ester, oxycarbonyl): -C(=O)OR, wherein R is an ester substituent, for example, C as defined above. 1-4 Alkyl group, C 3-7 A heterocyclyl group or a phenyl group, preferably C 1-4 Alkyl groups. Examples of ester groups include, but are not limited to, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)OC(CH3)3, and -C(=O)OPh.

[0084] Acyloxy (reverse ester): -OC(=O)R, wherein R is an acyloxy substituent, for example, C 1-4 Alkyl group, C 3-7 A heterocyclyl group or a phenyl group, preferably C 1-4 Alkyl groups. Examples of acyloxy groups include, but are not limited to, -OC(=O)CH3 (acetoxy), -OC(=O)CH2CH3, -OC(=O)C(CH3)3, and -OC(=O)Ph. Additional examples of acyloxy groups include, but are not limited to, methyl esters (C1), ethyl esters (C2), propyl esters (C3), and butyl esters (C4).

[0085] Naturally occurring amino acids: As used herein, the term "naturally occurring amino acids" pertains to monovalent moieties obtained by removing a hydrogen atom from a carboxyl group or an amino group on one of the amino acid compounds commonly found in nature (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine). The amino acids are particularly selected from isoleucine, leucine, and valine, most particularly valine.

[0086] In each of these groups, the carbon atom to which both the carboxyl and amino groups are bound is referred to as the alpha carbon, and the carboxyl and amino groups to which it is attached are alpha-carboxyl and alpha-amino groups. Naturally occurring amino acids are optionally substituted with protecting groups on the alpha-amino group or any other amino group on the moiety, including but not limited to acetyl, methyl and tert-butyl carbamate (boc) groups.

[0087] Phosphonate: -P(O)(OR)OR', wherein R and R' are independently selected from C as defined above 1-4 Examples of alkyl phosphonates include, but are not limited to, -P(O)(OEt)2.

[0088] Cyano: -C≡N.

[0089] Pivaloyloxymethyl: a group of the formula:

[0090]

[0091] Including other forms

[0092] Unless otherwise stated, the above includes the well-known ionic, salt, solvate and protected forms of these substituents. For example, a reference to a carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-CO -), its salts or solvates, and conventional protected forms. Similarly, reference to an amino group includes the protonated form (—N + HR 1 R 2 ), salts or solvates of amino groups (e.g., hydrochloride) and conventional protected forms of amino groups. Similarly, reference to a hydroxyl group also includes the anionic form (—O - ), its salts or solvates, and conventional protected forms.

[0093] Salt

[0094] It may be convenient or desirable to prepare, purify, and / or handle the active compound as a corresponding salt, e.g., a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge, et al., J. Pharm. Sci., 66, 1-19 (1977).

[0095] For example, if the compound is anionic, or has a functional group that can be anionic (e.g., -COOH can be -COO - ), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ As well as other cations such as Al +3 Examples of suitable organic cations include, but are not limited to, ammonium ions (i.e., NH4 + ) and substituted ammonium ions (e.g. NH3R + NH2R2 + 、NHR3 + NR4 + ). Some examples of suitable substituted ammonium ions are those derived from ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine and tromethamine, and amino acids such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3)4 + .

[0096] If the compound is cationic, or has a functional group that can be cationic (e.g., -NH2 can be -NH3 + ), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorous acid.

[0097] Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, ethylenediaminetetraacetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthalenecarboxylic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, phenylsulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, toluenesulfonic acid, trifluoroacetic acid, and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethylcellulose.

[0098] Solvate

[0099] It may be convenient or desirable to prepare, purify and / or process the corresponding solvate of the active compound. The term "solvate" is used herein in a conventional sense to refer to a complex of a solute (e.g., an active compound, a salt of an active compound) and a solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, such as a monohydrate, a dihydrate, a trihydrate, etc.

[0100] Isomers

[0101] Certain compounds of the present invention may exist in one or more specific geometric, optical, enantiomeric, diastereomeric, epimeric, atropisomer, stereoisomer, tautomer, conformational or anomer forms, including but not limited to cis and trans forms; E-form and Z-form; c-form, t-form and r-form; endo and exo forms; R-form, S-form and meso form; D-form and L-form; d-form and l-form; (+) form and (-) form; keto form, enol form and enolate form; cis and trans; syncline form and anticline form; α-form and β-form; axial form and equatorial form; boat form, chair form, twist form, envelope form and semi-chair form; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomer forms").

[0102] The term "chiral" refers to molecules that have the property of non-superimposability of their mirror image partner, whereas the term "achiral" refers to molecules that are superimposable on their mirror image partner.

[0103] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0104] "Diastereomers" refers to stereoisomers with two or more chiral centers, and whose molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated under high resolution analytical procedures such as electrophoresis and chromatography.

[0105] "Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of each other.

[0106] The stereochemical definitions and conventions used herein generally follow those of SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers and atropisomers, and mixtures thereof such as racemic mixtures, form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. When describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d and l or (+) and (-) are used to indicate the sign of rotation of a compound with respect to plane polarized light, where (-) or l indicates that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be referred to as enantiomers, and a mixture of such isomers is often referred to as an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

[0107] It should be noted that, in addition to the discussion below regarding tautomeric forms, specifically excluded from the term "isomer" as used herein are structural (or compositional) isomers (i.e., isomers that differ in the connectivity of the atoms rather than merely the position of the atoms in space). For example, a reference to a methoxy group -OCH3 should not be construed as a reference to its structural isomer, the hydroxymethyl group -CH2OH. Similarly, a reference to o-chlorophenyl should not be construed as a reference to its structural isomer, m-chlorophenyl. However, a reference to a class of structures is likely to include structural isomeric forms belonging to that class (e.g., C 1-7 The alkyl group includes n-propyl and isopropyl; the butyl group includes n-butyl, isobutyl, sec-butyl and tert-butyl; the methoxyphenyl group includes o-methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl).

[0108] The above exclusion does not apply to tautomeric forms, such as the keto form, the enol form and the enolate form, as in, for example, the following tautomeric pairs: keto / enol (described below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, N-nitroso / hydroxyazo and nitro / acid nitro.

[0109]

[0110] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions via reorganization of some of the bonding electrons.

[0111] Of particular relevance to the compounds of the present invention is the tautomerism illustrated below, wherein R N1 Yes H:

[0112]

[0113] It should be noted that the term "isomer" specifically includes compounds having one or more isotopic substitutions. For example, H can be in any isotopic form, including 1 H. 2 H(D), and 3 H(T);C can be in any isotopic form, including 12 C. 13 C. and 14 C; O can be in any isotopic form, including 16 O and 18 O; etc.

[0114] Examples of isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N. 18 F. 31 P. 32 P. 35 S. 36 Cl and 125 I. Various isotopically labeled compounds of the present invention, for example, incorporating radioactive isotopes such as 3 H. 13 C and 14 C compounds, included in the compounds of the present invention. Such isotope-labeled compounds can be used for metabolic studies, reaction kinetics studies, detection or imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), including drug or substrate tissue distribution determination, or for radiotherapy of patients. Deuterium-labeled or substituted therapeutic compounds of the present invention can have improved DMPK (drug metabolism and pharmacokinetics) properties, related to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium can provide certain therapeutic benefits due to higher metabolic stability, for example, increased in vivo half-life or reduced dosage requirements. 18 F-labeled compounds can be used in PET or SPECT studies. Isotopically labeled compounds of the invention or prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting readily available isotopically labeled reagents for non-isotopically labeled reagents. In addition, the use of heavier isotopes, particularly deuterium (i.e. 2 H or D) substitution can provide certain therapeutic benefits due to higher metabolic stability, for example, increased in vivo half-life or reduced dosage requirements or improvements in therapeutic index. It should be understood that deuterium is considered a substituent in this context. The concentration of such heavier isotopes, particularly deuterium, can be defined by an isotopic enrichment factor. In the compounds of the present invention, any atom that is not specifically designated as a particular isotope is meant to represent any stable isotope of the atom.

[0115] Unless otherwise indicated, reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallization and chromatographic means) of such isomeric forms are known in the art or are readily obtained by adapting the methods taught herein or known methods in a known manner.

[0116] Treatment Indications

[0117] The compounds disclosed herein may provide therapeutic benefit in a number of disorders, and in particular may provide therapeutic benefit in the treatment or prevention of diseases that are ameliorated by modulation of STING.

[0118] One aspect of the present invention provides a method for treating or preventing STING-mediated diseases and disorders, wherein stimulating STING is beneficial. Exemplary diseases / disorders include, but are not limited to, cancer and infectious diseases (such as diseases caused by viruses and bacteria, such as HIV, HBV, HCV, HPV and influenza). Another aspect of the present invention provides the use of STING agonists as vaccine adjuvants. In one embodiment, the present invention provides a compound of the present invention for use in therapy. The present invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in therapy. The present invention particularly provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in the treatment of STING-mediated diseases or disorders.

[0119] The present invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for use as a vaccine adjuvant. Therefore, an immunogenic composition or vaccine adjuvant is also provided, comprising a compound of formula I or a pharmaceutically acceptable salt thereof. In another embodiment of the present invention, a composition is provided, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and one or more immunostimulants.

[0120] In another embodiment, the present invention provides a compound of the present invention for use in treating a STING-mediated disease or disorder and / or as an immunogenic composition or vaccine adjuvant. In another embodiment, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in improving persistent organ damage or impairment caused by a STING-mediated disease or disorder.

[0121] The present invention also provides the use of the compounds of the present invention in the manufacture of a medicament for treating a STING-mediated disease or disorder. The present invention also provides the use of a compound of formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a STING-mediated disease or disorder, such as the diseases and disorders described herein.

[0122] The present invention also provides the use of a compound of formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, in the manufacture of a vaccine. Also provided is the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of an immunogenic composition comprising an antigen or an antigen composition for the treatment or prevention of a disease. Also provided is the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a vaccine composition comprising an antigen or an antigen composition for the treatment or prevention of a disease.

[0123] In another embodiment, the present invention relates to a method for treating a STING-mediated disease or disorder, comprising administering a therapeutically effective amount of a compound of the present invention to a human in need thereof. In another embodiment, the present invention relates to a method for treating a STING-mediated disease or disorder, comprising administering a therapeutically effective amount of a compound of formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a human in need thereof.

[0124] Infectious Diseases

[0125] The compounds of the present invention can be used to treat infectious diseases, and infectious diseases are any diseases caused by infection from pathogens or occurring simultaneously with infection from pathogens. Pathogens are broadly defined as any kind of organisms that are foreign to the human tissue environment. Common pathogenic pathogens include bacteria (many, such as TB), viruses (many, such as HBV, HIV, influenza viruses) and parasitic protozoa (such as Plasmodium falciparum that causes malaria). The compounds of the present invention can be used to treat infectious diseases caused by bacteria (such as TB infection (Mycobacterium tuberculosis), infectious diseases caused by chlamydia, tularemia infection (Francisella tularensis), Plasmodium infection or infection caused by DNA or RNA viruses. The compounds of the present invention can be used to treat infectious diseases derived from the following DNA virus families: Herpesviridae (herpes simplex virus-1, Kaposi's sarcoma-associated virus and Epstein-Barr virus), Papillomaviridae (human papillomavirus), adenovirus and Hepadnaviridae (hepatitis B virus). Examples of RNA virus families include Retroviridae (human immunodeficiency virus), Flaviviridae (dengue virus, hepatitis C virus), Orthomyxoviridae (influenza virus) and Coronaviridae (human coronavirus and SARS coronavirus).

[0126] cancer

[0127] As used herein, the terms "cancer", "neoplasm" and "tumor" are used interchangeably and, in the singular or plural, refer to cells that have undergone malignant transformation that makes them pathological to the host organism. Primary cancer cells can be easily distinguished from non-cancerous cells by well-established techniques, especially histological examination. The definition of cancer cells as used herein includes not only primary cancer cells, but also any cells derived from cancer cell ancestors. This includes metastatic cancer cells, and in vitro cultures and cell lines derived from cancer cells. When referring to a cancer that usually manifests as a solid tumor, a "clinically detectable" tumor is a tumor that is detectable based on tumor mass; for example, by procedures such as computed tomography (CT), magnetic resonance imaging (MRI), X-rays, ultrasound or physical examination palpation, and / or due to the expression of one or more cancer-specific antigens in a sample that can be obtained from a patient. A tumor can be a hematopoietic (or blood or hematology or blood-related) cancer that can be referred to as a "liquid tumor", for example, a cancer derived from blood cells or immune cells. Specific examples of hematological neoplasm-based clinical conditions include leukemias such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia; plasma cell malignancies such as multiple myeloma, MGUS, and Waldenstrom's macroglobulinemia; lymphomas such as non-Hodgkin's lymphoma, Hodgkin's lymphoma; and the like.

[0128] Cancer can be any cancer in which there is an abnormal number of germ cells or unwanted cell proliferation or is diagnosed as a hematological cancer, including lymphoid malignancies and myeloid malignancies. Myeloid malignancies include but are not limited to acute myeloid (or myeloid or myeloid or myeloblastic) leukemia (undifferentiated or differentiated), acute promyelocytic (or promyelocytic or promyelocytic or promyeloblastic) leukemia, acute myelomonocytic (or myelomonocytic) leukemia, acute monocytic (or monoblastic) leukemia, erythroleukemia and megakaryocyte (or megakaryoblastic) leukemia. These leukemias can be collectively referred to as acute myeloid (or myeloid or myeloblastic) leukemia (AML). Myeloid malignancies also include myeloproliferative disorders (MPD), which include but are not limited to chronic myeloid (or myeloid) leukemia (CML), chronic myelomonocytic leukemia (CMML), essential thrombocythemia (or thrombocythemia) and polycythemia vera (PCV). Myeloid malignancies also include myelodysplasia (or myelodysplastic syndrome or MDS), which may be referred to as refractory anemia (RA), refractory anemia with excess blasts (RAEB), and refractory anemia with excess transformed blasts (RAEBT); and myelofibrosis (MFS) with or without myeloid metaplasia of unknown etiology.

[0129] Hematopoietic cancers also include lymphoid malignancies, which may affect the lymph nodes, spleen, bone marrow, peripheral blood, and / or extranodal sites. Lymphatic cancers include B-cell malignancies, which include, but are not limited to, B-cell non-Hodgkin lymphoma (B-NHL). B-NHL can be indolent (or low-grade), intermediate (or aggressive), or high-grade (very aggressive). Indolent B-cell lymphomas include follicular lymphoma (FL); small lymphocytic lymphoma (SLL); marginal zone lymphoma (MZL), including nodal MZL, extranodal MZL, splenic MZL, and splenic MZL with villous lymphocytes; lymphoplasmacytic lymphoma (LPL); and mucosa-associated lymphoid tissue (MALT or extranodal marginal zone) lymphoma. Intermediate-grade B-NHLs include mantle cell lymphoma (MCL) with or without leukemic involvement, diffuse large cell lymphoma (DLBCL), follicular large cell (or grade 3 or 3B) lymphoma, and primary mediastinal lymphoma (PML). High-grade B-NHLs include Burkitt lymphoma (BL), Burkitt-like lymphoma, small non-cleaved cell lymphoma (SNCCL), and lymphoblastic lymphoma. Other B-NHLs include immunocytic lymphoma (or immunocytoma), primary effusion lymphoma, HIV-associated (or AIDS-associated) lymphoma, and post-transplant lymphoproliferative disorder (PTLD) or lymphoma. B cell malignancies also include, but are not limited to, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), Waldenstrom's macroglobulinemia (WM), hairy cell leukemia (HCL), large granular lymphocytic leukemia (LGL), acute lymphoid (or lymphocytic or lymphoblastic) leukemia, and Castleman's disease. NHL may also include T-cell non-Hodgkin's lymphoma (T-NHL), which includes, but is not limited to, T-cell non-Hodgkin's lymphoma not otherwise specified (NOS), peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoblastic disorder (AILD), nasal natural killer (NK) cell / T-cell lymphoma, gamma / delta lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, and Sezary syndrome.

[0130] Hematopoietic cancer also includes Hodgkin lymphoma (or disease), including classical Hodgkin lymphoma, nodular sclerosing Hodgkin lymphoma, mixed cell Hodgkin lymphoma, lymphocyte-dominated (LP) Hodgkin lymphoma, nodular LP Hodgkin lymphoma and lymphocyte-depleted Hodgkin lymphoma. Hematopoietic cancer also includes plasma cell disease or cancer, such as multiple myeloma (MM), including smoldering MM, monoclonal gammopathy (MGUS) of unclear significance (or unknown or unclear), plasmacytoma (bone, extramedullary), lymphoplasmacytic lymphoma (LPL), Waldenstrom's macroglobulinemia, plasma cell leukemia and primary amyloidosis (AL). Hematopoietic cancer can also include other cancers of other hematopoietic cells, including polymorphonuclear leukocytes (or neutrophils), basophils, eosinophils, dendritic cells, platelets, erythrocytes and natural killer cells. Tissues containing hematopoietic cells are referred to herein as "hematopoietic tissues" and include bone marrow; peripheral blood; thymus; and peripheral lymphoid tissues, such as spleen, lymph nodes, mucosa-associated lymphoid tissue (such as gut-associated lymphoid tissue), tonsils, Peyer's patches, and appendix, as well as lymphoid tissues associated with other mucosa, e.g., the bronchial lining.

[0131] Examples of cancer diseases and conditions in which the compounds of the invention may have potentially beneficial anti-tumor effects include, but are not limited to, cancer of the lung, bone, pancreas, skin, head, neck, uterus, ovary, stomach, colon, breast, esophagus, small intestine, intestinal cancer, endocrine system, thyroid, parathyroid, adrenal glands, urethra, prostate, penis, testis, ureter, bladder, kidney or liver; rectal cancer; cancer of the anal region; fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulva cancer, kidney or liver cancer; Glecular and renal cell carcinoma; soft tissue sarcoma; myxoma; rhabdomyoma; fibroma; lipoma; teratoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hemangioma; hepatocarcinoma; fibrosarcoma; chondrosarcoma; myeloma; chronic or acute leukemia; lymphocytic lymphoma; primary CNS lymphoma; CNS neoplasm; spinal cord axial tumor; squamous cell carcinoma; synovial sarcoma; malignant pleural mesothelioma; brain stem glioma; pituitary adenoma; bronchial adenoma; chondromatous hamartoma; mesothelioma; Hodgkin's disease, or a combination of one or more of the foregoing cancers. Suitably, the present invention relates to a method for treating or lessening the severity of a cancer selected from the group consisting of: brain (glioma), glioblastoma, astrocytoma, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck cancer, kidney cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid, lymphoblastic T-cell leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, hairy cell leukemia, Acute lymphoblastic leukemia, acute myeloid leukemia, chronic neutrophilic leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryocytic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoblastic T-cell lymphoma, Burkitt lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial carcinoma, vulvar cancer, cervical cancer, endometrial cancer, kidney cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular carcinoma, gastric cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor) and testicular cancer.

[0132] In some embodiments, the compounds of the present invention can be used to treat solid tumors or liquid tumors. In some embodiments, the compounds of the present invention can be used to treat sarcomas, breast cancer, colorectal cancer, gastroesophageal cancer, melanoma, non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (RCC), lymphoma, head and neck squamous cell carcinoma (SCCHN), hepatocellular carcinoma (HCC) and / or non-Hodgkin's lymphoma (NHL). Suitably, the present invention relates to a method for treating or alleviating the severity of a precancerous syndrome in a mammal (including humans), wherein the precancerous syndrome is selected from: cervical intraepithelial neoplasia, monoclonal gammopathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevus (pre-melanoma), prostatic intraepithelial (intraductal) neoplasia (PIN), ductal carcinoma in situ (DCIS), colon polyps and severe hepatitis or cirrhosis.

[0133] In one aspect, humans suffer from solid tumors. In one aspect, tumors are selected from head and neck cancer, gastric cancer, melanoma, renal cell carcinoma (RCC), esophageal cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer and pancreatic cancer. In one aspect, humans suffer from one or more of the following: colorectal cancer (CRC), esophageal cancer, cervical cancer, bladder cancer, breast cancer, head and neck cancer, ovarian cancer, melanoma, renal cell carcinoma (RCC), EC squamous cells, non-small cell lung cancer, mesothelioma and prostate cancer. On the other hand, humans suffer from liquid tumors, such as diffuse large B cell lymphoma (DLBCL), multiple myeloma, chronic lymphoblastic leukemia (CLL), follicular lymphoma, acute myeloid leukemia and chronic myeloid leukemia. In one embodiment, the compounds of the present invention can be used to treat skin cancer (e.g., non-melanoma skin cancer, squamous cell carcinoma, basal cell carcinoma) or actinic keratosis. In addition to the field effect for clearing superficial skin cancers, the compounds of the invention may prevent the development of subsequent skin cancers and precancerous actinic keratoses in treated patients.

[0134] Autoimmune diseases

[0135] Related autoimmune diseases include, but are not limited to, STING-associated vasculitis with infantile onset (SAVI), Aicardi Goutieres syndrome (AGS), lupus pernio, ataxia telangiectasia (also known as Louis-Barr syndrome), retinal vasculopathy with leukodystrophy (RCVL), systemic lupus erythematosus (SLE), cutaneous lupus, lupus nephritis, psoriasis, diabetes (including insulin-dependent diabetes mellitus (IDDM)), dermatomyositis, human immunodeficiency virus (HIV), AIDS, polymyositis, systemic sclerosis (scleroderma) and Sjögren's syndrome (SS), rheumatoid arthritis, psoriatic arthritis, polyarthritis, myasthenia gravis, polyarteritis nodosa, vasculitis, cutaneous vasculitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Henoch-Schonlein purpura (Henoch-Schonlein purpura), autoimmune hepatitis, primary sclerosing cholangitis, Wegener's granulomatosis, microscopic polyangiitis, Behcet's disease, spondylitis, giant cell arteritis, polymyalgia rheumatica, Raynaud's phenomenon, primary biliary cirrhosis, primary angiitis of the central nervous system, microscopic polyangiitis, neuromyelitis optica, and mixed connective tissue disease.

[0136] Inflammation

[0137] Inflammation represents a group of vascular, cellular and neural responses to trauma. Inflammation can be characterized as the movement of inflammatory cells such as monocytes, neutrophils and granulocytes into tissues. This is usually associated with reduced endothelial barrier function and tissue edema. Inflammation can be divided into acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli, and is achieved by the increased movement of plasma and leukocytes from the blood to damaged tissues. A series of biochemical events propagate and mature the inflammatory response involving the local vascular system, immune system and the damaged tissues. The long-term inflammation known as chronic inflammation causes the progressive changes in the cell types present at the site of inflammation, and is characterized in the simultaneous destruction and healing of tissues from the inflammatory process.

[0138] When inflammation occurs as part of an immune response to infection or as an acute response to trauma, it can be beneficial and is usually self-limiting. However, inflammation can be harmful in many cases. This includes the generation of excessive inflammation in response to infectious agents, which can lead to severe organ damage and death (e.g., in the case of sepsis). In addition, chronic inflammation is often harmful and is the root cause of many chronic diseases, causing severe and irreversible damage to tissues. In this case, the immune response is usually directed against one's own tissues (autoimmunity), although chronic reactions to foreign entities can also lead to bystander damage to one's own tissues.

[0139] Therefore, the goal of anti-inflammatory therapy is to reduce this inflammation, suppress autoimmunity (when present), and allow the physiological processes or healing and tissue repair to proceed.

[0140] The compounds of the present invention may be used to treat inflammation of any tissue or organ of the body, including musculoskeletal inflammation, vascular inflammation, neurological inflammation, digestive system inflammation, ocular inflammation, reproductive system inflammation, and other inflammations, as exemplified below.

[0141] Musculoskeletal inflammation refers to any inflammatory condition of the musculoskeletal system, particularly those affecting skeletal joints, including those of the hands, wrists, elbows, shoulders, jaws, spine, neck, hips, knees, ankles and feet, and those affecting tissues connecting muscle to bone, such as tendons. Examples of musculoskeletal inflammation that can be treated with the compounds of the invention include arthritis (including, for example, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute and chronic infectious arthritis, arthritis associated with gout and pseudogout, and juvenile idiopathic arthritis), tendinitis, synovitis, tenosynovitis, bursitis, fibrositis (fibromyalgia), epicondylitis, myositis, and osteitis (including, for example, Paget's disease, osteitis pubis, and osteitis fibrosa cystica).

[0142] Ocular inflammation refers to inflammation of any structure of the eye, including the eyelids. Examples of ocular inflammation that can be treated with the compounds of the invention include blepharitis, blepharchalasis, conjunctivitis, dacryoadenitis, keratitis, keratoconjunctivitis sicca (dry eyes), scleritis, trichiasis, and uveitis.

[0143] Examples of inflammatory diseases of the nervous system that may be treated with the compounds of the invention include encephalitis, Guillain-Barre syndrome, meningitis, neuromyotonia, narcolepsy, multiple sclerosis, myelitis, CNS vasculitis, and schizophrenia.

[0144] Examples of inflammation of the vasculature or lymphatic system that may be treated with the compounds of the invention include arthrosclerosis, arthritis, phlebitis, vasculitis and lymphangitis.

[0145] Examples of inflammatory disorders of the digestive system that may be treated with the compounds of the invention include cholangitis, cholecystitis, enteritis, enterocolitis, gastritis, gastroenteritis, inflammatory bowel disease (such as Crohn's disease and ulcerative colitis), ileitis, and proctitis.

[0146] Examples of inflammatory disorders of the reproductive system that may be treated with the compounds of the invention include cervicitis, chorioamnionitis, endometritis, epididymitis, omphalitis, oophoritis, orchitis, salpingitis, tubo-ovarian abscess, urethritis, vaginitis, vulvitis, and vulvodynia.

[0147] The compounds of the invention can be used to treat autoimmune disorders with an inflammatory component. Such disorders include acute disseminated alopecia universalis, Behcet's disease, Chagas disease, STING-associated vasculitis with infantile onset (SAVI), Aicardi Goutieres syndrome (AGS), pernio lupus, ataxia telangiectasia (also known as Louis-Barr syndrome), retinal vasculopathy with leukodystrophy (RCVL), ANCA-associated vasculitis, chronic fatigue syndrome, dysautonomia, encephalomyelitis, ankylosing spondylitis, aplastic anemia, suppurative hidradenitis, autoimmune hepatitis, autoimmune oophoritis, celiac disease, Crohn's disease, type 1 diabetes, giant cell arteritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, disease), Henlein-Schönlein purpura, Kawasaki disease, lupus erythematosus, microscopic colitis, microscopic polyarteritis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus, polyarteritis nodosa, polymyalgia, rheumatoid arthritis, Reiter's syndrome, Sjögren's syndrome, temporal arteritis, Wegener's granulomatosis, warm autoimmune hemolytic anemia, interstitial cystitis, Lyme disease, morphea, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, and vitiligo.

[0148] The compounds of the invention can be used to treat T cell mediated allergic diseases with an inflammatory component. Such conditions include contact hypersensitivity, contact dermatitis (including contact dermatitis caused by poison ivy), urticaria, skin allergies, respiratory allergies (hay fever, allergic rhinitis) and gluten sensitive enteropathy (celiac disease).

[0149] Other inflammatory conditions that can be treated with the compounds of the invention include, for example, appendicitis, dermatitis, dermatomyositis, endocarditis, fibrositis, gingivitis, glossitis, hepatitis, hidradenitis suppurativa, iritis, laryngitis, mastitis, myocarditis, nephritis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, pneumonia, prostatitis, pyelonephritis and stomatitis, transplant rejection (involving organs such as kidney, liver, heart, lung, pancreas (such as islet cells), bone marrow, cornea, small intestine, skin allograft, skin homograft, and heart valve xenograft, serum sickness and graft-versus-host disease), acute pancreatitis, chronic pancreatitis, acute respiratory distress syndrome, Sezary syndrome, congenital adrenal hyperplasia, non-suppurative thyroid inflammation, hypercalcemia associated with cancer, pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme, exfoliative dermatitis, seborrheic dermatitis, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, drug allergic reaction, allergic conjunctivitis, keratitis, herpetic eye, iritis and iridocyclitis, chorioretinitis, optic neuritis, symptomatic sarcoidosis, fulminant or disseminated pulmonary tuberculosis chemotherapy, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenic purpura in adults, acquired (autoimmune) hemolytic anemia, leukemia and lymphoma in adults, acute leukemia in children, regional enteritis, autoimmune vasculitis, multiple sclerosis, chronic obstructive pulmonary disease, solid organ transplant rejection, sepsis. Preferred treatments include treatment of transplant rejection, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, type 1 diabetes, asthma, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, chronic lung disease and inflammation associated with infectious conditions (e.g., sepsis).In one embodiment, the compounds of the invention may be used to treat asthma.

[0150] Cell proliferation

[0151] The compounds of the invention may also be used to treat one or more diseases afflicting mammals characterized by cell proliferation in areas of disturbance associated with neovascularization and / or vascular permeability, including vascular proliferative disorders including arthritis (rheumatoid arthritis) and restenosis; fibrotic disorders including cirrhosis and atherosclerosis; mesangial cell proliferative disorders including glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, proliferative retinopathy, organ transplant rejection and glomerular diseases; and metabolic disorders including psoriasis, diabetes, chronic wound healing, inflammation and neurodegenerative diseases.

[0152] Neurodegenerative diseases

[0153] The compounds of the present invention can be used to treat neurodegenerative diseases. Exemplary neurodegenerative diseases include, but are not limited to, multiple sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

[0154] combination

[0155] The compounds of the present invention can be used alone or in combination with other therapeutic agents. As modulators of immune responses, the compounds of the present invention can also be used in monotherapy, or in combination with another therapeutic agent for the treatment of diseases and conditions in which the regulation of STING is beneficial. Therefore, the combination therapy according to the present invention comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof, and at least one other therapeutic agent. In one embodiment, the combination therapy according to the present invention comprises administering at least one compound of Formula I or a pharmaceutically acceptable salt thereof, and at least one other therapeutic agent. The compound of Formula I or a pharmaceutically acceptable salt thereof and the other therapeutic agent can be administered together or separately in a single pharmaceutical composition, and when administered separately, the administration can occur simultaneously or sequentially in any order. The amount of the compound of Formula I and its pharmaceutically acceptable salt and the other therapeutic agent and the relative time of administration will be selected so as to achieve the desired combined therapeutic effect. Therefore, in another aspect, a combination is provided, the combination comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and one or more other therapeutic agents.

[0156] The compounds of Formula I and their pharmaceutically acceptable salts can be used in combination with: one or more other therapeutic agents useful for preventing or treating, for example, allergic diseases, inflammatory diseases or autoimmune diseases; antigen immunotherapy, antihistamines, steroids, NSAIDs, bronchodilators (e.g., β2 agonists, adrenergic agonists, anticholinergics, theophylline), methotrexate, leukotriene modifiers and the like; monoclonal antibody therapy, such as anti-IgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1 and the like; receptor therapy, such as etanercept and the like; antigen nonspecific immunotherapy (e.g., interferon or other cytokines / chemokines, cytokine / chemokine receptor modulators, cytokine agonists or antagonists, TLR agonists and the like).

[0157] The compounds of formula I and their pharmaceutically acceptable salts can be used in combination with radiation therapy and / or surgery and / or at least one other therapeutic agent useful for treating cancer and precancerous syndromes. Any anti-tumor agent that is active against the susceptible tumor being treated can be used in combination. Useful typical anti-tumor agents include, but are not limited to: (a) anti-microtubule agents, such as diterpenoids (e.g., paclitaxel, docetaxel) and vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine); (b) platinum coordination complexes (e.g., oxaliplatin, cisplatin, and carboplatin); (c) alkylating agents, such as nitrogen mustards (e.g., cyclophosphamide, melphalan, and chlorambucil), oxazaphosphorine, alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine), and triazenes (e.g., dacarbazine); (d) antibiotic agents, such as anthracyclines (e.g., daunorubicin and doxorubicin), actinomycins (e.g., (e) topoisomerase II inhibitors, such as epipodophyllotoxins (e.g., etoposide and teniposide); (f) antimetabolites, such as purine and pyrimidine analogs and antifolate compounds (e.g., fluorouracil, methotrexate, cytarabine, mercaptopurine, thioguanine and gemcitabine); (g) topoisomerase I inhibitors, such as camptothecins (e.g., irinotecan, topotecan and the various optical forms of 7-(4-methylpiperazinyl-methylene)-10,11-ethylenedioxy-20-camptothecin); (h) hormones and hormone analogs (e.g., adrenocortical steroids, such as prednisone and prednisolone, which can Used to treat childhood malignant lymphoma and acute leukemia; aminoglutethimide and other aromatase inhibitors, such as anastrozole, letrozole, vorozole and exemestane, which can be used to treat adrenocortical carcinoma and hormone-dependent breast cancer containing estrogen receptors; progestins, such as megestrol acetate, which can be used to treat hormone-dependent breast cancer and endometrial cancer; estrogens and anti-estrogens such as fulvestrant, flutamide, nilutamide, bicalutamide, cyproterone acetate and 5-reductase such as finasteride and dutasteride, which can be used to treat prostate cancer and benign prostatic hypertrophy; anti-estrogens such as tamoxifen, toremifene, raloxifene, droloxifene, edosterol 5,681,835, 5,877,219 and 6,207,716, which are useful in the treatment of hormone-dependent breast cancer and other susceptible cancers; and gonadotropin-releasing hormone (GnRH) and its analogs, which stimulate the release of leukocyte hormone (LH) and / or follicle stimulating hormone (FSH), useful in the treatment of prostate cancer, e.g., LHRH agonists and antagonists such as goserelin acetate and leuprolide); (i) signal transduction pathway inhibitors; (j) non-receptor tyrosine angiogenesis inhibitors;(k) immunotherapeutic agents (e.g., ex vivo and in vivo methods of increasing the immunogenicity of patient tumor cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, methods of reducing T cell energy, methods using transfected immune cells such as cytokine-transfected dendritic cells, methods using cytokine-transfected tumor cell lines and methods using anti-idiotypic antibodies); (l) pro-apoptotic agents (e.g., bcl-2 antisense oligonucleotides); (m) cell cycle signaling inhibitors; (n) immuno-oncology agents and (o) immunostimulatory agents. ;

[0158] Signal transduction pathway inhibitors

[0159] Signal transduction pathway inhibitors are those inhibitors that block or inhibit the chemical processes that cause changes in the cell. As used herein, this change is cell proliferation or differentiation. Signal transduction inhibitors that can be used for the present invention include inhibitors of receptor tyrosine kinases, non-receptor tyrosine kinases, SH2 / SH3 domain blockers, serine / threonine kinases, phosphatidylinositol-3 kinases, inositol signaling and Ras oncogenes.

[0160] Several protein tyrosine kinases catalyze the phosphorylation of specific tyrosyl residues in a variety of proteins involved in the regulation of cell growth. Such protein tyrosine kinases can be broadly classified as either receptor or non-receptor kinases.

[0161] Receptor tyrosine kinases are transmembrane proteins with an extracellular ligand binding domain, a transmembrane domain and a tyrosine kinase domain. Receptor tyrosine kinases are involved in the regulation of cell growth and are commonly referred to as growth factor receptors. Many inappropriate or uncontrolled activations of these kinases, i.e., abnormal kinase growth factor receptor activity, such as by overexpression or mutation, have been shown to lead to uncontrolled cell growth. Therefore, abnormal activity of such kinases has been associated with malignant tissue growth. Therefore, inhibitors of such kinases can provide cancer treatment methods. Growth factor receptors include, for example, epidermal growth factor receptor (EGFr), platelet-derived growth factor receptor (PDGFr), erbB2, erbB4, ret, vascular endothelial growth factor receptor (VEGFr), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), insulin growth factor-I (IGFI) receptor, macrophage colony stimulating factor (cfms), BTK, ckit, cmet, fibroblast growth factor (FGF) receptor, Trk receptor (TrkA, TrkB and TrkC), ephrin (eph) receptor and RET proto-oncogene. Several inhibitors of growth receptors are under development and include ligand antagonists, antibodies, tyrosine kinase inhibitors and antisense oligonucleotides. Growth factor receptors and agents that inhibit growth factor receptor function are described, for example, in Kath 2000; Shawver 1997; and Lofts 1994.

[0162] Tyrosine kinases that are not growth factor receptor kinases are referred to as non-receptor tyrosine kinases. Non-receptor tyrosine kinases that are targets or potential targets of anticancer drugs and that can be used in the present invention include cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (focal adhesion kinase), Bruton's tyrosine kinase, and Bcr-Abl. Such non-receptor kinases and agents that inhibit the function of non-receptor tyrosine kinases are described in Sinh 1999; and Bolen 1997.

[0163] SH2 / SH3 domain blockers are agents that disrupt SH2 or SH3 domain binding in a variety of enzymes or adaptor proteins including the PI3-K p85 subunit, Src family kinases, adaptor molecules (She, Crk, Nek, Grb2) and Ras-GAP. The SH2 / SH3 domain as a target for anticancer drugs is discussed in Smithgall 1995.

[0164] Inhibitors of serine / threonine kinases include: MAP kinase cascade blockers, including blockers of Raf kinase (rafk), mitogen or extracellular regulated kinase (MEK), and extracellular regulated kinase (ERK); and protein kinase C family member blockers, including blockers of PKC (α, β, γ, ε, μ, λ, ι, ζ), IkB kinase family (IKKa, IKKb), PKB family kinases, akt kinase family members, and TGFβ receptor kinase. Such serine / threonine kinases and their inhibitors are described in Yamamoto 1999; Brodt 2000; Massagué 1996; Philip 1995; Lackey 2000; U.S. Pat. No. 6,268,391; and Martínez-Lacaci 2000.

[0165] Inhibitors of members of the phosphatidylinositol-3 kinase family, including blockers of Pekinese, ATM, DNA-PK and Ku, may also be used in the present invention. Such kinases are discussed in Abraham 1996; Canman 1998; Jackson 1997; and Zhong 2000.

[0166] Also useful in the present invention are myo-inositol signaling inhibitors, such as phospholipase C blockers and myo-inositol analogs. Such signaling inhibitors are described in Powis 1994.

[0167] Another group of signal transduction pathway inhibitors are inhibitors of Ras oncogenes. Such inhibitors include inhibitors of farnesyltransferase, geranyl-geranyltransferase, and CAAX proteases, as well as antisense oligonucleotides, ribozymes, and immunotherapy. Such inhibitors have been shown to block ras activation in cells containing wild-type mutant ras, thereby acting as antiproliferative agents. Ras oncogene inhibition is discussed in Scharovsky 2000; Ashby 1998; and Oliff 1999.

[0168] As mentioned above, antibody antagonists for receptor kinase ligand binding can also be used as signal transduction inhibitors. This group of signal transduction pathway inhibitors includes the use of humanized antibodies directed against the extracellular ligand binding domain of receptor tyrosine kinases. For example, Imclone C225 EGFR-specific antibody (see Green 2000); erbB2 antibody (see Stern 2000); and 2CB VEGFR2-specific antibody (see Brekken 2000).

[0169] Non-receptor tyrosine angiogenesis inhibitors

[0170] Anti-angiogenic therapeutics including non-receptor MEK angiogenesis inhibitors may also be useful. Anti-angiogenic agents, such as those that inhibit the action of vascular endothelial growth factor (e.g., the anti-vascular endothelial growth factor antibody bevacizumab [Avastin TM ], and compounds that work by other mechanisms (e.g., linoamide, inhibitors of integrin αvβ3 function, endostatin, and angiostatin).

[0171] Cell cycle signaling inhibitors

[0172] Cell cycle signaling inhibitors inhibit molecules involved in the control of the cell cycle. The family of protein kinases known as cyclin-dependent kinases (CDKs) and their interaction with the protein family known as cyclins control the progression of the eukaryotic cell cycle. The coordination activation and inactivation of different cyclin / CDK complexes are necessary for the normal progression of the cell cycle. Several inhibitors of cell cycle signaling are under development. For example, cyclin-dependent kinases (including CDK2, CDK4 and CDK6) and examples of inhibitors thereof are described in, for example, Rosania 2000.

[0173] Immunomodulators

[0174] Other examples of other therapeutic agents (e.g., antitumor agents) for use in combination or co-administration with a compound of Formula I are immunomodulators. As used herein, "immunomodulator" refers to any substance that affects the immune system, including monoclonal antibodies. Immunomodulators can be used as antitumor agents for the treatment of cancer. For example, immunomodulators include but are not limited to anti-CTLA-4 antibodies, such as Ipilimumab (YERVOY) and anti-PD-1 antibodies (Opdivo / nivolumab and Keruida / pembrolizumab). Other immunomodulators include but are not limited to ICOS antibodies, OX-40 antibodies, PD-L1 antibodies, LAG3 antibodies, TIM-3 antibodies, 41BB antibodies, and GITR antibodies.

[0175] Anti-PD-L1 agents

[0176] Another example of other therapeutic agents (anti-tumor agents) for combined or co-administered with the compounds of the present invention is an anti-PD-L1 agent. Anti-PD-L1 antibodies and methods for preparing them are known in the art. Such antibodies against PD-L1 can be polyclonal or monoclonal, and / or recombinant, and / or humanized. Exemplary PD-L1 antibodies are disclosed in U.S. Patents Nos. 8217149, 8383796, 8552154, 9212224, and 8779108 and U.S. Patent Application Publication Nos. 2011 / 0280877, 2014 / 0341902, and 2013 / 0045201. Additional exemplary antibodies to PD-L1 (also known as CD274 or B7-H1) and methods of use thereof are disclosed in U.S. Pat. Nos. 7,943,743, 8,168,179, and 7,595,048; WO 2014 / 055897, WO 2016 / 007235; and U.S. Patent Application Publication Nos. 2013 / 0034559 and 2015 / 0274835. PD-L1 antibodies are being developed as immunomodulators for the treatment of cancer.

[0177] In one embodiment, the antibody to PD-L1 is an antibody disclosed in U.S. Patent No. 8217149. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of the antibody disclosed in U.S. Patent No. 8217149. In another embodiment, the antibody to PD-L1 is an antibody disclosed in U.S. Patent No. 8779108. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of the antibody disclosed in U.S. Application No. 8779108. In another embodiment, the antibody to PD-L1 is an antibody disclosed in U.S. Patent Application Publication No. 2013 / 0045201. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of the antibody disclosed in U.S. Patent Application Publication No. 2013 / 0045201. In one embodiment, the anti-PD-L1 antibody is BMS-936559 (MDX-1105) described in WO 2007 / 005874. In another embodiment, the anti-PD-L1 antibody is MPDL3280A (RG7446). In another embodiment, the anti-PD-L1 antibody is MEDI4736, which is an anti-PD-L1 monoclonal antibody described in WO 2011 / 066389 and US 2013 / 034559. In another embodiment, the anti-PD-L1 antibody is TECENTRIQ TM(atezolizumab), which is an anti-PD-L1 cancer immunotherapy, was approved in the United States in May 2016 for a specific type of bladder cancer. In another embodiment, the anti-PD-L1 antibody is YW243.55.S70, which is an anti-PD-L1 described in WO 2010 / 077634 and U.S. Pat. No. 8217149. Examples of anti-PD-L1 antibodies useful for the methods of the present invention and methods of making them are described in PCT patent applications WO 2010 / 077634, WO 2007 / 005874, WO 2011 / 066389, U.S. Pat. No. 8217149, and US 2013 / 034559.

[0178] PD-1 antagonists

[0179] Another example of other therapeutic agents (anti-tumor agents) used in combination or co-administration with the compounds of the present invention is a PD-1 antagonist. "PD-1 antagonist" refers to any chemical compound or biological molecule that blocks the binding of PD-L1 expressed on cancer cells to PD-1 expressed on immune cells (T cells, B cells or NKT cells), and preferably also blocks the binding of PD-L2 expressed on cancer cells to PD-1 expressed by immune cells. Alternative names or synonyms for PD-1 and its ligands include: for PD-1, PDCD1, PD1, CD279 and SLEB2; for PD-L1, PDCD1L1, PDL1, B7H1, B7-4, CD274 and B7-H; and for PD-L2, PDCD1L2, PDL2, B7-DC, Btdc and CD273. In any embodiment of the aspects or embodiments of the invention where a human subject is to be treated, the PD-1 antagonist blocks the binding of human PD-L1 to human PD-1, and preferably blocks the binding of both human PD-L1 and PD-L2 to human PD-1. The human PD-1 amino acid sequence can be found in NCBI Locus No. NP 005009. The human PD-L1 and PD-L2 amino acid sequences can be found in NCBI Locus Nos. NP054862 and NP 079515, respectively.

[0180] PD-1 antagonists useful in any aspect of the present invention include monoclonal antibodies (mAbs) or antigen-binding fragments thereof that specifically bind to PD-1 or PD-L1, and preferably specifically bind to human PD-1 or human PD-L1. mAbs can be human antibodies, humanized antibodies, or chimeric antibodies, and can include human constant regions. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in preferred embodiments, the human constant region is IgG1 or IgG4 constant region. In some embodiments, the antigen-binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.

[0181] Examples of mAbs that bind to human PD-1 and are useful in various aspects and embodiments of the invention are described in US7488802, US7521051, US8008449, US8354509, US8168757, WO2004 / 004771, WO2004 / 072286, WO2004 / 056875 and US2011 / 0271358. Specific anti-human PD-1 mAbs that can be used as PD-1 antagonists in any aspects and embodiments of the present invention include: MK-3475, a humanized IgG4 mAb having a structure described in WHO Drug Information, Vol. 27, No. 2, pp. 161-162 (2013), and comprising the heavy chain and light chain amino acid sequences shown in Figure 6; nivolumab, a human IgG4 mAb having a structure described in WHO Drug Information, Vol. 27, No. 1, pp. 68-69 (2013), and comprising the heavy chain and light chain amino acid sequences shown in Figure 7; humanized antibodies h409All, h409A16 and h409A17 described in WO2008 / 156712, and AMP-514 being developed by Medimmune.

[0182] Other PD-1 antagonists useful in any aspect and embodiment of the invention include immunoadhesins that specifically bind to PD-1, and preferably specifically bind to human PD-1, such as fusion proteins comprising the extracellular or PD-1 binding portion of PD-L1 or PD-L2, fused to a constant region such as the Fc region of an immunoglobulin molecule. Examples of immunoadhesion molecules that specifically bind to PD-1 are described in WO2010 / 027827 and WO2011 / 066342. Specific fusion proteins that can be used as PD-1 antagonists in the methods of treatment, medicaments and uses of the invention include AMP-224 (also known as B7-DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.

[0183] Other examples of mAbs that bind to human PD-L1 and can be used in the methods of treatment, medicines and uses of the present invention are described in WO2013 / 019906, WO2010 / 077634 and US8383796. Specific anti-human PD-L1 mAbs that can be used as PD-1 antagonists in the methods of treatment, medicines and uses of the present invention include MPDL3280A, BMS-936559, MEDI4736, MSB0010718C.

[0184] KEYTRUDA / pembrolizumab is an anti-PD-1 antibody marketed by Merck for the treatment of lung cancer. The amino acid sequence and methods of use of pembrolizumab are disclosed in U.S. Patent No. 8,168,757.

[0185] Opdivo / Nivolumab is a fully human monoclonal antibody sold by Bristol Myers Squibb that targets the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-l / PCD-1) and has immunoenhancing activity. Nivolumab binds to and blocks the activation of PD-1 (an Ig superfamily transmembrane protein) through its ligands PD-L1 and PD-L2, leading to the activation of T cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T cell activation and effector function by inhibiting the activation of the PI3K / Akt pathway. Other names for Nivolumab include: BMS-936558, MDX-1106, and ONO-4538. The amino acid sequence of Nivolumab and methods of use and preparation are disclosed in U.S. Patent No. US 8008449.

[0186] Anti-ICOS antibody

[0187] Another example of other therapeutic agents (anti-tumor agents) for use in combination or co-administration with the compounds of Formula I is an antibody against ICOS. ICOS is a co-stimulatory T cell receptor whose structure and function are related to the CD28 / CTLA-4-Ig superfamily (Hutloff 1999). Activation of ICOS occurs by binding to ICOS-L (B7RP-1 / B7-H2). Neither B7-1 nor B7-2 (ligands for CD28 and CTLA4) binds or activates ICOS. However, ICOS-L has been shown to bind weakly to both CD28 and CTLA-4 (Yao 2011). The expression of ICOS appears to be limited to T cells. The expression level of ICOS varies between different T cell subsets and in T cell activation states. ICOS expression has been shown on resting TH17, follicular helper T cells (TFH), and regulatory T cells (Treg); however, unlike CD28; it is not highly expressed in naive TH1 and TH2 effector T cell populations (Paulos 2010). ICOS expression is highly induced on CD4+ and CD8+ effector T cells following activation via TCR engagement (Wakamatsu 2013).

[0188] The CDRs of murine antibodies against human ICOS with agonistic activity are shown in PCT / EP2012 / 055735 (WO 2012 / 131004). Antibodies against ICOS are also disclosed in WO 2008 / 137915, WO 2010 / 056804, EP1374902, EP1374901 and EP1125585. Agonist antibodies against ICOS or ICOS binding proteins are disclosed in WO2012 / 131004, WO2014 / 033327, WO2016 / 120789, US20160215059 and US20160304610. In one embodiment, an agonist antibody against ICOS comprises an ICOS binding protein, or an antigen binding portion thereof, comprising one or more of: CDRH1 as set forth in SEQ ID NO: 1; CDRH2 as set forth in SEQ ID NO: 2; CDRH3 as set forth in SEQ ID NO: 3; CDRL1 as set forth in SEQ ID NO: 4; CDRL2 as set forth in SEQ ID NO: 5 and / or CDRL3 as set forth in SEQ ID NO: 6, or a direct equivalent of each CDR, wherein the direct equivalent has no more than two amino acid substitutions in the CDRs, as disclosed in WO2016 / 120789, which is incorporated herein by reference in its entirety. In one embodiment, the ICOS binding protein, or an antigen binding portion thereof, is an agonist antibody to ICOS comprising a VH domain comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 7 as set forth in WO2016 / 120789 and / or a VL domain comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 8 as set forth in WO2016 / 120789, wherein the ICOS binding protein specifically binds to human ICOS. In one embodiment, the ICOS binding protein is an agonist antibody to ICOS comprising a VH domain comprising an amino acid sequence set forth in SEQ ID NO: 7 as set forth in WO2016 / 120789 and a VL domain comprising an amino acid sequence set forth in SEQ ID NO: 8 as set forth in WO2016 / 120789. Yervoy (ipilimumab) is a fully human CTLA-4 antibody marketed by Bristol Myers Squibb. The protein structure and methods of use of ipilimumab are described in U.S. Patent Nos. 6,984,720 and 7,605,238.

[0189] CD134, also known as OX40, is a member of the TNFR receptor superfamily and, unlike CD28, is not constitutively expressed on resting naive T cells. OX40 is a secondary co-stimulatory molecule expressed 24 to 72 hours after activation; its ligand OX40L is also not expressed on resting antigen-presenting cells, but is expressed after their activation. The expression of OX40 depends on the full activation of T cells; in the absence of CD28, the expression of OX40 is delayed and the expression level is reduced fourfold. OX-40 antibodies, OX-40 fusion proteins and methods of use thereof are disclosed in U.S. Patent Nos. US 7504101; US ​​7758852; US 7858765; US7550140; US 7960515; WO2012 / 027328; WO2013 / 028231. In one embodiment, the OX40 antigen binding protein is an OX40 antigen binding protein disclosed in WO2012 / 027328 (PCT / US2011 / 048752), filed on August 23, 2011. In another embodiment, the antigen binding protein comprises a CDR of an antibody disclosed in WO2012 / 027328 (PCT / US2011 / 048752), filed on August 23, 2011, or a CDR with 90% identity to the disclosed CDR sequence. In a further embodiment, the antigen binding protein comprises a VH, a VL, or both of an antibody disclosed in WO2012 / 027328 (PCT / US2011 / 048752), filed on August 23, 2011, or a VH or VL with 90% identity to the disclosed VH or VL sequence.

[0190] In another embodiment, the OX40 antigen binding protein is disclosed in WO2013 / 028231 (PCT / US2012 / 024570), which has an international filing date of February 9, 2012, which is incorporated herein by reference in its entirety. In another embodiment, the antigen binding protein comprises a CDR of an antibody disclosed in WO2013 / 028231 (PCT / US2012 / 024570), which has an international filing date of February 9, 2012, or a CDR having 90% identity with the disclosed CDR sequence. In an additional embodiment, the antigen binding protein comprises a VH, a VL, or both of an antibody disclosed in WO2013 / 028231 (PCT / US2012 / 024570), which has an international filing date of February 29, 2012, or a VH or VL having 90% identity with the disclosed VH or VL sequence. In one embodiment, the OX40 antigen binding protein is an isolated agonist antibody against OX40 comprising a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 10 as set forth in WO2013 / 028231, and a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 4 as set forth in WO2013 / 028231. In one embodiment, the OX40 antigen binding protein is an isolated antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10 as set forth in WO2013 / 028231, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 as set forth in WO2013 / 028231.

[0191] Immunostimulants

[0192] For other therapeutic agents combined or co-administered with the compound of Formula I or its salt, other examples are immunostimulants. "Immunostimulant" as used herein refers to any agent that can stimulate the immune system. Immunostimulants as used herein include but are not limited to vaccine adjuvants, such as Toll-like receptor agonists, T cell checkpoint blockers, such as mAbs and T cell checkpoint agonists for PD-1 and CTL4, such as agonist mAbs for OX-40 and ICOS. "Immunostimulant" as used herein refers to any agent that can stimulate the immune system. Immunostimulants as used herein include but are not limited to vaccine adjuvants.

[0193] As used herein, the term "Toll-like receptor" (or "TLR") refers to a member of the Toll-like receptor protein family or a fragment thereof, which senses microbial products and / or initiates an adaptive immune response. In one embodiment, TLR activates dendritic cells (DC). Toll-like receptors (TLRs) are a family of pattern recognition receptors that were originally identified as sensors of the innate immune system that recognize microbial pathogens. TLRs recognize different structures in microorganisms, commonly referred to as "PAMPs" (pathogen-associated molecular patterns). The binding of ligands to TLRs triggers a series of intracellular signal transduction pathways that induce the production of factors involved in inflammation and immunity. In humans, 10 TLRs have been identified. TLRs expressed on the surface of cells include TLR-1, TLR-2, TLR-4, TLR-5, and TLR-6, ​​while TLR-3, TLR-7 / 8, and TLR-9 are expressed in the ER compartment. Human DC subsets can be identified based on different TLR expression patterns. For example, myeloid or “conventional” DC subsets (mDCs) express TLRs 1–TLR 8 upon stimulation and produce a range of activation markers (e.g., CD80, CD86, MHC class I and II, CCR7), proinflammatory cytokines, and chemokines. The result of this stimulation and resulting expression is the priming of antigen-specific CD4+ and CD8+ T cells. These DCs acquire an enhanced ability to take up antigens and present them to T cells in an appropriate form. In contrast, plasmacytoid DC subsets (pDCs) express only TLR7 and TLR9 upon activation, leading to the activation of NK cells as well as T cells. Because dying tumor cells may adversely affect DC function, it has been proposed that activation of DCs with TLR agonists may be beneficial for eliciting anti-tumor immunity in immunotherapy for the treatment of cancer. It has also been proposed that TLR4 activation is required for the successful treatment of breast cancer using radiation and chemotherapy.

[0194] TLR agonists known in the art and found to be used in the present invention include, but are not limited to, the following: Pam3Cys, a TLR1 / 2 agonist; CFA, a TLR2 agonist; MALP2, a TLR2 agonist; Pam2Cys, a TLR2 agonist; FSL-I, a TLR-2 agonist; Hib-OMPC, a TLR-2 agonist; polyinosinic acid:polycytidylic acid (Poly I:C), a TLR3 agonist; polyadenosine-polyuridylic acid (poly AU), a TLR3 agonist; polyinosinic acid-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (Hiltonol), a TLR3 agonist; bacterial flagellin, a TLR5 agonist; imiquimod, a TLR7 agonist; resiquimod, a TLR7 / 8 agonist; loxoribine, a TLR7 / 8 agonist; and non-methylated CpG dinucleotides (CpG-ODN), a TLR9 agonist.

[0195] Other TLR agonists known in the art and found to be used in the present invention also include but are not limited to aminoalkyl glucosamine phosphates (AGP) bound to TLR4 receptors, which are known to be used as vaccine adjuvants and immunostimulants for stimulating cytokine production, activating macrophages, promoting innate immune responses and enhancing antibody production in immune animals. The example of naturally occurring TLR4 agonists is bacterial LPS. The example of semi-synthetic TLR4 agonists is monophosphoryl lipid A (MPL). AGP and its immunomodulatory effect by TLR4 are disclosed in patent publications such as WO 2006 / 016997, WO 2001 / 090129 and / or U.S. Patent No. 6113918, and have been reported in the literature. Other AGP derivatives are disclosed in U.S. Patent No. 7129219, U.S. Patent No. 6525028 and U.S. Patent No. 6911434. Some AGPs serve as agonists of TLR4, while other AGPs are considered to be antagonists of TLR4.

[0196] In addition to the immunostimulants described above, the compositions of the present invention may also include other therapeutic agents that, due to their adjuvant properties, can be used to stimulate the immune system to respond to cancer antigens present on inactivated tumor cells. Such adjuvants include, but are not limited to, lipids, liposomes, inactivated bacteria that induce innate immunity (e.g., inactivated or attenuated Listeria monocytogenes), compositions that mediate innate immune activation through (NOD)-like receptors (NLR), retinoic acid-induced gene-based (RIG)-I-like receptors (RLR) and / or C-type lectin receptors (CLR). Examples of PAMPs include lipoproteins, lipopolypeptides, peptidoglycans, yeast polysaccharides, lipopolysaccharides, neisserial porins, flagellins, profillin, galactosylceramide, muramyl dipeptides. Peptidoglycans, lipoproteins, and lipoteichoic acid are cell wall components of gram-positive bacteria. Lipopolysaccharides are expressed by most bacteria, of which MPL is an example. Flagellin refers to the structural component of bacterial flagella secreted by pathogenic and commensal bacteria, rt-galactosylceramide (rt.-GalCer) is an activator of natural killer T (NKT) cells. Muramyl dipeptide is a biologically active peptidoglycan motif shared by all bacteria.

[0197] Due to their adjuvant properties, TLR agonists are preferably used in combination with other vaccines, adjuvants and / or immunomodulators, and can be combined in various combinations. Thus, in certain embodiments, the compounds of Formula I described herein that bind to STING and induce STING-dependent TBKI activation and inactivated tumor cells that express and secrete one or more cytokines that stimulate DC induction, recruitment and / or maturation, as described herein, can be administered together with one or more TLR agonists for therapeutic purposes.

[0198] Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunosuppressive enzyme that regulates anti-tumor immune responses by promoting the generation of regulatory T cells and blocking the activation of effector T cells, thereby promoting tumor growth by allowing cancer cells to evade immune surveillance (Lemos 2016; Munn 2016). The other active ingredient (antitumor agent) used in combination or co-administration with the compound of formula I of the present invention is an IDO inhibitor. Epacadostat ((Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[2-(aminosulfonylamino)ethylamino]-l,2,5-oxadiazole-3-carboxamide) is a highly potent and selective oral inhibitor of the IDO1 enzyme that reverses tumor-associated immunosuppression and restores effective anti-tumor immune responses. Epacadostat is disclosed in U.S. Patent No. 8,034,953.

[0199] Further examples of other therapeutic agents (anti-tumor agents) for combination or co-administration with compounds of Formula I are CD73 inhibitors and A2a and A2b adenosine antagonists.

[0200] The compounds of Formula I and their pharmaceutically acceptable salts may be used in combination with at least one other therapeutic agent useful in preventing or treating bacterial and viral infections. Examples of such agents include, but are not limited to, polymerase inhibitors such as those disclosed in WO 2004 / 037818, and those disclosed in WO 2004 / 037818 and WO 2006 / 045613; JTK-003, JTK-019, NM-283, HCV-796, R-803, R1728, R1626, and those disclosed in WO 2006 / 018725, WO 2004 / 074270, WO 2003 / 095441, US 2005 / 0176701, WO 2006 / 020082, WO 2005 / 080388, WO 2004 / 064925, WO 2004 / 065367, WO 2003 / 007945, WO 02 / 04425、WO 2005 / 014543、WO 2003 / 000254、EP 1065213、WO 01 / 47883、WO 2002 / 057287、WO those disclosed in 2002 / 057245 and similar agents; replication inhibitors such as acyclovir, famciclovir, ganciclovir, cidofovir, lamivudine and similar agents; protease inhibitors such as the HIV protease inhibitors saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, atazanavir, tipranavir, palinavir, lasinavir and the HCV protease inhibitors BILN2061, VX-950, SCH503034 and similar agents; nucleoside and nucleotide reverse transcriptase inhibitors such as zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, androxivir, efavirin, tenofovir disoproxil fumarate Pirofuroxil, tenofovir alafenamide fumarate / hemifumarate and similar agents; non-nucleoside reverse transcriptase inhibitors (including agents with antioxidant activity, such as immunocal, oltipraz, etc.) such as nevirapine, delavirdine, efavirenz, loviramide, immunocal, oltipraz, capravirine, TMC-278, TMC-125, etravirine, rilpivirine and similar agents; entry inhibitors such as enfuvirtide (T-20), T-1249, PRO-542, PRO-140, TNX-355, BMS-806, 5-Helix and similar agents; integrase inhibitors such as dolutegravir, elvitegravir, raltegravir L-870, 180 and similar agents; budding inhibitors such as PA-344 and PA-457 and similar agents;Chemokine receptor inhibitors, such as vicriviroc (Sch-C), Sch-D, TAK779, maraviroc (UK-427,857), TAK449, and those described in WO 02 / 74769, WO 2004 / 054974, WO 2004 / 055012, WO 2004 / 055010, WO 2004 / 0555016, WO 2004 / 055011 and 2004 / 054581 and similar agents; pharmacokinetic enhancers, such as cobicistat; neuraminidase inhibitors, such as CS-8958, zanamivir, oseltamivir, peramivir and similar agents; ion channel blockers, such as amantadine or rimantadine and similar agents; and interfering RNA and antisense oligonucleotides, and such as ISIS-14803 and similar agents; antiviral agents with an undetermined mechanism of action, such as those disclosed in WO2005 / 105761, WO 2003 / 085375, WO 2006 / 122011, ribavirin and similar agents. The compounds of formula I and their pharmaceutically acceptable salts may also be used in combination with other therapeutic agents useful for treating Kaposi's sarcoma-associated herpesvirus infection (KSHV and KSHV-associated), including but not limited to chemotherapeutic agents such as bleomycin, vinblastine, vincristine, cyclophosphamide, prednisone, alitretinoin and liposomal anthracyclines such as doxorubicin, daunorubicin, immunotherapeutic agents such as rituximab, tocilizumab, siltuximab and other agents such as paclitaxel and rapamycin. ;

[0201] In one embodiment of the present invention, at least one other therapeutic agent is an antimycobacterial agent or a bactericidal antibiotic. The compound of formula I and its pharmaceutically acceptable salt can also be used in combination with at least one other therapeutic agent that can be used to treat TB infection (Mycobacterium tuberculosis) and tularemia (Francisco tularensis), including but not limited to first-line oral agents isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, rifabutin; injections, including kanamycin, amikacin, capreomycin, streptomycin; fluoroquinolones, including levofloxacin, moxifloxacin, ofloxacin; oral antibacterial agents aminosalicylic acid, cycloserine, Terizidone, thiocarbamide, prothionamide; SQ-109, PNU-100480, rifapentine, linezolid, PA-824, AZD5847, gatifloxacin, moxifloxacin, Sirturo (bedaquiline), delamanid (OPC-67683) and agents with undetermined mechanisms of action for the treatment of drug-resistant TB, including clofazimine, linezolid, amoxicillin / clavulanic acid, thiophenylthiocarbamide, imipenem / cilastatin, high-dose isoniazid, clarithromycin, ciprofloxacin. The compounds of formula I and their pharmaceutically acceptable salts can also be used in combination with antimycobacterial agents (such as isoniazid (INH), ethambutol Rifampin and pyrazinamide (PZA)), bactericidal antibiotics (such as rifabutin or rifapentine ), aminoglycosides Fluoroquinolones (levofloxacin, moxifloxacin, ofloxacin), thioamides (ethionamide), cyclosporine Para-aminosalicylic acid Cycloserine Kanamycin Streptomycin, viomycin, capreomycin ), bedaquiline fumarate Oxazolidinone PNU-100480 or delamanid (OPC-67683) in combination.

[0202] The compounds of formula I and their pharmaceutically acceptable salts can also be used in combination with at least one other therapeutic agent useful for treating Chlamydia, including but not limited to azithromycin, doxycycline, erythromycin, levofloxacin, and ofloxacin.

[0203] The compounds of the present invention may also be used in combination with at least one other therapeutic agent useful for treating Plasmodium infection, including but not limited to chloroquine, atovaquone-proguanil, artemether-lumefantrine, mefloquine, quinine, quinidine, doxycycline, clindamycin, artesunate, and primaquine.

[0204] In the treatment of amyotrophic lateral sclerosis (ALS), the compound of formula I or a pharmaceutically acceptable salt thereof can be used in combination with a glutamate blocker (riluzole) ), Quinidine Anticholinergics Scopolamine patch (Transderm )), sympathomimetics (pseudoephedrine), mucolytics (guaifenesin), or analgesics (tramadol) Ketorolac Morphine; fentanyl patch ) used in combination.

[0205] In the treatment of multiple sclerosis, the compound of formula I or a pharmaceutically acceptable salt thereof can be used in combination with corticosteroids (prednisone, methylprednisolone), interferon β1-A Pegylated interferon beta-IA Glatiramer Acetate Glatiramer Acetate -General equivalent of Copaxone); Dimethyl fumarate Fingolimod ); teriflunomide Dalfampridine Daclizumab (Zinbryta); Alemtuzumab Natalizumab Mitoxantrone hydrochloride Used in combination.

[0206] The compounds of the invention may also be used as adjuvants to improve the immune response and / or reduce the reactogenicity / toxicity elicited by any given antigen in patients, particularly humans, in need thereof. Thus, the compounds of the invention may be used in conjunction with vaccine compositions to modify (particularly enhance) the immune response, for example by increasing the level or duration of protection and / or allowing a reduction in the antigen dose.

[0207] The compound of formula I and its pharmaceutically acceptable salt can be used in combination with one or more vaccines or immunogenic antigens that can be used to prevent or treat viral infections. Such vaccines or immunogenic antigens include, but are not limited to, pathogen-derived proteins or particles, such as attenuated viruses, viral particles, and viral proteins commonly used as immunogenic substances. Examples of viruses and viral antigens include, but are not limited to, poliovirus, Coronavirus family and coronavirus, rhinovirus (all subtypes), adenovirus (all subtypes), hepatitis A, hepatitis B, hepatitis C, hepatitis D, human papillomavirus (including all subtypes), rabies virus, human T-cell lymphotropic virus (all subtypes), rubella virus, mumps virus, coxsackie virus A (all subtypes), coxsackie virus B (all subtypes), human enterovirus, herpes virus (including cytomegalovirus), Epstein-Barr virus, human herpes virus (all subtypes), herpes simplex virus, varicella zoster virus, human immunodeficiency virus (HIV) (all subtypes), Epstein-Barr virus, reovirus (all subtypes), Filoviruses (including Marburg and Ebola (all strains)), Arenaviruses (including Lymphocytic Choriomeningitis, Lassa, Junin and Machupo), Arboviruses (including West Nile, Dengue (all serotypes), Zika, Colorado tick fever, Sindbis, Togaviridae, Flaviviridae, Bunyaviridae, Reoviridae, Rhabdoviridae, Orthomyxoviridae), Poxviruses (including Orthopoxviruses (Variola, Monkeypox, Vaccinia, Vaccinia), Topoxviruses (Tenapox, Yaba monkey tumor virus), Parapoxviruses, Molluscumpoxviruses, Yellow fever, Hantaviruses (including Hantavirus, Seoul, Dobrava, Sin Nombre virus, Puumala virus and Dobrava-like salama virus), human parainfluenza virus and influenza virus (all types), H1N1 influenza and swine influenza virus, respiratory syncytial virus (all subgroups), rotavirus (including human rotavirus AE, bovine rotavirus, rhesus monkey rotavirus), polyomavirus (including simian virus 40, JC virus, BK virus, tick virus, echinovirus, calciviruses) and Parvoviridae (including dependovirus, parvovirus and erythrovirus).

[0208] Therefore, the present invention provides an immunogenic composition comprising an antigen or antigenic composition and a compound of formula I or a pharmaceutically acceptable salt thereof. A vaccine composition is also provided, comprising an antigen or antigenic composition and a compound of formula I or a pharmaceutically acceptable salt thereof. The compound of formula I and its pharmaceutically acceptable salt may also be used in combination with at least one other therapeutic agent that can be used to prevent or treat viral infection, such as immunotherapy (e.g., interferon or other cytokines / chemokines, cytokine / chemokine receptor modulators, cytokine agonists or antagonists and the like); and therapeutic vaccines, antifibrotic agents, anti-inflammatory agents such as corticosteroids or NSAIDs (non-steroidal anti-inflammatory drugs) and the like.

[0209] Compounds that modulate STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, can be administered in combination with other anti-inflammatory agents, including oral or topical corticosteroids, anti-TNF agents, 5-aminosalicylic acid and mesalamine preparations, hydroxychloroquine, thiopurines, methotrexate, cyclophosphamide, cyclosporin, calcineurin inhibitors, mycophenolic acid, mTOR inhibitors, JAK inhibitors, Syk inhibitors, anti-inflammatory biologics, including anti-IL6 biologics, anti-IL1 agents, anti-IL17 biologics, anti-CD22, anti-integrin agents, anti-IFNa, anti-CD20 or CD4 biologics, and other cytokine inhibitors or biologics directed against T cell or B cell receptors or interleukins.

[0210] For example, in the treatment of systemic lupus erythematosus and related lupus disorders, compounds that modulate STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, can be administered in combination with at least one other therapeutic agent, including a corticosteroid (such as prednisolone ( Orapred, Millipred, prednisolone acetate (Omnipred), prednisolone acetate (Econopred), Flo-Pred), immunosuppressants (such as methotrexate Dexamethasone Mycophenolate mofetil B cell therapy (belimumab B cell inhibitors ( (anti-CD22), SBI-087 (anti-CD20), anti-BAFF antibody (LY2127399, A623), )), Azathioprine Triamcinolone acetonide Hydroxychloroquine Thalidomide Immunoglobulin therapy Anti-interferon-α therapy ( IFN Kinoid), TLR7 and TLR9 blockers (IMO-3100), anti-cytokine therapy (anti-IL6 (CNTO-136), anti-interferon gamma (AMG811), immunomodulatory therapy (Lupuzor TM , Abatacept, AMG557, laquinimod, paquinimod, leflunomide, anti-ICOS (Medi-570), anti-CD40 ligand antibody (CDP7657), and / or platelet aggregation inhibitor (aspirin).

[0211] In the treatment of vasculitis and diseases associated with inflammation of small or medium-sized vessels, compounds that modulate STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, can be combined with alkylating agents (cyclophosphamide, ), anti-rheumatic anti-CD20 antibody and anti-TNF inhibitors Combined administration.

[0212] In the treatment of psoriasis, compounds that modulate STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, may be administered in combination with ixekizumab, tildrakizumab (MK-3222) or secukinumab (AIN457). In one embodiment of the invention, at least one additional therapeutic agent is selected from an inhaled corticosteroid, a long-acting beta agonist, a combination of an inhaled corticosteroid and a long-acting beta agonist, a short-acting beta agonist, a leukotriene modifier, an anti-IgE, a methylxanthine bronchodilator, a mast cell inhibitor, and a long-acting muscarinic antagonist. For example, in the treatment of asthma, compounds that inhibit STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, may be administered in combination with an inhaled corticosteroid (ICS) such as fluticasone propionate. Beclomethasone dipropionate Budesonide (Pulmicort), triamcinolone Flunisolide Mometasone furoate Ciclesonide ), long-acting beta agonists (LABAs) such as formoterol fumarate Salmeterol xinafoate ), ICS and LABA combinations (such as fluticasone furoate and vilanterol (Breo ), formoterol / budesonide inhaler Beclomethasone dipropionate / Formoterol and fluticasone propionate / salmeterol Short-acting beta-agonists (SABAs) such as albuterol sulfate ( Proventil Ventolin Inhalation solution), levosalbutamol tartrate ( HFA), ipratropium / salbutamol Ipratropium bromide ( HFA), leukotriene modifiers (such as montelukast sodium Zafirlukast or Qiliutong and anti-IgE (such as omalizumab ), methylxanthine bronchodilators (such as theophylline Mast cell inhibitors (such as cromolyn sodium Nedocromil sodium ), long-acting muscarinic antagonists (LAMA) such as mometasone furoate / formoterol fumarate dihydrate ).

[0213] Other agents that may be suitable for combination therapy to treat asthma include protein tyrosine kinase inhibitors (masitinib), CRTH2 / D-prostaglandin receptor antagonists (AMG 853), indacaterol Epinephrine inhalation aerosol (E004), fluticasone furoate / fluticasone propionate, vinanterol inhaler / fluticasone furoate powder (Relovair TM ), Fluticasone Propionate / Formoterol Fumarate Dehydrating Agent Reslizumab, salbutamol dry powder inhaler, tiotropium bromide Formoterol / budesonide Fluticasone furoate Vectura's VR506, lebrikizumab (RG3637), and a combination of phosphodiesterase (PDE)-3 and (PDE)-4 inhibitors (RPL554).

[0214] In one embodiment of the invention, at least one other therapeutic agent is selected from a combination of a long-acting beta agonist, a long-acting inhaled anticholinergic or muscarinic antagonist, a phosphodiesterase inhibitor, an inhaled corticosteroid, a long-acting beta agonist, a short-acting beta agonist, and an inhaled corticosteroid. For example, in the treatment of COPD, a compound that modulates STING, particularly a compound of Formula I or a pharmaceutically acceptable salt thereof, can be administered in combination with a LABA (such as salmeterol xinafoate (Serevent), umeclidinium bromide / vilanterol (Anoro ), Umeclidinium bromide (Incruse ), Formoterol tartrate Formoterol Fumarate Inhalation Powder Indacaterol Maleate or fluticasone propionate / formoterol fumarate dehydrate ), long-acting inhaled anticholinergics (or muscarinic antagonists such as tiotropium and aclidinium bromide Phosphodiesterase (PDE-r) inhibitors (such as roflumilast, ), combined ICS / LABA (such as fluticasone furoate and vilanterol (Breo ), Fluticasone Propionate / Salmeterol Budesonide / Formoterol Mometasone / Formoterol Ipratropium bromide / salbutamol sulfate Salbutamol / ipratropium (Combivent )), SABA (such as ipratropium bromide and salbutamol sulfate ) and ICS (such as budesonide and fluticasone propionate Beclomethasone dipropionate

[0215] Other agents that may be suitable for combination therapy to treat COPD include SCH527123 (a CXCR2 antagonist), glycopyrrolate ((NVA237) ), glycopyrrolate and indacaterol maleate ((QVA149) ), glycopyrrolate and formoterol fumarate (PT003), indacaterol maleate (QVA149), olodaterol Tiotropium bromide / Odatero and aclidinium / formoterol inhaler.

[0216] In one embodiment of the invention, at least one additional therapeutic agent is selected from oral corticosteroids, antithymocyte globulin, thalidomide, chlorambucil, calcium channel blockers, topical emollients, ACE inhibitors, serotonin reuptake inhibitors, endothelin-1 receptor inhibitors, antifibrotic agents, proton pump inhibitors or imatinib, ARG201 and tocilizumab. For example, in the treatment of systemic scleroderma, compounds that modulate STING, in particular compounds of Formula I or pharmaceutically acceptable salts thereof, can be administered in combination with oral corticosteroids (such as prednisolone ( Orapred, Millipred, Omnipred, Econopred, Flo-Pred), immunosuppressants (such as methotrexate Cyclosporine Antithymocyte globulin Mycophenolate mofetil Cyclophosphamide FK506 (tacrolimus), thalidomide Chlorambucil Azathioprine ), calcium channel blockers (such as nifedipine or nicardipine Topical emollients (nitroglycerin ointment), ACE inhibitors (such as lisinopril Diltiazem ( Cardizem Cardizem )), serotonin reuptake inhibitors (such as fluoxetine ), endothelin-1 receptor inhibitors (such as bosentan Epoprostenol ), antifibrotic drugs (such as colchicine Para-aminobenzoic acid (PABA), dimethyl sulfoxide (DMSO), and D-penicillamine Interferon alpha and interferon gamma (INF-g), proton pump inhibitors (such as omeprazole Metoclopramide Lansoprazole Esomeprazole Pantoprazole Rabeprazole ) or imatinib ARG201 (arGentis Pharmaceutical), belimumab Tocilizumab

[0217] In the treatment of Sjögren's syndrome, compounds that modulate STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, can be administered in combination with anti-rheumatic agents (hydroxychloroquine and ), cholinergic agonists JAK inhibitors ( and anti-TNF therapeutics In one embodiment of the invention, at least one other therapeutic agent is ciliary neurotrophic growth factor or a gene transfer agent. For example, in the treatment of retinitis pigmentosa, a compound that modulates STING, particularly a compound of Formula I or a pharmaceutically acceptable salt thereof, can be administered in combination with ciliary neurotrophic growth factor (NT-501-CNTF) or a gene transfer agent. Combined administration.

[0218] In one embodiment of the invention, at least one other therapeutic agent is selected from a trivalent (IIV3) inactivated influenza vaccine, a quadrivalent (IIV4) inactivated influenza vaccine, a trivalent recombinant influenza vaccine, a quadrivalent live attenuated influenza vaccine, an antiviral agent, or an inactivated influenza vaccine. For example, in the treatment of influenza, a compound that modulates STING, particularly a compound of Formula I or a pharmaceutically acceptable salt thereof, can be administered in combination with a trivalent (IIV3) inactivated influenza vaccine (such as ), quadrivalent (IIV4) inactivated influenza vaccine (such as Quadrivalent, Quadrivalent, Quadrivalent), trivalent recombinant influenza vaccines (such as ), quadrivalent live attenuated influenza vaccine (such as Quadrivalent), antiviral agents (such as oseltamivir Zanamivir Rimantadine or amantadine ),or Fludase, Preflucel or

[0219] In the treatment of staphylococcal infections, compounds that modulate STING, particularly compounds of Formula I or pharmaceutically acceptable salts thereof, can be combined with antibiotics such as β-lactam cephalosporins ( etc.), nafcillin Sulfonamides (sulfamethoxazole and trimethoprim Sulfasalazine Acetylsulfadiazine etc.) or vancomycin ) combined administration.

[0220] In one embodiment of the invention, at least one additional therapeutic agent is selected from a topical immunomodulator or calcineurin inhibitor, a topical corticosteroid, an oral corticosteroid, interferon gamma, an antihistamine, or an antibiotic. For example, in the treatment of atopic dermatitis, a compound that modulates STING, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, can be administered in combination with a topical immunomodulator or calcineurin inhibitor (such as pimecrolimus). or tacrolimus ointment ), topical corticosteroids (such as hydrocortisone Betamethasone Flurandrenolide Fluticasone Triamcinolone acetonide Fluocinolone acetate and clobetasol ), oral corticosteroids (such as hydrocortisone Methylprednisolone or prednisolone Immunosuppressants (such as cyclosporine or interferon gamma ( IntronA, )), antihistamines (for itching, ), antibiotics (such as the penicillin derivative flucloxacillin or dicloxacillin Erythromycin ( etc.)), nonsteroidal immunosuppressants (such as azathioprine Methotrexate Cyclosporine Mycophenolate mofetil ).

[0221] The compounds of the present invention can also be formulated with vaccines as adjuvants to regulate their activity. Such compositions may include antibodies or antibody fragments or antigenic components, including but not limited to proteins, DNA, live or dead bacteria and / or viruses or virus-like particles, and one or more components with adjuvant activity, including but not limited to aluminum salts, oil and water emulsions, heat shock proteins, lipid A products and derivatives, glycolipids, other TLR agonists such as CpG DNA or similar agents, cytokines such as GM-CSF or IL-12 or similar agents. In another aspect of the present invention, a vaccine adjuvant is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof. A vaccine composition is also provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an antigen or antigen composition.

[0222] Treatment

[0223] The compounds of the present invention can be used in therapeutic methods. Also provided is a method of treatment comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of the present invention. The term "therapeutically effective amount" is an amount sufficient to show a benefit to the patient. Such a benefit may be at least an improvement in at least one symptom. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the condition being treated. Treatment prescriptions, such as decisions regarding dosage, are within the responsibility of general practitioners and other medical practitioners.

[0224] Application

[0225] The active compound or pharmaceutical composition comprising the active compound can be administered to the subject by any convenient route of administration, whether systemically / peripherally or at the desired site of action, including, but not limited to: oral (e.g., by ingestion); topical (including, for example, transdermal, intranasal, ocular, buccal and sublingual); pulmonary (e.g., by use of, for example, an aerosol, such as inhalation or insufflation therapy via the mouth or nose); rectal; vaginal; parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, intravitreal and intrasternal; by implantation of a depot, for example, by implantation of a depot subcutaneously, intravitreally or intramuscularly. The subject can be a eukaryote, an animal, a vertebrate, a mammal, a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), a murine (e.g., a mouse), a canine (e.g., a dog), a feline (e.g., a cat), an equine (e.g., a horse), a primate, a simian (e.g., a monkey or ape), a monkey (e.g., a marmoset, a baboon), an ape (e.g., a gorilla, a chimpanzee, an orangutan, a gibbon), or a human.

[0226] In one embodiment where a tumor is treated, intratumoral injection may be used.

[0227] preparation

[0228] Although the active compound can be administered alone, it is preferred to present it as a pharmaceutical composition (e.g., a formulation) comprising at least one active compound as defined above, and one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilizers, preservatives, lubricants or other materials well known to those skilled in the art, and optionally other therapeutic or prophylactic agents.

[0229] Therefore, the present invention also provides pharmaceutical compositions as defined above, and methods for preparing pharmaceutical compositions, comprising mixing at least one active compound as defined above with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilizers or other materials as described herein.

[0230] As used herein, the term "pharmaceutically acceptable" refers to compounds, materials, compositions and / or dosage forms that are within the scope of sound medical judgment and are suitable for contact with the tissues of subjects (humans) without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[0231] Suitable carriers, excipients, etc. can be found in standard pharmaceutical textbooks, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.

[0232] The preparation can be conveniently presented in unit dosage form and can be prepared by any method known in the pharmaceutical field. Such a method includes the step of combining the active compound with a carrier constituting one or more auxiliary components. Usually, the preparation is prepared by: the active compound is uniformly and closely combined with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, the product is shaped.

[0233] The formulation may be in the form of a liquid, solution, suspension, emulsion, elixir, syrup, tablet, lozenge, granules, powder, capsule, cachet, pill, ampoule, suppository, pessary, ointment, gel, paste, cream, spray, mist, foam, lotion, oil, pill, electuary, or aerosol.

[0234] Formulations suitable for oral administration (e.g., by ingestion) can be presented as discrete units such as capsules, sachets or tablets, each containing a predetermined amount of active compound; as a powder or granules; as a solution or suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.

[0235] Tablets can be prepared by conventional means such as compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing a free-flowing form of active compound such as powder or granules in a suitable machine, optionally with one or more adhesives (e.g., povidone, gelatin, gum arabic, sorbitol, tragacanth, hydroxypropyl methylcellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silicon dioxide); disintegrants (e.g., sodium starch glycolate, cross-linked polyvidone, cross-linked sodium carboxymethylcellulose); surfactants or dispersants or wetting agents (e.g., sodium lauryl sulfate); and preservatives (e.g., methylparaben, propylparaben, sorbic acid). Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating to provide release in parts of the intestine other than the stomach.

[0236] Preparations suitable for topical administration (e.g., transdermal, intranasal, intraocular, buccal, and sublingual) can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils. Alternatively, the preparation can include a patch or dressing, such as a bandage or adhesive plaster, impregnated with the active compound and optionally one or more excipients or diluents.

[0237] Formulations suitable for topical administration in the mouth include lozenges comprising the active compound in a flavored basis, usually sucrose and acacia or tragacanth; lozenges comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.

[0238] Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.

[0239] Formulations suitable for nasal administration in which the carrier is a solid include coarse powders having a particle size, for example, in the range of about 20 microns to about 500 microns, which are administered as a sniff, i.e., by rapid inhalation through the nasal cavity from a container of the powder held in close proximity to the nose. Suitable formulations in which the carrier is a liquid, administered as, for example, a nasal spray, nasal drops or by aerosol via a nebulizer, include aqueous or oily solutions of the active compound.

[0240] Formulations suitable for administration by inhalation include those presented as an aerosol spray from pressurized packs, with the use of a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.

[0241] Preparations suitable for topical application through the skin include ointments, creams and emulsions. When formulated into an ointment, the active compound can optionally be used with a paraffin or water-miscible ointment base. Alternatively, the active compound can be formulated into a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base can include, for example, at least about 30% w / w of a polyol, i.e., an alcohol with two or more hydroxyl groups, such as propylene glycol, 1,3-butylene glycol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. Topical preparations can desirably include compounds that enhance the absorption or penetration of the active compound through the skin or other affected areas. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogs.

[0242] When formulated into topical emulsions, the oil phase may optionally comprise only an emulsifier (emulsifier) ​​(also referred to as an emulgent), or it may comprise a mixture of at least one emulsifier and a fat or oil or both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier acting as a stabilizer. It is also preferred to include both oil and fat. In short, an emulsifier containing a stabilizer or not containing a stabilizer constitutes a so-called emulsifying wax, and wax, together with oil and / or fat, constitutes a so-called emulsified ointment base, which forms the oily dispersed phase of an emulsifiable paste formulation.

[0243] Suitable emulsifiers and emulsion stabilizers include Tween 60, Span 80, cetearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate. The selection of suitable oil or fat for preparation is based on obtaining the required cosmetic properties, because the solubility of active compound in most oils that may be used for pharmaceutical emulsion preparations may be very low. Therefore, emulsifiable paste should preferably be a non-greasy, non-staining and washable product with a suitable consistency to avoid leakage from pipes or other containers. Straight or branched mono- or dibasic alkyl esters can be used, such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acid, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a mixture of branched esters (known as Crodamol CAP), and the last three are preferred esters. These can be used alone or in combination, depending on the required performance.

[0244] Alternatively, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils may be used.

[0245] Formulations suitable for rectal administration may be presented as a suppository with a suitable base containing for example cocoa butter or a salicylate.

[0246] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound such carriers as are known in the art to be appropriate.

[0247] Formulations suitable for parenteral administration (e.g., by injection, including cutaneous, subcutaneous, intramuscular, intravenous, and intradermal) include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions, which may contain antioxidants, buffers, preservatives, stabilizers, bacteriostats, and solutes that make the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents, as well as liposomes or exosomes or other microparticle systems designed to target the compound to blood components or one or more organs. Examples of suitable isotonic vehicles for such formulations include sodium chloride injection, Ringer's solution, or lactated Ringer's injection. Typically, the concentration of the active compound in the solution is from about 1 ng / mL to about 10 μg / mL, for example, from about 10 ng / ml to about 1 μg / mL. The formulation can be presented in unit dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in freeze-dried (lyophilized) conditions, requiring only the addition of a sterile liquid carrier such as water for injection just prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets. The formulations can be in the form of liposomes or exosomes or other particulate systems designed to target the active compound to blood components or one or more organs.

[0248] dose

[0249] It will be appreciated by those skilled in the art that the appropriate dosage of the compound and the composition comprising the compound can vary from patient to patient. Determining the optimal dose will generally include balancing the treatment benefit level with any risk or harmful side effects. The selected dosage level will depend on a variety of factors, including but not limited to the activity of the specific compound, the route of administration, the administration time, the excretion rate of the compound, the duration of treatment, other drugs, compounds and / or materials used in combination, the severity of the disease and the species, sex, age, body weight, condition, usual health and previous medical history of the patient. The amount of the compound and the route of administration will ultimately be determined by a doctor, veterinarian or clinician, although usually the dosage will be selected to reach a local concentration at the site of action, and the local concentration reaches the desired effect without causing substantial harmful or toxic side effects.

[0250] The administration may be in one dose, continuously or intermittently (e.g., in separate doses at appropriate intervals) throughout the course of treatment. Methods for determining the most effective mode of administration and dosage are well known to those skilled in the art and will vary with the formulation used for therapy, the purpose of therapy, the target cell being treated, and the subject being treated. Single or multiple administrations may be performed at dosage levels and in a manner selected by the treating physician, veterinarian, or clinician.

[0251] In general, a suitable dose of the active compound is in the range of about 100 ng to about 25 mg (more typically about 1 μg to about 10 mg) per kilogram of subject body weight per day. When the active compound is a salt, ester, amide, prodrug, etc., the amount administered is calculated based on the parent compound, and therefore the actual weight to be used is increased proportionally.

[0252] In one embodiment, the active compound is administered to a human patient according to the following dosage regimen: about 100 mg, 3 times a day.

[0253] In one embodiment, the active compound is administered to a human patient according to the following dosage regimen: about 150 mg, twice a day.

[0254] In one embodiment, the active compound is administered to a human patient according to the following dosage regimen: about 200 mg, twice a day.

[0255] In one embodiment, however, the active compound is administered to a human patient according to the following dosage regimen: about 50 mg or about 75 mg, 3 or 4 times a day.

[0256] In one embodiment, the active compound is administered to a human patient according to the following dosage regimen: about 100 mg or about 125 mg, twice a day.

[0257] treat

[0258] The term "treatment" as used herein, in the context of treating a condition, generally refers to treatment and therapy, whether for humans or animals (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, e.g., inhibiting the progression of the condition, and includes a reduction in the rate of progression, a cessation of the rate of progression, regression of the condition, amelioration of the condition, and cure of the condition. Treatment as a preventive measure (i.e., prophylaxis, prevention) is also included.

[0259] As used herein, the term "therapeutically effective amount" refers to an amount of an active compound, or a material, composition or dosage comprising an active compound, which, when administered according to the desired treatment regimen, is effective to produce some desired therapeutic effect, commensurate with a reasonable benefit / risk ratio.

[0260] Similarly, the term "prophylactically effective amount" as used herein refers to an amount of an active compound, or a material, composition or dosage comprising an active compound, which, when administered according to the desired treatment regimen, is effective to produce some desired prophylactic effect, commensurate with a reasonable benefit / risk ratio.

[0261] Subjects / Patients

[0262] The subject / patient can be an animal, a mammal, a placental mammal, a marsupial (e.g., a kangaroo, a wombat), a monotreme (e.g., a platypus), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), a murine (e.g., a mouse), a lagomorph (e.g., a rabbit), an avian (e.g., a bird), a canine (e.g., a dog), a feline (e.g., a cat), an equine (e.g., a horse), a porcinan (e.g., a pig), an ovine (e.g., a sheep), a bovine (e.g., a cow), a primate, a simian (e.g., a monkey or ape), a monkey (e.g., a marmoset, a baboon), an ape (e.g., a gorilla, a chimpanzee, an orangutan, a gibbon), or a human.

[0263] Furthermore, the subject / patient may be in any developmental form thereof, e.g., a fetus. In a preferred embodiment, the subject / patient is a human.

[0264] General Synthesis Methods

[0265] The compounds of the present invention can be prepared using the following general methods and the procedures described in detail in the examples. The reaction conditions involved are illustrative and non-restrictive, and for example, a variety of synthetic methods can be used by those skilled in the art to synthesize the desired compounds, such as, but not limited to, methods described in the literature (for example, but not limited to, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition; or Larock's Comprehensive Organic Transformations: Comprehensive Organic Transformations: A Guide to Functional Group Preparations).

[0266] Compounds of formula 1 as described above can be prepared by the synthetic strategies outlined below, wherein the above definitions apply.

[0267] General Synthesis 1

[0268]

[0269] Option 1a

[0270] Scheme 1a illustrates the synthesis of compounds having structure G8. The first step comprises the reaction of a suitably substituted ketone G1 with ethyl 2-mercaptoacetate G2 in the presence of a suitable base such as, but not limited to, K2CO3. Bromination of product G3 may be carried out to form alkyl bromide G4 using a suitable bromine source such as, but not limited to, N-bromosuccinimide in the presence of an initiator such as, but not limited to, benzoyl peroxide. Oxidation of G4 may be carried out to give compounds of type G5 using a suitable oxidant such as, but not limited to, N-methylmorpholine N-oxide. Compounds of formula G7 may be prepared by condensation of a suitably substituted benzothiophene, thienopyridine or thienopyrimidine G5 with a suitably substituted diphenylamine G6 in the presence of (a) a suitable acid such as, but not limited to, acetic acid or (b) sodium bisulfite or (c) sodium pyrosulfite. Carboxylic acid G8 may be formed by hydrolysis of ester G7 with a base such as, for example, an alkali metal hydroxide or an acid such as aqueous hydrochloric acid.

[0271]

[0272] Option 1b

[0273] The reaction is carried out by reacting a suitably substituted diphenylamine G9 (wherein R C2 or R C3 Compounds of formula G11 can be prepared by reacting one of the following: =C(=O)NH2) with a suitably substituted benzothiophene, thienopyridine or thienopyrimidine G5 to give compounds of type G10 (Scheme 1b), wherein R C2 or R C3 =C(=O)NH2. Carboxylic acid G11 can be formed by hydrolysis of ester G10 with a base such as an alkali metal hydroxide or an acid such as aqueous hydrochloric acid. Scheme 1c shows the formation of carboxylic acid G11 by reacting G7 (where R N1 =H) with an alkyl halide such as but not limited to iodomethane to give a mixture of regioisomers (Isomer 1: R C2 =C(=O)NH2, R C3 =H and isomer 2:R C3 =C(=O)NH2, R C2 =H), which can be separated by chromatography methods known to those skilled in the art, and can also form a compound of formula G10.

[0274]

[0275] Solution 1c

[0276] General Synthesis 2

[0277]

[0278] Solution 2

[0279] Compounds of structure G1 can be obtained by reaction of an appropriately substituted aldehyde G12 with a Grignard reagent such as methylmagnesium bromide to provide alcohol G13. Methods for oxidation of alcohol G13 to provide ketone G1 will be apparent to those skilled in the art but include, for example, the use of reagents such as chromium trioxide and sulfuric acid.

[0280] General Synthesis 3

[0281]

[0282] Solution 3

[0283] Compounds of structure G12 can be prepared by treating an appropriately substituted arene or heteroarene GX with an alkyl lithium such as, but not limited to, n-butyl lithium or a lithium amide base such as, but not limited to, lithium diisopropylamide, and subsequently quenching the resulting lithiated species with N,N-dimethylformamide. Optionally, the lithiated species formed by treating GX with an alkyl lithium or lithium amide can be quenched directly with acetaldehyde to provide compound G13.

[0284] General Synthesis 4

[0285]

[0286] Option 4a

[0287] The conditions for converting the acid G8 to the ester or amide G15 will be apparent to those skilled in the art, but include an excess of a suitable nucleophile G14 and a catalyst such as concentrated sulfuric acid (for ester formation), as shown in Scheme 4a. Optionally, G8 can be first activated with a coupling agent such as, but not limited to, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or N,N'-dicyclohexylcarbodiimide, and then reacted with a nucleophile G14 in the presence of a catalyst such as, but not limited to, 4-dimethylaminopyridine (for ester or amide formation) or in the presence of a base such as, but not limited to, N,N-diisopropylethylamine (for amide formation).

[0288] As shown in Scheme 4b, esters G17 can be obtained by reaction of acid G8 with a suitable alkyl halide G16 in the presence of a suitable base such as but not limited to cesium carbonate.

[0289]

[0290] Option 4b

[0291] General Synthesis 5

[0292]

[0293] Solution 5

[0294] Compounds of type G7 may also be formed by condensation of an appropriately substituted benzothiophene, thienopyridine or thienopyrimidine G5 with an appropriately substituted diphenylamine benzoic acid G18 in the presence of (a) a suitable acid such as, but not limited to, acetic acid or (b) sodium bisulfite or (c) sodium metabisulfite. Formation of G7 from acid G19 may then be carried out using a coupling reagent such as, but not limited to, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or N,N'-dicyclohexylcarbodiimide prior to reaction with an ammonia source such as, but not limited to, ammonium chloride in the presence of a base such as N,N-diisopropylethylamine.

[0295] Additional embodiments

[0296] R N1

[0297] When R N1 When R is H, the amido-benzimidazole moiety exhibits tautomerism. C1 and R C4 When H is C2 =C(=O)NH2 and R C3 =H, and R C3 =C(=O)NH2 and R C2 =H compounds are tautomers.

[0298] On the contrary, when R N1 When Me is present, the amido-benzimidazole moiety does not show tautomerism. C1 and R C4 When H is C2 =C(=O)NH2 and R C3 =H, and R C3 =C(=O)NH2 and R C2 =H compounds are regioisomers.

[0299] In some embodiments, R N1 It's H.

[0300] In some embodiments, R N1 It's me.

[0301] R 1

[0302] In some embodiments, R C2 is C(=O)NH2, W is O and R 1 is H. In these embodiments, the compound is of Formula Ia1:

[0303]

[0304] Among them A 1 -A 4 , R N1 , R C1 , R C3 and R C4 is as defined above.

[0305] In some embodiments, R C3 is C(=O)NH2, W is O and R 1 is H. In these embodiments, the compound is of Formula Ia2:

[0306]

[0307] Among them A 1 -A 4 , R N1 , R C1 , R C2 and R C4 is as defined above.

[0308] In other embodiments, R C2 is C(=O)NH2, W is NH and R 1 is H. In these embodiments, the compound is of Formula Ic1:

[0309]

[0310] Among them A 1 -A 4 , R N1 , R C1 , R C3 and R C4 is as defined above.

[0311] In other embodiments, R C3 is C(=O)NH2, W is NH and R 1 is H. In these embodiments, the compound is of Formula Ic2:

[0312]

[0313] Among them A 1 -A 4 , R N1 , R C1, R C2 and R C4 is as defined above.

[0314] In other embodiments, R C2 is C(=O)NH2, W is O or NH and R 1 YesR 1B . R 1B Selected from C 3-6 Cycloalkyl, optionally substituted C 3-7 heterocyclic group and optionally substituted straight or branched C 1-4 In these embodiments, the compound is of Formula Ib1:

[0315]

[0316] Among them A 1 -A 4 , R N1 , R C1 , R C3 and R C4 is as defined above and R 1B Selected from C 3-6 Cycloalkyl, optionally substituted C 3-7 heterocyclic group and optionally substituted straight or branched C 1-4 alkyl.

[0317] In other embodiments, R C3 is C(=O)NH2, W is O or NH and R 1 YesR 1B . R 1B Selected from C 3-6 Cycloalkyl, optionally substituted C 3-7 heterocyclic group and optionally substituted straight or branched C 1-4 In these embodiments, the compound is of Formula Ib2:

[0318]

[0319] Among them A 1 -A 4 , R N1 , R C1 , R C2 and R C4 is as defined above and R 1B Selected from C 3-6 Cycloalkyl, optionally substituted C 3-7 heterocyclic group and optionally substituted straight or branched C 1-4 alkyl.

[0320] In some embodiments, R 1 / R1B is an optionally substituted straight or branched chain C 1-4 In some embodiments, R 1 / R 1B is the unsubstituted C 1-4 In some embodiments, R 1 / R 1B is replaced by C 1-4 alkyl.

[0321] When R 1 / R 1B It is C 1-4 When alkyl, in some of these embodiments, R 1 / R 1B is methyl. In other of these embodiments, R 1 / R 1B In other of these embodiments, R 1 / R 1B is propyl (e.g., isopropyl, n-propyl). In other of these embodiments, R 1 / R 1B is butyl (e.g., isobutyl, sec-butyl, tert-butyl, n-butyl).

[0322] In some embodiments, R 1 / R 1B It is C 3-6 In some of these embodiments, R 1 / R 1B In other of these embodiments, R 1 / R 1B In other of these embodiments, R 1 / R 1B In other of these embodiments, R 1 / R 1B It is cyclohexyl.

[0323] In some embodiments, R 1 / R 1B It is C 3-7 In some of these embodiments, C 3-7 The heterocyclyl group has a single nitrogen ring atom. In some of these embodiments, R 1 / R 1B is azetidinyl, pyrrolidinyl or piperidinyl. In some of these embodiments, R 1 / R 1B In some of these embodiments, R 1 / R 1B It is piperidinyl.

[0324] R 1 Substituents on

[0325] In some embodiments, when R 1 / R 1B It is C 3-7 When R is a heterocyclic group, it is substituted by a group selected from the group consisting of methyl and ester. 1 / R 1B It is C 3-7 In some embodiments, when R 1 / R 1B It is C 3-7 When it is a heterocyclic group, it is substituted by an ester.

[0326] In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 When it is alkyl, it is substituted by a group selected from the group consisting of alkoxy, amino, acylamino, acylamido, acyloxy, alkylcarboxylate, alkylcarbamoyl, alkylcarbamoyl ester, phenyl, phosphonate, C 2- or C 3-substituted groups optionally selected from methyl and oxo. 3-7 heterocyclyl, and a naturally occurring amino acid optionally N-substituted with a group selected from methyl, acetyl and boc.

[0327] In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 alkyl, it is substituted by a group selected from the group consisting of acyloxy and phenyl. 1 / R 1B is a straight or branched C 1-4 When it is an alkyl group, it is a pivaloyloxymethyl group; a group of the formula:

[0328]

[0329] In some embodiments, when R 1 / R 1B is a straight or branched C 1-4 When it is an alkyl group, it is propionyloxyisobutyl; a group of the formula:

[0330]

[0331] In some embodiments, when R 1 / R 1B is a straight or branched chain C substituted with a phenyl group 1-4 When it is an alkyl group, it is a benzyl group.

[0332] In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 alkyl, it is substituted with a naturally occurring amino acid optionally N-substituted with a group selected from methyl, acetyl and boc. 1 / R 1B It is a straight or branched chain C 1-4 In some embodiments, when R 1 / R 1B It is a straight or branched chain C 1-4 alkyl, the naturally occurring amino acid is N-methyl valine. In some embodiments, when R 1 / R 1B It is a straight or branched chain C 1-4 alkyl, the naturally occurring amino acid is N-acetyl valine. In some embodiments, when R 1 / R 1B It is a straight or branched chain C 1-4 When alkyl, the naturally occurring amino acid is N-boc valine.

[0333] In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 When the alkyl group is alkyl, it is substituted with a phosphonate.

[0334] In some embodiments, when R 1 / R 1B Is it a straight chain or branched chain C 1-4 alkyl, it is optionally substituted by a group selected from methyl and oxo. 3-7 In some embodiments, when R 1 / R 1B Is C 3-7 Heterocyclic substituted straight or branched chain C 1-4 When alkyl, C 3-7 Heterocyclyl is dioxole optionally substituted by a group selected from methyl and oxo.

[0335] The compounds of formula (Ib1), (Ib2), (Ic1) and (Ic2) are prodrugs of the acids of formula (Ia1) and (Ia2).

[0336] A 1 -A 4

[0337] In some embodiments, A 1 Yes CR A .

[0338] In other embodiments, A 1 It is N.

[0339] In some embodiments, A 2 Yes CR B .

[0340] In other embodiments, A 2 It is N.

[0341] In some embodiments, A 3 Yes CR C .

[0342] In other embodiments, A 3 It is N.

[0343] In some embodiments, A 4 Yes CR D .

[0344] In other embodiments, A4 It is N.

[0345] In some embodiments, A 1 , A 2 , A 3 and A 4 Two of them are N.

[0346] In other embodiments, A 1 , A 2 , A 3 and A 4 One of them is N.

[0347] In other embodiments, A 1 , A 2 , A 3 and A 4 None of them is N, that is, A 1 , A 2 , A 3 and A 4 CR A , CR B , CR C , and CR D .

[0348] In some embodiments, the compound of Formula I is selected from compounds of Formula (IIIa1)-(IIIe1):

[0349]

[0350]

[0351] In some embodiments, the compound of Formula I is selected from compounds of Formula (IIIa2)-(IIIe2):

[0352]

[0353]

[0354] R A , R B , R C and R D (if any)

[0355] In some embodiments, R A , R B , R C and R D (if present) is selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH.

[0356] In some embodiments, R A , R B , R C and R D One of the above (if present) is selected from the group consisting of F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH. The remaining (if present) are H.

[0357] In other embodiments, R A , R B , R C and R D Two of the above (if present) are selected from F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH. The remaining (if present) is H.

[0358] In some embodiments, R A , R B , R C and R D One or two (if present) of is selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano and OMe and the remainder (if present) is H. In some of these embodiments, R A , R B , R C and R D One or two of (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl and OMe. The remainder (if present) is H. In some of these embodiments, R A , R B , R C and R D One or two of (if present) are selected from H, F, Cl, Br, Me, CF3 and OMe. The remainder (if present) is H. In some of these embodiments, R A , R B , R C and R D One or two of (if present) are selected from H, F, Cl, Br and OMe. The rest (if present) are H.

[0359] In some embodiments, R A and R D is selected from the group consisting of H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, and OMe; and R B and R C is H. In some embodiments, R A and R Dis selected from the group consisting of H, F, Cl, Br and OMe; and R B and R C It's H.

[0360] In some embodiments, R A is selected from the group consisting of H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, and CH2OMe. In some embodiments, R A is selected from the group consisting of H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, and OMe. A is selected from Cl, Br and OMe. A is selected from Cl, Br, Me and CF3. In some embodiments, R A is Cl. In some embodiments, R A is Br. In some embodiments, R A It's OMe.

[0361] In some embodiments, R D is selected from the group consisting of H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, CH2OH, and CH2OMe. D is selected from the group consisting of H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, and OMe. D is selected from the group consisting of H, F, Br, Me and OMe. D is selected from H and F. In some embodiments, R D is H. In some embodiments, R D is F. In some embodiments, R D is Br. In some embodiments, R D is Me. In some embodiments, R D It's OMe.

[0362] In some embodiments, A 1 , A 2 , A 3 and A 4 Select from combinations 1-9 in the following table:

[0363] combination <![CDATA[A 1 ]]> <![CDATA[A 2 ]]> <![CDATA[A 3 ]]> <![CDATA[A 4 ]]> 1 CCl CH CH CH 2 CCl CH CH <![CDATA[CCH3]]> 3 CCl CH CH CBr 4 CBr CH CH CH 5 CCl CH CH CF 6 CCl CH CH <![CDATA[C-OCH3]]> 7 CBr CH CH CF 8 <![CDATA[C-OCH3]]> CH CH CH 9 <![CDATA[C-OCH3]]> N CH Br

[0364] In some embodiments, combinations 1, 5, 7, and 8 are preferred.

[0365] R C1 , R C2 , R C3 and R C4

[0366] In some embodiments, R C1 and R C4 , and R C2 and R C3 One of is independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3 and CH2OH. In some of these embodiments, R C1 and R C4 , and R C2 and R C3 One of is independently selected from H, Cl, F, CF3, OMe and CH2OH. In further embodiments of these embodiments, R C1 and R C4 , and R C2 and R C3 One of the above is independently selected from H, Cl, F and OMe.

[0367] In some embodiments, R C1 and R C4 , and R C2 and R C3 One of them is all H.

[0368] In other embodiments, R C1 , R C3 and R C4 Two or R C1 , R C2 and R C4 Two of them are H, and the other is selected from the defined groups (excluding H). In some of these embodiments, R C4 is F. In some of these embodiments, R C1 is OMe. In some of these embodiments, R C1 It is Cl.

[0369] In other embodiments, R C1 , R C3 and R C4 One or R C1 , R C2 and R C4 One of is H, and the other two are independently selected from the defined groups (excluding H). In some of these embodiments, R C1 OMe and R C4 It's F.

[0370] Other Implementations

[0371] In some embodiments, the present invention relates to compounds of formula IV:

[0372]

[0373] in:

[0374] W is O or NH;

[0375] R 1 Selected from:

[0376] (i) H;

[0377] (ii)C 3-6 Cycloalkyl;

[0378] (iii)C 3-7 A heterocyclic group, which is optionally substituted by a group selected from:

[0379] Methyl; and

[0380] Esters; and

[0381] (iv) Straight or branched chain C 1-4 Alkyl, which is optionally substituted by a group selected from:

[0382] Alkoxy;

[0383] Amino;

[0384] Acylamino;

[0385] acylamido;

[0386] acyloxy;

[0387] Alkyl carboxyl esters;

[0388] Alkylcarbamoyl;

[0389] Alkylcarbamoyl esters;

[0390] Phenyl;

[0391] Phosphonates;

[0392] C optionally substituted by a group selected from methyl and oxo 3-7 heterocyclyl; and

[0393] a naturally occurring amino acid, which is optionally N-substituted with a group selected from methyl, acetyl and boc;

[0394] A 1 Yes CR A or N;

[0395] A 2 Yes CR B or N;

[0396] A 3 Yes CR C or N;

[0397] A4 Yes CR D or N;

[0398] Among them A 1 , A 2 , A 3 , and A 4 No more than two of them can be N;

[0399] R A , R B , R C and R D One or two of (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH;

[0400] The rest of R A , R B , R C and R D (if any) is H;

[0401] R N1 It is H;

[0402] R C1 , R C3 and R C4 independently selected from H, Cl, F, Br, Me, OMe, cyano, CF3, CH2OH, CH2OMe, C 2-4 alkenyl and C5 heterocyclic group. Example

[0403] The following examples are provided only to illustrate the invention and are not intended to limit the scope of the invention as described herein.

[0404] Acronyms

[0405] For convenience, many chemical moieties are represented using well-known abbreviations, including but not limited to methyl (Me), ethyl (Et), n-propyl (nPr), isopropyl (iPr), n-butyl (nBu), tert-butyl (tBu), phenyl (Ph), benzyl (Bn), methoxy (MeO), ethoxy (EtO), trimethylsilyl (TMS), and acetyl (Ac).

[0406] For convenience, many chemical compounds are represented using well-known abbreviations, including but not limited to methanol (MeOH), deuterated methanol (MeOD-d4 or CD3OD), ethanol (EtOH), isopropanol (i-PrOH), ether or diethyl ether (Et2O), ethyl acetate (EtOAc), acetic acid (AcOH), acetonitrile (MeCN or ACN), dichloromethane (methylene chloride, DCM), trifluoroacetic acid (TFA), dimethylformamide (DMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), deuterated chloroform (CDCl3), diethylamine (DEA), deuterated dimethyl sulfoxide (DMSO-d6), N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCl.HCl), m-chloroperbenzoic acid (mCPBA), 1,1'-bis(diphenylphosphino)ferrocene (dppf), tert-butoxycarbonyl (Boc, BOC), 2-(trimethylsilyl)ethoxymethyl (SEM), triethylamine (Et3N or TEA), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3 -Tetramethyluronium hexafluorophosphate (HATU), 4-dimethylaminopyridine (DMAP), N,N-diisopropylethylamine (DIPEA or DIEA), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (PdCl2(dppf)), trans-dichlorobis(triphenylphosphine)palladium(II) (PdCl2(PPh3)2), tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4), propylphosphonic anhydride (T3P), hexamethylphosphine HMPA, 1,2-dichloroethane (DCE), chromium (VI) oxide (CrO3), n-bromosuccinimide (NBS), potassium hydroxide (KOH), benzoyl peroxide (BPO), carbon tetrachloride (CCl4), petroleum ether (Pet.Ether), potassium carbonate (K2CO3), sodium sulfate (Na2SO4), lithium diisopropylamine (LDA), azobisisobutyronitrile (AIBN), N-methylmorpholine N-oxide (NMO), benzoyl peroxide (BPO) and 1-hydroxybenzotriazole (HOBt).

[0407] Other abbreviations: thin layer chromatography (TLC), retention time (rt).

[0408] General experimental details

[0409] Unless otherwise stated, the following generalizations apply. 1H NMR spectra were recorded on a Bruker Ultrashield Plus (400 MHz) or a Bruker AVANCE III (400 MHz). The multiplicities of the signals are indicated by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; dd, double of doublets; dt, double of triplets; tt, triplet of triplets; td, triplet of doublets; ddd, double of doublets; br, broad; m, multiplet. All observed coupling constants J are reported in Hertz. Exchangeable protons are not always observed.

[0410] LCMS data were generated using the following conditions. Chlorine isotopes are reported as 35 Cl, bromine isotopes are reported as 79 Br or 81 Br or 79 Br / 81 Br both.

[0411] LCMS method A (LCMS-A):

[0412] Device Information

[0413] LC model: Agilent 1200

[0414] (Pump type: binary pump, detector type: DAD)

[0415] MS Model: Agilent G6110A Quadrupole

[0416] LCMS parameters

[0417] LC: Column: Xbridge-C18, 2.5 μm, 2.1×30 mm

[0418] Column temperature: 30°C

[0419] Wavelength collection: 214nm, 254nm

[0420] Mobile phase: A: 0.07% HCOOH aqueous solution, B: MeOH

[0421] MS: Ion source: ES+ (or ES-) MS range: 50-900 m / z

[0422] Fragmentor voltage: 60 Drying gas flow: 10L / min

[0423] Atomizer pressure: 35psi Drying gas temperature: 350℃

[0424] Vcap: 3.5kV

[0425] Gradient table:

[0426] Flow rate (mL / min) T(minutes) A(%) B(%) 0.5 0.0 70 30 0.5 0.2 70 30 0.5 1.8 5 95 0.5 2.4 5 95 0.5 2.6 70 30 0.5 3.5 70 30

[0427] Sample preparation

[0428] The sample was dissolved in methanol at a concentration of about 0.11-1 mg / mL and then filtered through a 0.22 μm syringe filter (injection volume: 1-10 μL).

[0429] LCMS method B (LCMS-B):

[0430] Device Information

[0431] LC model: Agilent 1200

[0432] (Pump type: binary pump, detector type: DAD)

[0433] MS Model: Agilent G6110A Quadrupole

[0434] LCMS parameters

[0435] LC: Column: Xbridge-C18, 2.5 μm, 2.1×30 mm

[0436] Column temperature: 30°C

[0437] Wavelength collection: 214nm, 254nm

[0438] Mobile phase: A: 0.07% HCOOH aqueous solution, B: MeOH

[0439] MS: Ion source: ES+ (or ES-) MS range: 50-900 m / z

[0440] Fragmentation voltage: 60 Drying gas flow rate: 10L / min

[0441] Atomizer pressure: 35psi Drying gas temperature: 350℃

[0442] Vcap: 3.5kV

[0443] Gradient table:

[0444] Flow rate (mL / min) T(min) A(%) B(%) 0.5 0.0 70 30 0.5 0.3 70 30 0.5 0.6 50 50 0.5 0.9 40 60 0.5 1.2 30 70 0.5 3.2 5 95 0.5 3.5 5 95 0.5 4.0 70 30 0.5 5.0 70 30

[0445] Sample preparation

[0446] The sample was dissolved in methanol at a concentration of about 0.11-1 mg / mL and then filtered through a 0.22 μm syringe filter (injection volume: 1-10 μL).

[0447] LC-MS method C (LCMS-C):

[0448] Device Information

[0449] LC model: Waters 2695alliance (Pump type: quaternary pump, Detector type: 2996 photodiode array detector)

[0450] MS Model: Micromass ZQ

[0451] LCMS parameters

[0452] LC column: Xbridge-C18, 3.5 μm, 2.1 × 50 mm

[0453] Column temperature: 30°C

[0454] Wavelength collection: 214nm, 254nm

[0455] Mobile phase: A: 0.07% HCOOH aqueous solution, B: MeOH

[0456] MS: Ion source: ES+ (or ES-) MS range: 50-900 m / z

[0457] Capillary: 3kV Cone: 3V Extractor: 3V

[0458] Dry gas flow rate: 600L / h Cone hole: 50L / h

[0459] Desolvation temperature: 300°C

[0460] Source temperature: 100°C

[0461] Gradient table:

[0462] Flow rate (mL / min) T(minutes) A(%) B(%) 0.3 0.0 80 20 0.3 0.5 80 20 0.3 0.8 50 50 0.3 1.2 35 65 0.3 2.0 20 80 0.3 4.0 5 95 0.3 5.0 5 95 0.3 5.8 15 85 0.3 6.2 80 20 0.3 8.0 80 20

[0463] Sample preparation

[0464] The sample was dissolved in methanol at a concentration of about 0.11-1 mg / mL and then filtered through a 0.22 μm syringe filter (injection volume: 1-10 μL).

[0465] LC-MS method D (LCMS-D):

[0466] Device Information

[0467] LC model: Waters 2695alliance

[0468] (Pump type: quaternary pump, detector type: 2996 photodiode array detector)

[0469] MS Model: Micromass ZQ

[0470] LCMS parameters

[0471] LC column: Xbridge-C18, 2.5 μm, 2.1×30 mm

[0472] Column temperature: 30°C

[0473] Wavelength collection: 214nm, 254nm

[0474] Mobile phase: A: 0.05% HCOOH aqueous solution, B: MeOH

[0475] Run time: 5 minutes

[0476] MS: Ion source: ES+ (or ES-) MS range: 50-900 m / z

[0477] Capillary: 3.5kV Cone: 35V Extractor: 3V

[0478] Dry gas flow rate: 350L / h Cone hole: 50L / h

[0479] Desolvation temperature: 300°C

[0480] Source temperature: 120°C

[0481] Run time: 5 minutes

[0482] Gradient table:

[0483]

[0484]

[0485] Sample preparation

[0486] The sample was dissolved in methanol at a concentration of about 0.11-1 mg / mL and then filtered through a 0.22 μm syringe filter (injection volume: 1-10 μL).

[0487] Preparative RP-HPLC:

[0488] Instrument type: Varian 940-LC series;

[0489] Pump type: quaternary pump;

[0490] Detector Type: Diode Array Detector

[0491] HPLC conditions: Waters Sunfire prep C18 OBD, 5 μm 19×100 mm column, eluted with a gradient of MeOH in water with 0.07% TFA at a flow rate of 15 mL / min. Collection wavelengths 214 nm, 254 nm.

[0492] Analytical thin layer chromatography was performed on Merck silica gel 60F254 aluminum backed plates visualized using fluorescence quenching under UV light or infusion in alkaline KMnO4 or ninhydrin.

[0493] Preparative thin layer chromatography (preparative TLC) was performed using Tklst (China), special grade: (HPTLC): 8±2 μm>80%; (TLC): 10-40 μm. Type: GF254. Compounds were visualized by UV (254 nm).

[0494] Use Grace or Silica gel cartridges and flash chromatography were performed using the Biotage Isolera purification system.

[0495] Column chromatography was performed using Tklst (China), special grade, 100-200 mesh silica gel.

[0496] Microwave irradiation was achieved using a CEM Explorer SP microwave reactor.

[0497] When necessary, anhydrous solvents were purchased from Sigma-Aldrich or dried using conventional methods. Solutions of inorganic acids or bases were constituted as aqueous solutions unless otherwise stated.

[0498] The other cartridges used were as follows:

[0499] Phase Separator:

[0500] Manufacturer: Biotage

[0501] product: Phase separator (3 mL, unless otherwise stated)

[0502] SCX and SCX-2 boxes:

[0503] Manufacturer: Biotage

[0504] product: SCX 1g, (6mL SPE cartridge unless otherwise specified)

[0505] Manufacturer: Biotage

[0506] product: SCX-2 1g, (6mL column)

[0507] Manufacturer: Silicycle

[0508] Product: SCX-2 500mg or 5g

[0509] Manufacturer: Agilent

[0510] Product: Bond SCX 10g

[0511] Sample extraction box

[0512] Manufacturer: Waters

[0513] product: HLB 35cc(6g)LP Extraction Box

[0514] Unless otherwise stated, solutions of hydrogen chloride, sodium hydroxide, potassium carbonate and sodium bicarbonate are aqueous solutions.

[0515] Intermediate preparation

[0516] (i) 3,4-Diaminobenzamide (I1)

[0517]

[0518] A solution of 3,4-diaminobenzonitrile (1.0 g, 7.51 mmol) / concentrated sulfuric acid (20 mL) was stirred at room temperature overnight. Water (100 mL) was added and the resulting mixture was adjusted to pH 10 with 4M NaOH aqueous solution and extracted with EtOAc (100 mL×3). The combined organic extracts were concentrated under reduced pressure to give the title compound I1 (800 mg, 70%) as a light yellow solid. LCMS-A (ES-API): rt 0.31 min, m / z 152.0 [M+H] + .

[0519] (ii) 3,4-Diamino-5-fluorobenzamide (I4)

[0520]

[0521] (a) 4-Amino-3-fluoro-5-nitrobenzonitrile (I2)

[0522] To a solution of 4-bromo-2-fluoro-6-nitroaniline (9.23 g, 39.3 mmol) / DMF (150 mL) was added CuCN (7.04 g, 78.6 mmol) and the mixture was heated at 165 ° C overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / EtOAc=10:1) to give the title compound I2 (5.0 g, 70%) as a yellow solid.

[0523] LCMS-B(ES-API):rt 0.30min,m / z 182.0[M+H] + .

[0524] (b) 4-Amino-3-fluoro-5-nitrobenzamide (I3)

[0525] A solution of 4-amino-3-fluoro-5-nitrobenzonitrile (I2) (1.5 g, 8.28 mmol) in concentrated H2SO4 (15 mL) was stirred at room temperature overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were concentrated under reduced pressure, and the residue was purified by silica gel chromatography (DCM / MeOH=50:1) to give the title compound I3 (1.63 g, 99%) as a yellow solid.

[0526] LCMS-B(ES-API):rt 0.30min,m / z 200.0[M+H] + .

[0527] (c) 3,4-Diamino-5-fluorobenzamide (I4)

[0528] To a solution of 4-amino-3-fluoro-5-nitrobenzamide (I3) (1.63 g, 8.19 mmol) in MeOH (50 mL) and THF (50 mL) was added 10% Pd / C (87 mg), and the mixture was stirred at room temperature under H2 atmosphere overnight. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (DCM / MeOH=10:1) to give the title compound I4 (1.2 g, 87%) as a green solid.

[0529] LCMS-B(ES-API):rt 0.29min,m / z 170.0[M+H] + .

[0530] 1 H NMR (400MHz, DMSO-d6) δ7.74(s,2H),7.56-7.47(m,2H),7.45(s,2H),7.26-7.12(m,2H).

[0531] (iii) 3,4-Diamino-2-methoxybenzoic acid (I5)

[0532]

[0533] To a solution of methyl 3,4-diamino-2-methoxybenzoate (200 mg, 1.02 mmol) in THF (10 ml) and water (5 mL) was added NaOH (122 mg, 3.06 mmol) and the mixture was heated at 50° C. overnight. Most of the THF was removed under reduced pressure and the aqueous residue was adjusted to pH 5 with 1M HCl aqueous solution and then concentrated under reduced pressure. The residue was suspended in MeOH, filtered and the filtrate was concentrated under reduced pressure to give the title compound I5 (183 mg, 98%) as a black solid.

[0534] LCMS-B(ES-API):rt 0.29min,m / z 205.0[M+Na] + .

[0535] 1 H NMR (400MHz, DMSO-d6) δ6.76 (d, J = 8.0 Hz, 1H), 6.19 (d, J = 8.1 Hz, 1H), 4.52 (s, 2H), 4.02 (s, 2H), 3.69 (s, 3H).

[0536] (iv) 4-chloro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I8)

[0537]

[0538] (a) 4-Chloro-3-methylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I6)

[0539] A solution of 1-(2-chloro-6-fluorophenyl)ethanone (25.0 g, 145 mmol), ethyl 2-mercaptoacetate (17.4 g, 145 mmol) and K2CO3 (30.0 g, 217 mmol) in DMF (200 mL) was heated at 100 °C overnight. The mixture was cooled to room temperature and then poured into water (1.0 L) and EtOAc (500 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (500 mL×3). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by recrystallization from petroleum ether / EtOAc to give the title compound I6 (28.0 g, 76%) as a yellow solid.

[0540] LCMS-A:rt 2.82min; m / z 255.0[M+H] + .

[0541] (b) Ethyl 3-(bromomethyl)-4-chlorobenzo[b]thiophene-2-carboxylate (I7)

[0542] A suspension of ethyl 4-chloro-3-methylbenzo[b]thiophene-2-carboxylate (I6) (28.0 g, 0.11 mol), NBS (19.6 g, 0.11 mol) and BPO (2.67 g, 0.011 mol) in CCl4 (200 mL) was heated at 115° C. for 1.5 hours. The mixture was cooled to room temperature and then concentrated under reduced pressure, and the residue was purified by recrystallization from DCM / petroleum ether to give the title compound I7 (26.0 g, 71%) as a purple solid.

[0543] 1 H NMR (400MHz, CDCl3) δ7.74(dd,J=8.0,1.2Hz,1H),7.46(dd,J=7.6,0.8Hz,1H),7.40(t,J=8.0Hz,1H),5.61(s,2H),4.44(q,J=7.1Hz 2H), 1.44 (t, J = 7.1Hz, 3H).

[0544] (c) 4-Chloro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I8)

[0545] A mixture of ethyl 3-(bromomethyl)-4-chlorobenzo[b]thiophene-2-carboxylate (I7) (10.00 g, 29.97 mmol) and NMO (14.00 g, 119.88 mmol) in THF (250 mL) was heated under reflux for 16 hours. The mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (petroleum ether / EtOAc=100:1 to 50:1) to give the title compound I8 (2.70 g, 34%) as a white solid.

[0546] LCMS-B(ES-API):rt 4.16min,m / z 269.0[M+H] + ,290.9[M+Na] + .

[0547] 1 H NMR (400MHz, DMSO-d6) δ10.7(s,1H),8.17(dd,J=7.6,1.5Hz,1H),7.66-7.58(m,2H),4.36(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,3H).

[0548] (v) 4-Chloro-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I13)

[0549]

[0550] (a) 1-(6-Chloro-2,3-difluorophenyl)ethan-1-ol (I9)

[0551] n-BuLi (2.5M n-hexane solution, 17.6mL, 43.9mmol) was added dropwise to a solution of diisopropylamine (4.4g, 43.9mmol) / anhydrous THF (100mL) at -78°C under nitrogen, followed by 4-chloro-1,2-difluorobenzene (5.0g, 33.8mmol) and the mixture was stirred for 1 hour. Acetaldehyde (4.4g, 101.4mmol) was added dropwise and the mixture was warmed to room temperature and stirred overnight. The reaction mixture was quenched by adding saturated NH4Cl aqueous solution and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:0 to 20:1) to give the title compound (3.0g, 46%), a yellow oil.

[0552] LCMS-B:rt 3.39min; m / z 175.0[M-OH] + .

[0553] 1 H NMR (400MHz, DMSO-d6) δ7.41-7.33(m,1H),7.31-7.25(m,1H),5.54(d,J=4.4Hz,1H),5.25-5.16(m,1H),1.45(d,J=6.7Hz,3H).

[0554] (b) 1-(6-Chloro-2,3-difluorophenyl)ethan-1-one (I10)

[0555] To a solution of 1-(6-chloro-2,3-difluorophenyl)ethan-1-ol (I9) (3.0 g, 15.6 mmol) in anhydrous DCM (50 mL) was added Dess-Martin periodinane (19.8 g, 46.7 mmol) and the mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate was diluted with water and extracted with EtOAc. The combined organic extracts were washed with saturated aqueous NaHCO3, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether) to give the title compound (2.3 g, 79%), a yellow oil, which was used directly in the next step.

[0556] (c) 4-Chloro-7-fluoro-3-methylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I11)

[0557] Under nitrogen, to a mixture of 1-(6-chloro-2,3-difluorophenyl)ethan-1-one (I10) (1.8 g, 9.3 mmol) and K2CO3 (3.9 g, 28.0 mmol) in DMF (20 mL) was added ethyl 2-mercaptoacetate (1.3 g, 11.2 mmol), and the mixture was stirred at room temperature overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with water, brine and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:0) to give the title compound (1.5 g, 60%), a brown solid.

[0558] LCMS-A:rt 3.54min; m / z 273.0[M+H] + .

[0559] 1 H NMR (400MHz, DMSO-d6) δ7.55-7.50 (m, 1H), 7.40 (t, J = 8.7Hz, 1H), 4.35 (q, J = 7.1Hz, 2H), 2.97 (s, 3H), 1.34 (t, J = 7.1Hz, 3H).

[0560] (d) 3-(Bromomethyl)-4-chloro-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (I12)

[0561] To a solution of ethyl 4-chloro-7-fluoro-3-methylbenzo[b]thiophene-2-carboxylate (I11) (1.5 g, 5.5 mmol) in CCl4 (50 mL) was added NBS (978 mg, 5.5 mol) and AIBN (451 mg, 2.75 mmol) and the mixture was heated at 80° C. under N2 overnight. The mixture was diluted with water, extracted with EtOAc and the combined organic extracts were washed with water, brine and concentrated under reduced pressure to give the title compound (1.3 g, 80%) as a yellow solid.

[0562] 1 H NMR (400MHz, DMSO-d6) δ7.67-7.61 (m, 1H), 7.50 (t, J = 8.7Hz, 1H), 5.47 (s, 2H), 4.41 (q, J = 7.1Hz, 2H), 1.36 (t, J = 7.0Hz, 3H).

[0563] (e) 4-Chloro-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I13)

[0564] Under N2, NMO (1.33 g, 11.4 mmol) was added to a solution of 3-(bromomethyl)-4-chloro-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (I12) (1.0 g, 2.8 mmol) / THF (20 mL) and the mixture was heated under reflux for 16 hours. The mixture was diluted with water, extracted with EtOAc and the combined organic extracts were washed with brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:0 to 100:1) to give the title compound (250 mg, 31%) as a white solid.

[0565] LCMS-B:rt 4.39min; m / z 286.9[M+H] + ,308.9[M+Na] + .

[0566] 1 H NMR (400MHz, DMSO-d6) δ10.7(s,1H),7.73-7.66(m,1H),7.57(t,J=8.9Hz,1H),4.38(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,3H).

[0567] (vi) 4-bromo-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I15)

[0568]

[0569] I14 is compound I52 of WO2019 / 219820.

[0570] 4-Bromo-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I15)

[0571] A solution of ethyl 4-bromo-3-(bromomethyl)-7-fluorobenzo[b]thiophene-2-carboxylate (I14) (676 mg, 1.71 mmol) and NMO (800 mg, 6.84 mmol) in THF (5 mL) was heated at reflux under N2 for 16 hours. The mixture was partitioned between water (30 mL) and EtOAc (30 mL), the layers were separated and the aqueous layer was further extracted with EtOAc (30 mL×3). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=100:1 to 30:1) to give the title compound (243 mg, 43%) as a white solid.

[0572] 1H NMR (400MHz, DMSO-d6) δ 10.8 (s, 1H), 7.85 (dd, J = 8.4, 4.4Hz, 1H), 7.52 (t, J = 9.2Hz, 1H), 4.39 (q, J = 7.2Hz, 2H), 1.33 (t, J = 7.2Hz, 3H).

[0573] (vii) 7-bromo-3-formyl-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid ethyl ester (I18)

[0574]

[0575] I16 is compound I29 of WO2019 / 219820.

[0576] (a) 7-Bromo-3-(bromomethyl)-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid ethyl ester (I17)

[0577] To a solution of ethyl 4-methoxy-3-methylthieno[3,2-c]pyridine-2-carboxylate (I16) (2.0 g, 7.96 mmol) and NBS (2.2 g, 11.9 mmol) in ACN (50 mL) was added AIBN (654 mg, 3.98 mmol) and the mixture was heated at 80 °C for 3 h. The mixture was partitioned between water and EtOAc, the layers were separated and the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product (3.2 g) as a yellow solid. NMR analysis showed the presence of a 1:2 mixture of the title compound and ethyl 7-bromo-4-methoxy-3-methylthieno[3,2-c]pyridine-2-carboxylate. This mixture was used in the next step without further purification.

[0578] The title compound 1 H NMR (minor component):

[0579] 1 H NMR (400MHz, DMSO-d6) δ8.34 (s, 1H), 5.29 (s, 2H), 4.41 (q, J = 7.2Hz, 2H), 4.08 (s, 3H), 1.38 (t, J = 7.2Hz, 3H).

[0580] 7-Bromo-4-methoxy-3-methylthieno[3,2-c]pyridine-2-carboxylic acid ethyl ester (multiple components) 1 H NMR:

[0581] 1H NMR (400MHz, DMSO-d6) δ8.24 (s, 1H), 4.36 (q, J = 7.2Hz, 2H), 4.02 (s, 3H), 2.85 (s, 3H), 1.34 (t, J = 7.2Hz, 3H).

[0582] (b) 7-bromo-3-formyl-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid ethyl ester (I18)

[0583] To a 1:2 mixture of ethyl 7-bromo-3-(bromomethyl)-4-methoxythieno[3,2-c]pyridine-2-carboxylate / ethyl 7-bromo-4-methoxy-3-methylthieno[3,2-c]pyridine-2-carboxylate (I17) (2.5 g, assuming 2.3 mmol of ethyl 7-bromo-3-(bromomethyl)-4-methoxythieno[3,2-c]pyridine-2-carboxylate) in THF (50 mL) was added NMO (5.4 g, 30.3 mmol) and the mixture was heated at reflux overnight. The mixture was partitioned between water and EtOAc, the layers were separated and the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1 / 0 to 5 / 1) to give the title compound as a yellow solid (350 mg, 13% in two steps from ethyl 4-methoxy-3-methylthieno[3,2-c]pyridine-2-carboxylate 116).

[0584] 1 H NMR (400MHz, DMSO-d6) δ10.5 (s, 1H), 8.37 (s, 1H), 4.39 (q, J = 7.2Hz, 2H), 3.99 (s, 3H), 1.33 (t, J = 7.2Hz, 3H).

[0585] (viii) 3,4-Diamino-2-methoxybenzamide (I23)

[0586]

[0587] (a) 4-Acetylamino-5-chloro-2-methoxy-3-nitrobenzoic acid methyl ester (I19)

[0588] The title compound was prepared from commercially available methyl 4-acetamido-5-chloro-2-methoxybenzoate according to the procedure described in WO2008 / 65508.

[0589] 1 H NMR (400MHz, DMSO-d6) δ10.3(s,1H),8.15(s,1H),3.90(s,3H),3.87(s,3H),2.03(s,3H).

[0590] (b) 4-Acetylamino-5-chloro-2-methoxy-3-nitrobenzoic acid (I20)

[0591] To a solution of methyl 4-acetamido-5-chloro-2-methoxy-3-nitrobenzoate (I19) (4.0 g, 0.013 mol) in EtOH / water (10:1, 30 mL) was added NaOH (5.2 g, 0.13 mol) and the mixture was stirred at room temperature overnight. Most of the EtOH was removed under reduced pressure and the aqueous residue was acidified to pH 7 with 2M HCl aqueous solution. The resulting precipitate was collected by filtration and dried under vacuum to give the title compound (2.3 g, 61%) as a white solid.

[0592] LCMS-B(ES-API):rt 1.70min,m / z 310.9,312.9[M+Na] + .

[0593] 1 H NMR (400MHz, DMSO-d6) δ10.3(s,1H),8.10(s,1H),3.87(s,3H),2.03(s,3H).

[0594] (c) 4-Amino-5-chloro-2-methoxy-3-nitrobenzoic acid (I21)

[0595] A mixture of 4-acetylamino-5-chloro-2-methoxy-3-nitrobenzoic acid (I20) (2.3 g, 0.008 mol) and NaOH (3.2 g, 0.08 mol) in MeOH (20 mL) was heated at 70 ° C for 16 hours. The mixture was diluted with water and most of the MeOH was removed under reduced pressure. The aqueous residue was acidified to pH 6 with 2M HCl aqueous solution and extracted with EtOAc (40 mL×3). The combined organic extracts were washed with brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=20:1 to 8:1) to obtain the title compound (1.36 g, 69%) as a white solid.

[0596] LCMS-B(ES-API):rt 2.90min,m / z 247.0,249.0[M+H] + .

[0597] 1 H NMR (400MHz, DMSO-d6) δ13.0(s,1H),7.83(s,1H),6.74(s,2H),3.81(s,3H).

[0598] (d) 4-Amino-5-chloro-2-methoxy-3-nitrobenzamide (I22)

[0599] A mixture of 4-amino-5-chloro-2-methoxy-3-nitrobenzoic acid (I21) (1.36 g, 5.5 mmol), NH4Cl (0.44 g, 8.3 mmol), HOBt (1.12 g, 8.3 mmol), EDCI.HCl (1.27 g, 6.6 mmol) and DIPEA (1.08 g, 8.3 mmol) in DMF (20 mL) was stirred overnight at room temperature under N2. Water (30 mL) was added and the mixture was extracted with EtOAc (30 mL×3). The combined organic extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=20:1 to 3:1) to give the title compound (1.2 g, 89%) as a yellow solid.

[0600] LCMS-B(ES-API):rt 2.70min,m / z 246.0,247.9[M+H] + .

[0601] 1 H NMR (400MHz, DMSO-d6) δ7.67(s,1H),7.53(br s,2H),6.50(s,2H),3.79(s,3H).

[0602] (e) 3,4-Diamino-2-methoxybenzamide (I23)

[0603] A solution of 4-amino-5-chloro-2-methoxy-3-nitrobenzamide (I22) (1.2 g, 5.9 mmol) in MeOH (30 mL) was degassed by N2 bubbling for 10 minutes. 10% Pd / C (1.5 g) was added, followed by Et3N (30 mL), and the resulting mixture was stirred under H2 (5 atm) for 6 hours. The mixture was filtered through a Celite pad, washed with MeOH and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM / MeOH=100:1 to 90:1) to give the title compound (534 mg, 50%) as a white solid.

[0604] LCMS-B(ES-API):rt 0.8min,m / z 182.0[M+H] + .

[0605] 1H NMR (400MHz, DMSO-d6) δ7.38 (s, 1H), 7.05 (s, 1H), 6.97 (d, J = 8.3Hz, 1H), 6.34 (d, J = 8.4Hz, 1H), 5.11 (s, 2H), 4.35 (s, 2H), 3.65 (s, 3H).

[0606] Example

[0607] 3-(5-Carbamoyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (1)

[0608]

[0609] To a solution of 3,4-diaminobenzamide (I1) (50 mg, 0.33 mmol) and ethyl 4-chloro-3-formylbenzo[b]thiophene-2-carboxylate (I8) (89 mg, 0.33 mmol) in EtOH (5 mL) was added AcOH (2 drops), and the mixture was stirred at room temperature for 48 hours. The mixture was concentrated under reduced pressure, and the residue was purified by preparative TLC (DCM / MeOH=15:1) to give the title compound 1 (40 mg, 30%) as a white solid.

[0610] LCMS-A(ES-API):rt 0.72min,m / z 399.9[M+H] + .

[0611] 1 H NMR(400MHz,DMSO-d6)δ13.0-12.9(m,1H),8.26-8.11(m,2H),8.00-7.99(m,1H),7.85-7.78 (m,1H),7.70-7.56(m,3H),7.28-7.25(m,1H),4.09(q,J=7.2Hz,2H),0.88(t,J=7.2Hz,3H).

[0612] 3-(5-Carbamoyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid (2)

[0613]

[0614] To a solution of ethyl 3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate (1) (50 mg, 0.13 mmol) in methanol (6 mL) and water (2 mL) was added KOH (35 mg, 0.63 mmol) and the mixture was heated at 60° C. for 1 hour. Most of the methanol was removed under reduced pressure and the aqueous residue was adjusted to pH 5 with 1 M aqueous HCl solution. The resulting precipitate was collected by filtration, washed with water (10 mL) and dried under reduced pressure to give the title compound 2 (20 mg, 42%) as a white solid.

[0615] LCMS-A(ES-API):rt 0.39min,m / z 371.9[M+H] + .

[0616] 1 H NMR (400MHz, DMSO-d6) δ8.26-8.19(m,2H),8.03(br s,1H),7.86(d,J=8.5Hz,1H),7.68(d,J=8.5Hz,1H),7.65-7.53(m,2H),7.30(br s,1H).

[0617] 3-(5-Carbamoyl-7-fluoro-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (3)

[0618]

[0619] To a solution of 3,4-diamino-5-fluorobenzamide (I4) (300 mg, 1.77 mmol), ethyl 4-chloro-3-formylbenzo[b]thiophene-2-carboxylate (I8) (477 mg, 1.77 mmol) / EtOH (20 mL) was added AcOH (0.3 mL), and the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was purified by silica gel chromatography (DCM / MeOH=50:1) to give the title compound 3 (80 mg, 10%) as a white solid.

[0620] LCMS-D(ES-API):rt 1.20min,m / z 417.9[M+H] + .

[0621] 1H NMR (400MHz, DMSO-d6) δ13.6-13.3(m,1H),8.24(d,J=8.0Hz,1H),8.20-7.96(m,2H) ,7.70-7.54(m,3H),7.45-7.38(m,1H),4.12(q,J=7.0Hz,2H),0.91(t,J=7.2Hz,3H).

[0622] 3-(6-Carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (4)

[0623]

[0624] (a) 2-(4-chloro-2-(ethoxycarbonyl)benzo[b]thien-3-yl)-7-methoxy-1H-benzo[d]imidazole-6-carboxylic acid (A1)

[0625] To a solution of 3,4-diamino-2-methoxybenzoic acid (I5) (90 mg, 0.49 mmol) / DMF (10 mL) was added 4-chloro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I8) (133 mg, 0.49 mmol) and NaHSO3 (103 mg, 0.99 mmol), and the mixture was heated at 80 ° C under N2 overnight. Water was added and the mixture was extracted with EtOAc (50 mL×3). The combined organic extracts were washed with water (50 mL×3), brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=15:1) to give the title compound A1 (66 mg, 31%) as a white solid.

[0626] LCMS-B(ES-API):rt 3.41min; m / z 431.0[M+H] + .

[0627] (b) 3-(6-Carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (4)

[0628] A mixture of 2-(4-chloro-2-(ethoxycarbonyl)benzo[b]thiophen-3-yl)-7-methoxy-1H-benzo[d]imidazole-6-carboxylic acid (A1) (77 mg, 0.18 mmol), NH4Cl (19. mg, 0.36 mmol), HATU (82 mg, 0.21 mmol) and DIPEA (69 mg, 0.54 mmol) in DMF (5 mL) was stirred overnight at room temperature under N2. The mixture was poured into water (50 mL), extracted with EtOAc (50 mL×3) and the combined organic extracts were washed with water (50 mL×3), brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=15:1) to give the title compound 4 (60 mg, 78%) as a white solid.

[0629] LCMS-B(ES-API):rt 3.28min; m / z 430.0[M+H] + .

[0630] 1 H NMR (400MHz, DMSO-d6) δ13.2-13.1(m,1H),8.24(d,J=7.9Hz,1H),7.84-7.68(m,2H),7.68-7.51(m, 2H), 7.41 (s, 1H), 7.24 (d, J = 8.6Hz, 1H), 4.36 (s, 3H), 4.11 (q, J = 7.2Hz, 2H), 0.92 (t, J = 7.2Hz, 3H).

[0631] 3-(5-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester and 3-(6-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (5.1 and 5.2)

[0632]

[0633] A suspension of ethyl 3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate (1) (0.050 g, 0.13 mmol), MeI (0.054 mg, 0.38 mmol) and KCO (0.052 g, 0.38 mmol) in DMF (5 mL) was stirred overnight at room temperature. Water (50 mL) was added and the mixture was extracted with EtOAc (50 mL×2). The combined organic extracts were washed with water (50 mL×2), brine (50 mL), dried over NaSO, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (Agilent ProStar, YMC-C18, 150×20 mm column, eluting with a gradient of MeOH / water with 0.07% TFA at a flow rate of 20 mL / min) to give regioisomer D5.1 as the first eluting (“peak 1”) and regioisomer 5.2 as the second eluting (“peak 2”). The structures shown for 5.1 and 5.2 are merely illustrative, as no structures have been assigned.

[0634] Peak 1-5.1 (HPLC: rt 6.36 min): (15 mg, 29%), white solid.

[0635] LCMS-A(ES-API):rt 0.25min; m / z 413.9[M+H] + .

[0636] 1 H NMR (400MHz, DMSO-d6) δ8.37-8.22(m,2H),8.07(br s,1H),7.95-7.84(m,1H),7.82-7.56(m,3H),7.41(br s,1H),4.11(br s,2H),3.65(s,3H),0.87(br s,3H).

[0637] Peak 2-5.2 (HPLC: rt 6.75 min): (5 mg, 9%), white solid.

[0638] LCMS-A(ES-API):rt 0.28min; m / z 413.9[M+H] + .

[0639] 1H NMR (400MHz, DMSO-d6) δ8.30-8.24(m,2H),8.08(br s,1H),7.96(dd,J=8.5,1.5Hz,1H),7.80(d,J=8.6Hz,1H),7.69-7.58(m,2H),7.34(br s, 1H), 4.15 (q, J = 7.2Hz, 2H), 3.65 (s, 3H), 0.87 (t, J = 7.2Hz, 3H).

[0640] 3-(5-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid and 3-(6-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid (6.1 and 6.2)

[0641]

[0642] (a) 3-(5-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester and 3-(6-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (A2)

[0643] A suspension of ethyl 3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate (1) (0.200 g, 0.501 mmol), MeI (0.214 g, 1.50 mmol) and K2CO3 (0.208 g, 1.50 mmol) in DMF (10 mL) was stirred overnight at room temperature. Water (50 mL) was added and the mixture was extracted with EtOAc (50 mL×2). The combined organic extracts were washed with water (100 mL×3), brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=20:1) to give a mixture of the two title compounds (30 mg, 14%) as a white solid.

[0644] (b) 3-(5-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid and 3-(6-Carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid 6.1 and 6.2

[0645] To a mixture of ethyl 3-(5-carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate and ethyl 3-(6-carbamoyl-1-methyl-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate (A2) (0.030 g, 0.07 mmol) in a solution of methanol (10 mL) and water (3 mL) was added KOH (0.21 g, 0.36 mmol) and the mixture was heated at 60° C. for 1 hour. Most of the methanol was removed under reduced pressure and the aqueous residue was adjusted to pH 5 with 1M aqueous HCl (5 mL) solution. The resulting precipitate was collected by filtration, washed with water (10 mL), Et2O (10 mL) and dried under reduced pressure to give a mixture of the two title compounds (0.023 g, 85%) as a yellow solid. The ratio of the unspecified regioisomers in the mixture is about 2:1, as determined by 1 The structures shown for 6.1 and 6.2 are illustrative only, as no assignments have been made.

[0646] LCMS-A(ES-API):rt 0.39min,m / z 386.1[M+H] + .

[0647] 1 H NMR(400MHz,DMSO-d6)δ8.54(s,1H),8.36(s,0.5H),8.33-8.28(m,1.5H),8.22(br s,1.5H),8.08-8.03(m,1.5H),7.95(d,J=8.4Hz,0.5H),7.88(d,J=8.4Hz,1H),7.68-7.61(m,3H),7.52(br s,1H),7.45(br s,0.5H),3.77(s,3H),3.74(s,1.5H).

[0648] 4-Bromo-3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (7) and 4-Bromo-3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid (8)

[0649]

[0650] (a) 4-bromo-3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (7)

[0651] A solution of ethyl 4-bromo-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylate (I15) (0.218 g, 0.66 mmol), 3,4-diaminobenzamide (I1) (0.200 g, 0.66 mmol) and NaHSO (0.069 g, 0.66 mmol) in DMF (10 mL) was heated at 80 °C under N overnight. Water (50 mL) was added and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried over NaSO, filtered and concentrated under reduced pressure to give the title compound (280 mg, 92%) as a white solid.

[0652] LCMS-B(ES-API):rt 3.27min,m / z 462.0,464.0[M+H] + .

[0653] 1 H NMR(400MHz,DMSO-d6)δ8.36-8.19(m,1H),8.15-8.00(m,1H),7.99-7.66(m,3H ),7.65-7.25(m,1H),7.42-7.25(m,1H),4.13-4.01(m,2H),1.02-0.82(m,3H).

[0654] (b) 4-Bromo-3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid (8)

[0655] A mixture of ethyl 4-bromo-3-(5-carbamoyl-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylate (7) (0.120 g, 0.26 mmol) and LiOH.H2O (0.0326 g, 0.78 mmol) in water (1 mL) and THF (9 mL) was stirred at room temperature overnight. The mixture was diluted with water (50 mL) and washed with EtOAc (50 mL×3). The aqueous phase was acidified with aqueous HCl and extracted with DCM (50 mL×4). The combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound (65 mg, 57%) as a white solid.

[0656] LCMS-B(ES-API):rt 2.62min,m / z 433.9,435.9[M+H] + .

[0657] 1H NMR (400MHz, DMSO-d6) δ8.19(s,1H),7.99(br s,1H),7.81(d,J=8.4Hz,1H),7.79-7.73(m,1H),7.64(d,J=8.3Hz,1H),7.47(t,J=8.9Hz,1H),7.23(br s,1H).

[0658] 3-(6-Carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid (9)

[0659]

[0660] A mixture of ethyl 3-(6-carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate (4) (0.060 g, 0.14 mmol) and LiOH.HO (0.018 g, 0.42 mmol) in THF (4 mL) and water (2 mL) was stirred overnight at room temperature. The mixture was concentrated under reduced pressure and the residue was diluted with water (2 mL) and adjusted to pH 4-5 with 2M aqueous HCl. The resulting precipitate was collected by filtration and dried under vacuum at 55°C for 1 hour to give the title compound (20 mg, 35%) as a white solid.

[0661] LCMS-B(ES-API):rt 2.76min,m / z 402.0,404.0[M+H] + .

[0662] 1 H NMR (400MHz, DMSO-d6) δ8.28(dd,J=7.6,1.6Hz,1H),7.81(br s,1H),7.78(d,J=8.5Hz,1H),7.68-7.61(m,2H),7.59(br s, 1H), 7.49 (d, J = 8.5Hz, 1H), 4.19 (s, 3H).

[0663] 4-Bromo-3-(6-carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (10) and 4-Bromo-3-(6-carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid (11)

[0664]

[0665] (a) 2-(4-bromo-2-(ethoxycarbonyl)-7-fluorobenzo[b]thien-3-yl)-7-methoxy-1H-benzo[d]imidazole-6-carboxylic acid (A3)

[0666] To a solution of 3,4-diamino-2-methoxybenzoic acid (I5) (408 mg, 2.24 mmol) / DMF (23 mL) was added 4-bromo-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylic acid ethyl ester (I15) (742 mg, 2.24 mmol) and NaHSO3 (233 mg, 2.24 mmol), and the mixture was heated at 80 ° C overnight under N2. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with water, brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM / MeOH=100:1 to 90:1) to give the title compound (238 mg, 22%) as a brown solid.

[0667] LCMS-C(ES-API):rt 4.05min,m / z 493.0,495.0[M+H] + .

[0668] 1 H NMR(400MHz,DMSO-d6)δ13.1(br s,1H),7.82(dd,J=8.5,4.7Hz,1H),7.61(d,J=8.4Hz,1H),7.57-7.50(m,1H),7 .26(d,J=8.5Hz,1H), 4.26(s,3H), 4.14(q,J=7.1Hz,2H), 0.93(t,J=7.1Hz,3H).

[0669] (b) 4-bromo-3-(6-carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (10)

[0670] To a solution of 2-(4-bromo-2-(ethoxycarbonyl)-7-fluorobenzo[b]thiophen-3-yl)-7-methoxy-1H-benzo[d]imidazole-6-carboxylic acid (A3) (228 mg, 0.462 mmol) in DMF (9 mL) was added EDCI.HCl (133 mg, 0.693 mmol), HOBt (94 mg, 0.69 mmol), DIPEA (299 mg, 2.31 mmol) and concentrated NH4OH aqueous solution (65 mg, 1.85 mmol), and the mixture was stirred at room temperature overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=20:1) to give the title compound (65 mg, 29%) as a white solid.

[0671] LCMS-C(ES-API):rt 3.85min,m / z 491.9,493.9[M+H] + .

[0672] 1 H NMR (400MHz, DMSO-d6) δ13.1(br s,1H),7.84-7.78(m,2H),7.72(br s,1H),7.56-7.51(m,1H),7.41(br s, 1H), 7.26 (d, J = 8.5Hz, 1H), 4.37 (s, 3H), 4.14 (q, J = 7.1Hz, 2H), 0.93 (t, J = 7.1Hz, 3H).

[0673] (c) 4-Bromo-3-(6-carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid (11)

[0674] To a solution of ethyl 4-bromo-3-(6-carbamoyl-7-methoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylate (10) (0.060 g, 0.12 mmol) in EtOH / water (6 mL / 3 mL) was added NaOH (15 mg, 0.37 mmol) and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure and the residue was diluted with water, adjusted to pH 4-5 with 2M aqueous HCl solution and the resulting precipitate was collected by filtration and dried under reduced pressure to give the title compound (48 mg, 84%) as a white solid.

[0675] LCMS-C(ES-API):rt 2.85min,m / z 464.0,466.0[M+H]+ .

[0676] 1 H NMR (400MHz, DMSO-d6) δ7.81-7.74(m,2H),7.70(br s,1H),7.49(t,J=8.9Hz,1H),7.42(br s,1H),7.27(d,J=8.5Hz,1H),4.32(s,3H).

[0677] 3-(5-Carbamoyl-4-chloro-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (12)

[0678]

[0679] (a) 4-Bromo-3-chloro-2-nitroaniline (A4)

[0680] A solution of 3-chloro-2-nitroaniline (25.0 g 0.145 mol) and NBS (25.8 g 0.145 mol) in acetic acid (1 L) was heated at reflux under N2 overnight. Water (1 L) was added and the insoluble material was collected by filtration to give the title compound (22.3 g, 62%) as a grey solid.

[0681] LCMS-C(ES-API):rt 3.84min; m / z 250.9,252.9[M+H] + .

[0682] 1 H NMR (400MHz, DMSO-d6) δ7.56 (d, J = 9.2 Hz, 1H), 6.84 (d, J = 9.2 Hz, 1H), 6.41 (s, 2H).

[0683] (b) Methyl 3,4-diamino-2-chlorobenzoate (A5)

[0684] A mixture of 4-bromo-3-chloro-2-nitroaniline (A4) (18.9 g 75.5 mmol), Pd(dppf)Cl2 (8.27 g, 11.3 mmol) and Et3N (22.9 g, 226.5 mmol) in MeOH (250 mL) was heated under reflux under a carbon monoxide atmosphere for 48 hours. The mixture was poured into water (500 mL) and extracted with EtOAc (250 mL×3). The combined organic extracts were washed with brine (250 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=5:1 to 2:1) to obtain the title compound (1.0 g, 6%) as a yellow solid.

[0685] 1 H NMR (400MHz, DMSO-d6) δ7.08 (d, J = 8.4 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.58 (s, 2H), 4.89 (s, 2H), 3.72 (s, 3H).

[0686] (c) 3,4-Diamino-2-chlorobenzoic acid (A6)

[0687] A mixture of methyl 3,4-diamino-2-chlorobenzoate (A5) (0.200 g, 1.0 mmol) and NaOH (400 mg, 10 mmol) in EtOH / H2O (8 mL / 2 mL) was heated at 80°C for 5 hours. The pH of the mixture was adjusted to about 4-5 with 2M HCl aqueous solution, diluted with water (50 mL) and extracted with EtOAc (50 mL×3). The combined organic extracts were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (160 mg, 86%) as a red solid.

[0688] LCMS-C(ES-API):rt 0.48min; m / z 187.0,189.0[M+H] + .

[0689] (d) 4-chloro-2-(4-chloro-2-(ethoxycarbonyl)benzo[b]thiophen-3-yl)-1H-benzo[d]imidazole-5-carboxylic acid (A7)

[0690] A solution of 3,4-diamino-2-chlorobenzoic acid (A6) (150 mg, 0.8 mmol), ethyl 4-chloro-3-formylbenzo[b]thiophene-2-carboxylate (I8) (215 mg, 0.8 mmol) and NaHSO3 (167 mg, 1.6 mmol) / DMF (15 mL) was heated at 120 °C under N2 overnight. The mixture was poured into water (100 mL) and extracted with EtOAc (50 mL×3). The combined organic extracts were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc) to give the title compound (250 mg, 72%) as a black solid.

[0691] LCMS-C(ES-API):rt 3.70min; m / z 434.9,436.9[M+H] + .

[0692] (e) 3-(5-Carbamoyl-4-chloro-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid ethyl ester (12)

[0693] A solution of 4-chloro-2-(4-chloro-2-(ethoxycarbonyl)benzo[b]thiophene-3-yl)-1H-benzo[d]imidazole-5-carboxylic acid (A7) (0.200 g, 0.46 mmol), EDCI.HCl (0.132 g, 0.69 mmol), DIPEA (0.297 g, 2.3 mmol) and HOBt (0.093 g, 0.69 mmol) in DMF (10 mL) was stirred at room temperature for 15 minutes. NH4Cl (0.123 g, 2.3 mmol) was then added and the mixture was stirred at room temperature overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:1 to 1:4) to give the title compound (110 mg, 55%) as a white solid.

[0694] LCMS-C(ES-API):rt 3.28min; m / z 433.96,435.98[M+H] + .

[0695] 1 H NMR(400MHz,DMSO-d6)δ13.2(s,1H),8.26-8.22(m,1H),7.96-7.83(m,1H),7.6 8-7.53(m,4H),7.35-7.33(m,1H),4.13(q,J=7.2Hz,2H),0.98(t,J=7.2Hz,3H).

[0696] 3-(5-Carbamoyl-4-chloro-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylic acid (13)

[0697]

[0698] A solution of ethyl 3-(5-carbamoyl-4-chloro-1H-benzo[d]imidazol-2-yl)-4-chlorobenzo[b]thiophene-2-carboxylate (12) (50 mg, 0.1 mmol) and NaOH (40 mg, 10 mmol) in EtOH / water (4 mL / 1 mL) was heated at 80°C for 6 hours. The solvent was removed under reduced pressure and the residue was diluted with water (2 mL) and acidified to pH 4-5 with 2M aqueous HCl. The resulting precipitate was collected by filtration to give the title compound (30 mg, 75%) as a white solid.

[0699] LCMS-C(ES-API):rt 2.42min; m / z 405.9,407.9[M+H] + .

[0700] 1 H NMR (400MHz, DMSO-d6) δ8.22 (dd, J = 8.0, 0.8Hz 1H), 7.86 (s, 1H), 7.61-7.53 (m, 4H), 7.32 (d, J = 8.2Hz 1H).

[0701] 4-Bromo-3-(6-carbamoyl-7-ethoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (14)

[0702]

[0703] (a) Methyl 4-fluoro-2-hydroxybenzoate (A8)

[0704] A mixture of 4-fluoro-2-hydroxybenzoic acid (50.0 g, 320.3 mmol) and concentrated H2SO4 (40 mL, 672.7 mmol) in MeOH (600 mL) was heated under reflux for 16 hours under N2. The mixture was poured into water (500 mL) and extracted with EtOAc (500 mL×3). The combined organic extracts were washed with water (500 mL×2), brine (500 mL), dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=100:1 to 20:1) to obtain the title compound (50.0 g, 91%) as a white solid.

[0705] LCMS-A(ES-API):rt 1.80min,m / z 171.1[M+H] + .

[0706] 1 H NMR (400MHz, DMSO-d6) δ10.8 (s, 1H), 7.83 (dd, J = 8.9, 6.8Hz, 1H), 6.90-6.70 (m, 2H), 3.88 (s, 3H).

[0707] (b) Methyl 4-fluoro-2-hydroxy-3-nitrobenzoate (A9)

[0708] At 0°C under N2, concentrated HNO3 (8 mL) was added dropwise to a solution of 4-fluoro-2-hydroxybenzoic acid methyl ester (A8) (20.0 g, 117 mmol) / concentrated H2SO4 (40 mL) and the mixture was stirred at 0°C overnight. The mixture was diluted with water, extracted with EtOAc and the combined organic extracts were washed with brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:0 to 100:1) to obtain the title compound (1.7 g, 6%) as a white solid.

[0709] 1 H NMR (400MHz, DMSO-d6) δ8.08 (dd, J=9.1, 6.4Hz, 1H), 7.17 (t, J=9.3Hz, 1H), 3.93 (s, 3H).

[0710] (c) 2-ethoxy-4-fluoro-3-nitrobenzoic acid methyl ester (A10)

[0711] To a solution of 4-fluoro-2-hydroxy-3-nitrobenzoic acid methyl ester (A9) (900mg, 4.2mmol) / DMF (20mL), iodoethane (980mg, 6.3mmol) and K2CO3 (1.74g, 12.6mmol) were added and the mixture was stirred overnight at room temperature under N2. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:0 to 100:1) to obtain the title compound (600mg, 58%), a yellow solid.

[0712] 1 H NMR (400MHz, DMSO-d6) δ 8.10 (dd, J = 9.1, 6.5 Hz, 1H), 7.48 (t, J = 9.0 Hz, 1H), 4.13 (d, J = 7.0 Hz, 2H), 3.89 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H).

[0713] (d) 4-amino-2-ethoxy-3-nitrobenzoic acid methyl ester (A11)

[0714] A mixture of 2-ethoxy-4-fluoro-3-nitrobenzoic acid methyl ester (A10) (0.900 g, 4.2 mmol) and 0.5 M NH3 in a solution of 1,4-dioxane (200 mL) was heated at 100 ° C overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1:0 to 100:1) to obtain the title compound (600 mg, 67%), a yellow solid.

[0715] 1 H NMR (400MHz, DMSO-d6) δ7.68 (d, J = 9.0 Hz, 1H), 6.68 (s, 2H), 6.64 (d, J = 9.0 Hz, 1H), 4.00 (q, J = 7.0 Hz, 2H), 3.77 (s, 3H), 1.24 (t, J = 7.0 Hz, 3H).

[0716] (e) 4-Amino-2-ethoxy-3-nitrobenzoic acid (A12)

[0717] To a solution of methyl 4-amino-2-ethoxy-3-nitrobenzoate (A11) (0.900 g, 3.75 mmol) / EtOH (10 mL) was added a solution of NaOH (1.5 g, 37.5 mmol) / water (10 mL) and the resulting mixture was stirred at room temperature overnight. Most of the EtOH was removed under reduced pressure and the aqueous residue was adjusted to pH 5 with 1M HCl aqueous solution. The resulting precipitate was collected by filtration and dried under vacuum to give the title compound (570 mg, 67%) as a yellow solid.

[0718] LCMS-B(ES-API):rt 2.85min,m / z 226.8[M+H] + .

[0719] 1 H NMR (400MHz, DMSO-d6) δ12.5 (s, 1H), 7.67 (d, J = 9.0Hz, 1H), 6.61 (d, J = 9.0Hz, 1H), 6.56 (s, 2H), 4.03 (q, J = 7.0Hz, 2H), 1.23 (t, J = 7.0Hz, 3H).

[0720] (f) 3,4-Diamino-2-ethoxybenzoic acid (A13)

[0721] To a solution of 4-amino-2-ethoxy-3-nitrobenzoic acid (A12) (0.470 g, 2.08 mmol) / EtOH (22 mL) was added Zn turnings (0.816 g, 12.5 mmol) and saturated NH4Cl aqueous solution (11 mL), and the mixture was stirred at room temperature overnight. Most of the EtOH was removed under reduced pressure and the aqueous residue was freeze-dried. The residue was washed with 10:1 DCM / MeOH (50 mL) and the filtrate was concentrated under reduced pressure to give the title compound (400 mg, 98%) as a black solid.

[0722] 1 H NMR (400MHz, DMSO-d6) δ6.98 (d, J = 8.4Hz, 1H), 6.30 (d, J = 8.4Hz, 1H), 5.24 (s, 2H), 4.25 (s, 2H), 3.85 (q, J = 7.0Hz, 2H), 1.30 (t, J = 7.0Hz, 3H).

[0723] (g) 2-(4-bromo-2-(ethoxycarbonyl)-7-fluorobenzo[b]thien-3-yl)-7-ethoxy-1H-benzo[d]imidazole-6-carboxylic acid (A14)

[0724] To a solution of 3,4-diamino-2-ethoxybenzoic acid (A13) (110 mg, 0.56 mmol) / DMF (6 mL) was added NaHSO3 (59 mg, 0.56 mmol) and ethyl 4-bromo-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylate (I15) (185 mg, 0.56 mmol), and the mixture was heated at 80 ° C overnight under N2. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=15:1) to give the title compound (80 mg, 28%) as a yellow solid.

[0725] LCMS-B(ES-API):rt 3.81min,m / z 507.0,509.0[M+H] + .

[0726] 1H NMR(400MHz,DMSO-d6)δ13.1(br s,1H),12.3(br s,1H),7.82(dd,J=8.8,4.8Hz,1H),7.60(d,J=8.4Hz,1H),7.53(t,J=8.9Hz,1H),7.25(d,J=8.5H z, 1H), 4.70 (q, J = 7.0Hz, 2H), 4.14 (q, J = 6.8Hz, 2H), 1.30 (t, J = 7.0Hz, 3H), 0.92 (t, J = 7.1Hz, 3H).

[0727] (h) 4-Bromo-3-(6-carbamoyl-7-ethoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (14)

[0728] To a solution of 2-(4-bromo-2-(ethoxycarbonyl)-7-fluorobenzo[b]thiophene-3-yl)-7-ethoxy-1H-benzo[d]imidazole-6-carboxylic acid (A14) (0.080 g, 0.16 mmol) / DMF (4 mL) was added EDCI.HCl (0.045 g, 0.24 mmol), HOBt (0.032 g, 0.24 mmol), DIPEA (0.102 g, 0.79 mmol) and concentrated NH4OH aqueous solution (0.022 g, 0.62 mmol), and the mixture was stirred at room temperature overnight. Water was added and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH=15:1) to give the title compound (7.0 mg, 9%) as a white solid.

[0729] LCMS-B(ES-API):rt 3.62min,m / z 506.1,508.1[M+H] + .

[0730] 1 H NMR (400MHz, DMSO-d6) δ13.0 (br s, 1H), 7.85-7.76 (m, 3H), 7.53 (t, J = 8.7Hz, 1H), 7.42 (br s, 1H), 7.26 (d, J = 8.3Hz, 1H), 4.70 (q, J = 6.7Hz, 2H), 4.13 (q, J = 7.2Hz, 2H), 1.34 (t, J = 7.0Hz, 3H), 0.92 (t, J = 7.2Hz, 3H).

[0731] 4-Bromo-3-(6-carbamoyl-7-ethoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylic acid (15)

[0732]

[0733] To a solution of ethyl 4-bromo-3-(6-carbamoyl-7-ethoxy-1H-benzo[d]imidazol-2-yl)-7-fluorobenzo[b]thiophene-2-carboxylate (14) (0.050 g, 0.099 mmol) in EtOH (2 mL) was added a solution of NaOH (0.040 g, 0.99 mmol) in water (2 mL) and the mixture was stirred at room temperature overnight. Most of the EtOH was removed under reduced pressure and the aqueous residue was adjusted to pH 5 with 1 M aqueous HCl. The resulting precipitate was collected by filtration and purified by preparative HPLC (Varian-940-LC, BOSTON, 250×2.12 mm, 10 μm column, eluted with a gradient of ACN / water with 0.1% formic acid at a flow rate of 20.0 mL / min) to give the title compound (5 mg, 10%) as a white solid.

[0734] LCMS-B(ES-API):rt 2.88min,m / z 478.0,480.0[M+H] + .

[0735] 1 H NMR(400MHz,DMSO-d6)δ12.9(br s,1H),7.78-7.75(m,2H),7.68,(br s,1H),7.39-7.35(m,2H),7.27-7.19(m,1H),4.88-4.75(m,2H),1.34(t,J=6.0Hz,3H).

[0736] 7-Bromo-3-(5-carbamoyl-4-methoxy-1H-benzo[d]imidazol-2-yl)-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid ethyl ester (16) and 7-Bromo-3-(5-carbamoyl-4-methoxy-1H-benzo[d]imidazol-2-yl)-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid (17)

[0737]

[0738] (a) 7-Bromo-3-(5-carbamoyl-4-methoxy-1H-benzo[d]imidazol-2-yl)-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid ethyl ester (16)

[0739] A mixture of ethyl 7-bromo-3-formyl-4-methoxythieno[3,2-c]pyridine-2-carboxylate (I18) (100 mg, 0.3 mmol), 3,4-diamino-2-methoxybenzamide (I23) (52.6 mg, 0.3 mmol) and NaHSO (15.6 mg, 0.15 mmol) in DMF (5 mL) was heated at 80 °C under N overnight. Water (5 mL) was added and the mixture was extracted with EtOAc (5 mL x 3). The combined organic extracts were washed with water and brine, dried over NaSO, filtered and concentrated under reduced pressure to give the title compound (126 mg, 83%) as a yellow solid.

[0740] LCMS-B(ES-API):rt 3.44min,m / z 505.0,507.0[M+H] + .

[0741] 1 H NMR (400MHz, DMSO-d6) δ12.9(s,1H),8.41(s,1H),7.81(d,J=8.5Hz,1H),7.73(s,1H),7.42(s,1H ), 7.26 (d, J = 8.5Hz, 1H), 4.39 (s, 3H), 4.15 (q, J = 6.9Hz, 2H), 3.70 (s, 3H), 0.97 (t, J = 7.1Hz, 3H).

[0742] (b) 7-Bromo-3-(5-carbamoyl-4-methoxy-1H-benzo[d]imidazol-2-yl)-4-methoxythieno[3,2-c]pyridine-2-carboxylic acid (17)

[0743] A mixture of ethyl 7-bromo-3-(5-carbamoyl-4-methoxy-1H-benzo[d]imidazol-2-yl)-4-methoxythieno[3,2-c]pyridine-2-carboxylate (16) (118 mg, 0.23 mmol) and NaOH (93.4 mg, 2.3 mmol) in 10:1 EtOH / H2O (5 mL) was stirred overnight at room temperature. Most of the EtOH was removed under reduced pressure and the aqueous residue was adjusted to pH 6 with 2M aqueous HCl. The resulting precipitate was collected by filtration and dried under vacuum to give the title compound (92 mg, 84%) as a yellow solid.

[0744] LCMS-B(ES-API):rt 2.85min,m / z 477.0,479.0[M+H] + .

[0745] 1H NMR (400MHz, DMSO-d6) δ8.38(s,1H),7.76(d,J=8.5Hz,1H),7.73(s,1H),7.43(s,1H),7.28(d,J=8.5Hz,1H),4.34(s,3H),3.68(s,3H).

[0746] 3-(5-Carbamoyl-7-chloro-4-methoxy-1H-benzo[d]imidazol-2-yl)-4-chloro-7-fluorobenzo[b]thiophene-2-carboxylic acid ethyl ester (18)

[0747]

[0748] A mixture of ethyl 4-chloro-7-fluoro-3-formylbenzo[b]thiophene-2-carboxylate (I13) (0.100 g, 0.35 mmol), 4-amino-5-chloro-2-methoxy-3-nitrobenzamide (I22) (0.086 g, 0.35 mmol), NaHSO (18.2 mg, 0.175 mmol) and NaS O (183 mg, 1.05 mmol) in DMF (5 mL) was heated at 80 °C under N overnight. Water (10 mL) was added and the mixture was extracted with EtOAc (10 mL x 3). The combined organic extracts were washed with water, brine, dried over Na SO, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM / MeOH = 100: 1) to give the title compound (69 mg, 41%) as a white solid.

[0749] LCMS-B(ES-API):rt 3.56min,m / z 482.0,484.0[M+H] + .

[0750] 1 H NMR (400MHz, DMSO-d6) δ13.5 (s, 1H), 7.76 (s, 1H), 7.69-7.56 (m, 4H), 4.37 (s, 3H), 4.18 (q, J = 7.2Hz, 2H), 0.94 (t, J = 7.2Hz, 3H).

[0751] Further embodiments

[0752] The following example compounds were prepared by similar methods.

[0753]

[0754]

[0755] Determination

[0756] Protein production and purification

[0757] Biophysical experiments were performed with three different recombinant human STING protein variants designated according to the allelic nomenclature of Yi et al. (2013). Codon-optimized DNA sequences encoding amino acid residues 149 to 345 (Swiss Prot Q86WV6) of human STING (WT), human STING (HAQ), and human STING (R232H) for expression in E. coli were synthesized by GenScript USA Inc (Piscataway, New Jersey, USA). They were ligated into a modified E. coli expression vector pET43a designed to encode an N-terminal His tag followed by a tobacco etch virus protease (TEV) cleavage site and the STING gene sequence. The resulting protein sequences of the three allelic variants are listed below:

[0758] His-TEV-hSTING(WT)

[0759]

[0760] His-TEV-hSTING(R232H)

[0761]

[0762] His-TEV-hSTING(HAQ)

[0763]

[0764] To produce recombinant human STING protein, expression plasmids encoding the above constructs were transformed into E. coli BL21 DE3 strain and grown at 37 °C in 2 × 1 L volumes of Terrific broth (TB) supplemented with 100 μg / ml ampicillin with shaking until an OD of 0.8 was reached. 600 The culture was then cooled to 16°C and protein expression was induced by adding isopropyl β-D-1-thiogalactopyranoside to a final concentration of 0.5 mM and the culture was shaken overnight for an additional 16 hours. After expression, the cell culture was centrifuged at 5000×g for 20 minutes and the cell pellet was stored frozen at −70°C.

[0765] Protein purification was started by thawing cell pellets in lysis buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM DTT, 2 mM MgCl2, 10 mM imidazole, 0.5 mg / ml lysozyme, universal nuclease [EMDMillipore], 1 mM PMSF, EDTA-free complete protease inhibitor tablets [Roche]) using a ratio of 7 ml buffer per 1 g of cells. Cells were further lysed by passing through an ice-cold Avestin C5 cell disruptor 3 times and then centrifuged at 48,000 × g at 4 ° C. The supernatant (cell lysate) was filtered through a 5 μm filter and loaded onto a 5 mL HiTrap IMAC Sepharose FF column (GE Healthcare) pre-equilibrated with IMAC wash buffer 1 (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM DTT, 10 mM imidazole) using a Profinia affinity chromatography purification system (Bio-Rad). The IMAC column was then washed sequentially with IMAC wash buffer 1 and IMAC wash buffer 2 (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM DTT, 20 mM imidazole) and bound to the His-TEV-hSTING protein eluted with IMAC elution buffer (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM DTT, 250 mM imidazole). The IMAC eluted protein was further purified by passing through a HiLoad 26 / 60 Superdex 75 column pre-equilibrated in storage buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM DTT 0.02% [w / v] sodium azide). Finally, hSTING protein was concentrated to ≥2 mg / ml using Amicon ultracentrifugal filter units (Utra-15 MWCO 10 kDa), snap-frozen in liquid nitrogen, and stored in a -70 °C freezer.

[0766] Differential Scanning Fluorescence (DSF)

[0767] Differential scanning fluorimetry (DSF) is a rapid screening method for identifying low molecular weight ligands that bind and, in the process, stabilize (or sometimes destabilize) a purified protein (Niesen 2007). DSF monitors the thermal unfolding of a protein in the presence of a fluorescent dye and is typically performed using a real-time PCR instrument. The temperature at which a protein unfolds is measured by the increase in fluorescence of a dye that has an affinity for the hydrophobic parts of the protein that are gradually exposed during unfolding. The fluorescence of the dye is quenched in an aqueous environment, but increases when the dye binds to hydrophobic sites on the unfolding protein. Plotting the fluorescence intensity as a function of temperature produces an S-shaped curve that can be described by a two-state transition. The inflection point (T m ) is calculated using simple equations such as the Boltzmann equation.

[0768] The thermal stability of STING protein (with or without bound ligand) was measured using a previously described method (Seabrook & Newman 2013), where samples were tested in triplicate using a 96-well PCR microplate (AB Gene, ABGAB-0600 / W). In a final volume of 20 μL, 2 μM protein in 1× HBS buffer (50 mM HEPES, pH 7.4, 150 mM NaCl) was mixed with SYPRO Orange dye (Sigma-Aldrich S5692, final reaction mix dilution 1:1200) and compound (final concentration 100 μM). The sealed plate was placed in a Bio-Rad CFX96 / C1000 thermal cycler and the FRET scanning mode (λ 激发 is 490nm, and the λ at 570nm 发射 Melting curves were recorded from 20°C to 100°C in increments of 0.5°C every 30 seconds, with readings taken at each increment. Data were analyzed using the "Meltdown analysis" protocol described by Rosa (2015). T values ​​obtained for proteins incubated with ligands were m The melting temperature T obtained for STING protein alone (1% [v / v] DMSO) was subtracted from m ) to produce the ΔT listed in the table below m DSF data were generated for each compound for three different STING protein variants - human STING (WT), human STING (HAQ) and human STING (R232H).

[0769]

[0770] Surface Plasmon Resonance (SPR)

[0771] Surface plasmon resonance (SPR) was used to quantify the binding interaction of the ligand with the STING protein, where minimally biotinylated STING protein was immobilized on a streptavidin chip surface. In this way, a highly active STING protein surface was obtained that was not affected by the low pH required for the amine coupling method. Minimal biotinylation of purified huSTING protein was performed using a previously described method (Chhabra 2012). Briefly, approximately 20 nmol of recombinant STING protein in 1× TBS buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM DTT) was mixed with the EZ-Link TM Sulfo-NHS-LC-LC-biotin (Thermofisher Science, cat# 21338) was mixed at a molar ratio of 1:0.6 and incubated on ice for 2 hours. To remove any unreacted biotin reagent, the protein / biotin mixture was passed through a Superdex 75 (10 / 300GL) column equilibrated with 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM DTT, 5% [v / v] glycerol. The protein peak containing biotinylated huSTING protein was collected and stored in aliquots at -80°C.

[0772] Streptavidin was immobilized simultaneously in all four channels of a CM5 sensor chip docked to a Biacore instrument (Biacore S200 or Biacore T200, GE Healthcare) as described previously (Zender 2013). Minimally biotinylated STING protein was captured onto the streptavidin-coated chip surface by gradual injection in a single channel at a constant flow rate of 2 μL / min at 8°C in SPR binding buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 2% [v / v] DMSO) until the desired capture level was reached, typically 3000 RU to 7000 RU (1 RU = 1 pg / mm 2 ).

[0773] All binding experiments were performed at 8 °C in SPR binding buffer. To determine binding affinity, dose response experiments were used to analyze the interaction of compounds with immobilized STING protein. Fresh 10 mM DMSO solutions of compounds were diluted directly into SPR binding buffer, typically to a concentration of 50 μM, and then further diluted 2-fold or 3-fold, targeting a 5-point or 7-point concentration series range. Each ligand concentration series was injected at a constant flow rate of 60 μL / min, with a 90 s association time and 180 s dissociation time. These were modified for compounds with longer residence times so that the curve could reach a steady state, or so that the compound would be completely dissociated before a subsequent injection. Where appropriate, tighter binding compounds (roughly K ) were tested using a single cycle kinetic format (Karlsson 2006). D <1 μM), with long association and dissociation times (typically 450 s and 1800 s, respectively).

[0774] Scrubber 2 (biologic.com.au) was used for data processing, where the signal was referenced to a blank surface (streptavidin + D-biotin) and further corrected for DMSO refractive index changes and then "double referenced" (Papalia, 2006) using a buffer blank injection. To determine binding affinity from dose response experiments (50% occupancy as a surrogate K for two binding events occurring) D ), the binding response at equilibrium was fitted to the Hill equation, where the Hill coefficient was floating (≤ 2). For single cycle kinetic experiments, the sensorgrams were fitted to a two-step kinetic model, where two analyte molecules bind sequentially (Biacore T200 or S200 evaluation software).

[0775]

[0776]

[0777] THP-1 reporter cell line assay

[0778] THP-1 STING Lucia ISG cells (Invivogen #thpI-isg) were cultured in RPMI-1640 containing 2mM L-glutamine, 25mM HEPES, 100μg / mL Normocin (InvivoGen) and 10% heat-inactivated FBS. The cells were seeded at a density of 7×105 cells / mL and maintained at 37°C / 5% CO2 and passaged every 3-4 days. The selection pressure was maintained by adding 100μg / mL Zeocin every other generation.

[0779] Assay conditions: Cells were harvested and resuspended in fresh growth medium at a concentration of 5×105 cells / mL. In this cell preparation, 20 μL / well was dispensed into 384-well cell culture plates (Greiner, #781098X) and incubated at 37°C / 5% CO2 for 2 hours.

[0780] Concentration response curves (usually 11 doses) were prepared by 2.5-fold descending dilutions starting from a 10 mM compound stock solution in DMSO. Compound dilutions were transferred to cell culture plates using a needle tool (0.1 μL transfer), and control wells were matched to DMSO. Positive control wells received ML RR-S2 CDA (Med Chem Express HY12885B) in 5 μL culture medium to a final concentration of 40 μM. All other wells received only an additional 5 μL culture medium to balance the volume. The plates were incubated at 37°C / 5% CO2 for 24 hours.

[0781] For the detection step, QUANTI-Luc (Invivogen # rep-qlc1) was prepared according to the manufacturer's instructions and 10 μL was added per well to incubate the plate. The plate was shaken on an orbital shaker for 10 seconds and placed in the dark at room temperature for two minutes before reading the fluorescence on a Perkin Elmer Envision plate reader.

[0782] Data Analysis: Fluorescence raw data were normalized to % activity relative to the signal from positive control wells and negative control wells not treated with compound. Normalized % activity from raw signal was calculated using the following formula:

[0783] % Activity = (Sample - Negative) / (Positive - Negative)

[0784] THP-1STING Lucia ISG Cell EC 50 An assessment of the activity of the human HAQ isoform of STING is provided. For the assessment of compound activity against the WT human STING isoform, an equivalent method was performed, wherein the cells used were THP-1-double KI-hSTING-R232 (InvivoGen #thpd-r232).

[0785]

[0786]

[0787] Claim of Invention

[0788] 1. Compounds of formula I:

[0789]

[0790] in:

[0791] W is O or NH;

[0792] R 1 Selected from:

[0793] (i) H;

[0794] (ii)C 3-6 Cycloalkyl;

[0795] (iii)C 3-7 A heterocyclic group, which is optionally substituted by a group selected from:

[0796] Methyl; and

[0797] Esters; and

[0798] (iv) Straight or branched chain C 1-4 Alkyl, which is optionally substituted by a group selected from:

[0799] Alkoxy;

[0800] Amino;

[0801] Acylamino;

[0802] acylamido;

[0803] acyloxy;

[0804] Alkyl carboxyl esters;

[0805] Alkylcarbamoyl;

[0806] Alkylcarbamoyl esters;

[0807] Phenyl;

[0808] Phosphonates;

[0809] C optionally substituted by a group selected from methyl and oxo 3-7 heterocyclyl; and

[0810] a naturally occurring amino acid, which is optionally N-substituted with a group selected from methyl, acetyl and boc;

[0811] A 1 Yes CR A or N;

[0812] A 2 Yes CR B or N;

[0813] A 3 Yes CR C or N;

[0814] A 4 Yes CRD or N;

[0815] Among them A 1 , A 2 , A 3 , and A 4 No more than two of them can be N;

[0816] R A , R B , R C and R D One or two of (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH;

[0817] The rest of R A , R B , R C and R D (if any) is H;

[0818] R N1 is H or Me;

[0819] R C2 and R C3 one of which is C(=O)NH2; the other is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C 2-4 Alkenyl and C5 heterocyclic group;

[0820] R C1 and R C4 independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C 2-4 alkenyl and C5 heterocyclic group.

[0821] 2. The compound according to claim 1, wherein W is O.

[0822] 3. The compound according to statement 1, wherein W is NH.

[0823] 4. A compound according to any one of claims 1 to 3, wherein R 1 It's H.

[0824] 5. The compound according to claim 1, wherein R 1 Selected from C 3-6 Cycloalkyl, optionally substituted C 3-7 heterocyclic group, and an optionally substituted straight or branched chain C 1-4 alkyl.

[0825] 6. A compound according to any one of statements 1 to 3 and statement 5, wherein R 1 It is C 3-6 Cycloalkyl.

[0826] 7. The compound according to claim 6, wherein R 1 It is cyclopropyl.

[0827] 8. The compound according to claim 6, wherein R 1 It is cyclobutyl.

[0828] 9. The compound according to claim 6, wherein R 1 It is cyclopentyl.

[0829] 10. The compound according to claim 6, wherein R 1 It is cyclohexyl.

[0830] 11. A compound according to any one of statements 1 to 3 and statement 5, wherein R 1 is optionally substituted C 3-7 Heterocyclic group.

[0831] 12. The compound according to claim 11, wherein R 1 is an optionally substituted C containing a single nitrogen ring atom 3-7 Heterocyclic group.

[0832] 13. The compound according to claim 12, wherein R 1 is optionally substituted azetidinyl.

[0833] 14. The compound according to claim 12, wherein R 1 is optionally substituted pyrrolidinyl.

[0834] 15. The compound according to claim 12, wherein R 1 is optionally substituted piperidinyl.

[0835] 16. A compound according to any one of statements 11 to 15, wherein R 1 is substituted by methyl.

[0836] 17. A compound according to any one of statements 11 to 15, wherein R 1 is ester substituted.

[0837] 18. A compound according to any one of statements 1 to 3 and statement 5, wherein R 1 is an optionally substituted straight or branched chain C 1-4 alkyl.

[0838] 19. The compound according to claim 18, wherein R 1 is optionally substituted methyl.

[0839] 20. The compound according to claim 18, wherein R 1 is optionally substituted ethyl.

[0840] 21. The compound according to claim 18, wherein R 1 is optionally substituted propyl.

[0841] 22. The compound according to claim 18, wherein R 1 is optionally substituted butyl.

[0842] 23. The compound according to claim 18, wherein R 1 is optionally substituted isopropyl.

[0843] 24. The compound according to claim 18, wherein R 1 is optionally substituted sec-butyl.

[0844] 25. The compound according to claim 18, wherein R 1 is optionally substituted isobutyl.

[0845] 26. The compound according to claim 18, wherein R 1 is optionally substituted tert-butyl.

[0846] 27. A compound according to any one of statements 18 to 26, wherein R 1 is substituted by alkoxy groups.

[0847] 28. A compound according to any one of statements 18 to 26, wherein R 1 It is substituted with amino group.

[0848] 29. A compound according to any one of statements 18 to 26, wherein R 1 is substituted by acylamino.

[0849] 30. A compound according to any one of statements 18 to 26, wherein R 1 It is substituted by acylamido.

[0850] 31. A compound according to any one of statements 18 to 26, wherein R 1 is substituted by acyloxy.

[0851] 32. The compound according to claim 31, wherein R 1 It is pivaloyloxymethyl.

[0852] 33. The compound according to claim 31, wherein R 1 It is propionyloxyisobutyl.

[0853] 34. A compound according to any one of statements 18 to 26, wherein R1 It is substituted by alkyl carboxyl ester.

[0854] 35. A compound according to any one of statements 18 to 26, wherein R 1 It is substituted by an alkylcarbamoyl group.

[0855] 36. A compound according to any one of statements 18 to 26, wherein R 1 is substituted by alkylcarbamoyl ester.

[0856] 37. A compound according to any one of statements 18 to 26, wherein R 1 It is substituted by phenyl.

[0857] 38. The compound according to claim 37, wherein R 1 It's benzyl.

[0858] 39. A compound according to any one of statements 18 to 26, wherein R 1 is substituted with phosphonate.

[0859] 40. A compound according to any one of statements 18 to 26, wherein R 1 Is C 3-7 Heterocyclic substituted.

[0860] 41. A compound according to any one of statements 18 to 26, wherein R 1 Is C 3-7 Heterocyclic substituted, the C 3-7 The heterocyclic group is substituted by a methyl group.

[0861] 42. A compound according to any one of statements 18 to 26, wherein R 1 Is C 3-7 Heterocyclic substituted, the C 3-7 The heterocyclic group is substituted by oxo.

[0862] 43. A compound according to any one of statements 18 to 26, wherein R 1 are substituted with naturally occurring amino acids.

[0863] 44. A compound according to any one of statements 18 to 26, wherein R 1 is substituted with a naturally occurring amino acid which is N-substituted with a methyl group.

[0864] 45. A compound according to any one of statements 18 to 26, wherein R 1 is substituted with a naturally occurring amino acid which is N-substituted with an acetyl group.

[0865] 46. ​​A compound according to any one of statements 18 to 26, wherein R 1 is substituted with a naturally occurring amino acid which is N-substituted with a boc group.

[0866] 47. The compound according to any one of statements 43-46, wherein the naturally occurring amino acid is valine.

[0867] 48. A compound according to any one of statements 1 to 47, wherein A 1 Yes CR A .

[0868] 49. A compound according to any one of statements 1 to 47, wherein A 1 It is N.

[0869] 50. A compound according to any one of statements 1 to 49, wherein A 2 Yes CR B .

[0870] 51. A compound according to any one of statements 1 to 49, wherein A 2 It is N.

[0871] 52. A compound according to any one of statements 1 to 51, wherein A 3 Yes CR C .

[0872] 53. A compound according to any one of statements 1 to 51, wherein A 3 It is N.

[0873] 54. A compound according to any one of statements 1 to 53, wherein A 4 Yes CR D .

[0874] 55. A compound according to any one of statements 1 to 53, wherein A 4 It is N.

[0875] 56. A compound according to any one of statements 1 to 47, wherein A 1 Yes CR A , A 2 Yes CR B , A 3 Yes CR C , and A 4 Yes CR D .

[0876] 57. A compound according to any one of statements 1 to 47, wherein A 1 , A 2 , A 3 and A 4 One of them is N.

[0877] 58. A compound according to any one of statements 1 to 47, wherein A 1 , A 2 , A 3 and A 4 Two of them are N.

[0878] 59. A compound according to any one of statements 1 to 47, wherein the compound is of formula IIIb1 or IIIb2:

[0879]

[0880] 60. A compound according to any one of statements 1 to 47, wherein the compound is of formula IIIc1 or IIIc2:

[0881]

[0882] 61. A compound according to any one of statements 1 to 47, wherein the compound is of formula IIId1 or IIId2:

[0883] 62. A compound according to any one of statements 1 to 47, wherein the compound is of formula IIIe1 or IIIe2:

[0884]

[0885] 63. A compound according to any one of statements 1 to 62, wherein R A , R B , R C and R D One or two (if present) of are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano and OMe, and the rest (if present) are H.

[0886] 64. A compound according to any one of statements 1 to 62, wherein R A , R B , R C and R D One or two (if present) of are selected from H, F, Cl, Br, Me, CF3 and OMe, and the rest (if present) are H.

[0887] 65. A compound according to any one of statements 1 to 62, wherein R A , R B , R C and R D One or two (if present) of are selected from H, F, Cl, Br and OMe, and the rest (if present) are H.

[0888] 66. A compound according to any one of statements 1 to 62, wherein:

[0889] R A (if present) selected from the group consisting of H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt and CH2OMe;

[0890] R B (if any) is H;

[0891] R C (if any) is H;

[0892] R D (if present) is selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, CH2OH and CH2OMe.

[0893] 67. A compound according to any one of statements 1 to 62, wherein:

[0894] R A (if present) selected from Cl, Br and OMe;

[0895] R B (if any) is H;

[0896] R C (if any) is H;

[0897] R D (if present) is selected from H, Me, F, Br, OMe.

[0898] 68. The compound according to claim 56, wherein:

[0899] R A It is Cl;

[0900] R B It is H;

[0901] R C It is H;

[0902] R D It's H.

[0903] 69. The compound according to claim 56, wherein:

[0904] R A It is Cl;

[0905] R B It is H;

[0906] R C It is H;

[0907] R D It's me.

[0908] 70. The compound according to claim 56, wherein:

[0909] R A It is Cl;

[0910] R B It is H;

[0911] R C It is H;

[0912] R D It's Br.

[0913] 71. The compound according to claim 56, wherein:

[0914] R A It is Br;

[0915] R B It is H;

[0916] R C It is H;

[0917] R D It's H.

[0918] 72. The compound according to claim 56, wherein:

[0919] R A It is Cl;

[0920] R B It is H;

[0921] R C It is H;

[0922] R D It's F.

[0923] 73. The compound according to claim 56, wherein:

[0924] R A It is Cl;

[0925] R B It is H;

[0926] R C It is H;

[0927] R D It's OMe.

[0928] 74. The compound according to claim 56, wherein:

[0929] R A It is Br;

[0930] R B It is H;

[0931] R C It is H;

[0932] R D It's F.

[0933] 75. The compound according to claim 56, wherein:

[0934] R A It’s OMe;

[0935] R B It is H;

[0936] R C It is H;

[0937] R D It's H.

[0938] 76. A compound according to any one of statements 1 to 75, wherein R C1 and R C4 With R C2 and R C3 One of them is independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3 and CH2OH.

[0939] 77. A compound according to any one of statements 1 to 75, wherein R C1 and R C4 With R C2 and R C3 One of which is independently selected from H, Cl, F, CF3, OMe and CH2OH.

[0940] 78. A compound according to any one of statements 1 to 75, wherein R C1 and R C4 With R C2 and R C3 One of which is independently selected from H, Cl, F and OMe.

[0941] 79. A compound according to any one of statements 1 to 78, wherein R C1 , R C3 and R C4 Two or R C1 , R C2 and R C4 Two of them are H, and the other one is selected from the defined groups, excluding H.

[0942] 80. A compound according to any one of statements 1 to 78, wherein R C1 , RC3 and R C4 One or R C1 , R C2 and R C4 One of the R and R is H, and the other two R and R are independently selected from the defined groups, excluding H.

[0943] 81. A compound according to any one of statements 1 to 75, wherein R C1 and R C4 With R C2 and R C3 One of them is H.

[0944] 82. A compound according to any one of statements 1 to 75, wherein:

[0945] R C1 It is H;

[0946] R C2 or R C3 is H; and

[0947] R C4 It's F.

[0948] 83. A compound according to any one of statements 1 to 75, wherein:

[0949] R C1 It’s OMe;

[0950] R C2 or R C3 is H; and

[0951] R C4 It's H.

[0952] 84. A compound according to any one of statements 1 to 75, wherein:

[0953] R C1 It’s OMe;

[0954] R C2 or R C3 is H; and

[0955] R C4 It's F.

[0956] 85. A compound according to any one of statements 1 to 75, wherein:

[0957] R C1 It is Cl;

[0958] R C2 or R C3 is H; and

[0959] R C4 It's H.

[0960] 86. A compound according to any one of statements 1 to 85, wherein:

[0961] R N1 It's H.

[0962] 87. A compound according to any one of statements 1 to 85, wherein:

[0963] R N1 It's me.

[0964] 88. A compound as defined in any one of statements 1 to 87 for use in a method of therapy.

[0965] 89. A pharmaceutical composition comprising a compound as defined in any one of statements 1 to 87, and a pharmaceutically acceptable excipient.

[0966] 90. A method for treating or preventing a disease ameliorated by modulation of STING, comprising administering a compound as defined in any one of statements 1 to 87, or a pharmaceutical composition according to statement 89, to a patient in need of treatment.

[0967] 91. Use of a compound as defined in any one of statements 1 to 87 in the manufacture of a medicament for treating or preventing a disease ameliorated by modulation of STING.

[0968] 92. A compound as defined in any one of statements 1 to 87, or a pharmaceutical composition thereof, for use in treating or preventing a disease ameliorated by modulation of STING.

[0969]

[0970]

[0971]

[0972]

[0973]

[0974]

[0975]

[0976]

[0977]

[0978]

Claims

1. Compounds of formula I: in: W is O or NH; R 1 Selected from: (i) H; (ii)C 3-6 Cycloalkyl; (iii) a 3- to 7-membered heterocyclic group, which is optionally substituted by a group selected from the following: Methyl; and -C(=O)OR, wherein R is selected from C 1-4 an alkyl group, a 3- to 7-membered heterocyclyl group, or a phenyl group; and (iv) Straight or branched chain C 1-4 Alkyl, which is optionally substituted by a group selected from: -OC 1-4 alkyl; -N(R)R', wherein R and R' are independently selected from H and C 1-4 alkyl; -C(=O)N(R)R', wherein R and R' are independently selected from H and C 1-4 alkyl; -N(R)C(=O)R', wherein R and R' are independently selected from H and C 1-4 alkyl; -OC(=O)R, wherein R is selected from C 1-4 an alkyl group, a 3- to 7-membered heterocyclic group or a phenyl group; -OC(=O)OC 1-4 alkyl; -NHC(=O)OC 1-4 alkyl; -OC(=O)NR'R", wherein R' and R" are independently selected from H and C 1-4 alkyl; Phenyl; -P(O)(OC 1-4 alkyl) 2 ; a 3- to 7-membered heterocyclic group optionally substituted by a group selected from methyl and oxo; and Naturally occurring amino acids, which are optionally selected from methyl, -C(O)-CH 3 and the group N-substituted with boc; A 1 Yes CR A or N; A 2 Yes CR B or N; A 3 Yes CR C or N; A 4 Yes CR D or N; Among them A 1 , A 2 , A 3 , and A 4 No more than two of them are N; R A , R B , R C and R D One or two of, if present, are selected from H, F, Cl, Br, Me, CF 3 , cyclopropyl, cyano, OMe, OEt, CH 2 OH, CH 2 OMe and OH; The rest of R A , R B , R C and R D , if present, is H; R N1 is H or Me; R C2 and R C3 One of them is C(=O)NH 2 ; another is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF 3 , CH 2 OH, CH 2 OMe, C 2-4 Alkenyl and 5-membered heterocyclic group; R C1 and R C4 independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF 3 , CH 2 OH, CH 2 OMe, C 2-4 alkenyl and 5-membered heterocyclyl; and Each heterocyclic group contains 1 or 2 heteroatoms selected from N and O.

2. The compound according to claim 1, wherein W is O.

3. A compound according to claim 1 or 2, wherein R 1 It's H.

4. A compound according to claim 1 or 2, wherein R 1 Selected from C 3-6 cycloalkyl, an optionally substituted 3- to 7-membered heterocyclic group, and an optionally substituted straight or branched C 1-4 alkyl.

5. A compound according to any one of claims 1 or 2, wherein R 1 is an optionally substituted straight or branched chain C 1-4 alkyl.

6. A compound according to claim 5, wherein R 1 is optionally substituted ethyl.

7. A compound according to any one of claims 1, 2 and 6, wherein A 1 Yes CR A , A 2 Yes CR B , A 3 Yes CR C , and A 4 Yes CR D .

8. The compound according to any one of claims 1, 2 and 6, wherein the compound is selected from the compounds of formula IIIb1, IIIc1, IIId1 and IIIe1:

9. A compound according to any one of claims 1, 2 and 6, wherein the compound is selected from the group consisting of compounds of formula IIIb2, IIIc2, IIId2 and IIIe2:

10. A compound according to any one of claims 1, 2 and 6, in: R A , if present, is selected from Cl, Br and OMe; R B , if present, is H; R C , if present, is H; R D , if present, is selected from H, Me, F, Br, OMe.

11. A compound according to any one of claims 1, 2 and 6, wherein A 1 , A 2 , A 3 and A 4 Select from combination 1-9:

12. A compound according to any one of claims 1, 2 and 6, wherein R C1 ; R C2 or R C3 ; and R C4 Selected from combination 1-5:

13. A compound according to any one of claims 1, 2 and 6, wherein R N1 It's H.

14. A compound according to claim 1, selected from:

15. A compound according to claim 1, selected from:

16. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 15, and a pharmaceutically acceptable excipient.

17. Use of a compound as defined in any one of claims 1 to 15 in the manufacture of a medicament for the treatment or prevention of a disease, disorder and / or condition ameliorated by modulation of STING.

18. The use according to claim 17, wherein the disease, disorder or condition is selected from cancer, autoimmune disease, inflammation, cell proliferation, neurodegenerative disease and infectious disease.

19. The use according to claim 18, in: The cancer is selected from the group consisting of lung cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, neck cancer, uterine cancer, ovarian cancer, stomach cancer, colon cancer, breast cancer, esophageal cancer, small intestine cancer, intestinal cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, urethra cancer, prostate cancer, penis cancer, testicular cancer, ureter cancer, bladder cancer, kidney cancer or liver cancer; rectal cancer; cancer of the anal area; fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, renal pelvis, renal cell cancer; soft tissue carcinoma tumor; myxoma; rhabdoid tumor; fibroma; lipoma; teratoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hemangioma; hepatocarcinoma; fibrosarcoma; chondrosarcoma; myeloma; chronic or acute leukemia; lymphocytic lymphoma; primary CNS lymphoma; CNS neoplasm; spinal axis tumor; squamous cell carcinoma; synovial sarcoma; malignant pleural mesothelioma; brainstem glioma; pituitary adenoma; bronchial adenoma; chondromatous hamartoma; mesothelioma; Hodgkin's disease, or a combination thereof; The autoimmune disease is selected from lupus pernio, systemic lupus erythematosus (SLE), cutaneous lupus, lupus nephritis, diabetes, human immunodeficiency virus (HIV), AIDS, polymyositis, systemic sclerosis and polyarthritis, vasculitis, primary sclerosing cholangitis, spondylitis, polymyalgia rheumatica, Raynaud's phenomenon, primary biliary cirrhosis, neuromyelitis optica, and mixed connective tissue disease; The inflammation has one or more of the following inflammatory features: musculoskeletal inflammation, vascular inflammation, neuroinflammation, digestive system inflammation, eye inflammation, reproductive system inflammation, acute disseminated alopecia universalis, Chagas disease, pernio lupus, chronic fatigue syndrome, autonomic dysautonomia, encephalomyelitis, ankylosing spondylitis, aplastic anemia, suppurative hidradenitis, autoimmune oophoritis, celiac disease, Crohn's disease, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, lupus erythematosus, microscopic colitis, mixed connective tissue disease, opsoclonus-myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus, polymyalgia, Reiter's syndrome, warm autoimmune hemolytic anemia, interstitial cystitis, Lyme disease, morphea, sarcoidosis, ulcerative colitis and vitiligo, contact hypersensitivity, urticaria, skin allergies, respiratory allergies and gluten-sensitive enteropathy, i.e., celiac disease, appendicitis, dermatitis, endocarditis, fibrosis Inflammation, gingivitis, glossitis, hepatitis, iritis, laryngitis, mastitis, myocarditis, nephritis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, pneumonia, prostatitis, pyelonephritis, stomatitis, transplant rejection, acute respiratory distress syndrome, Sezary syndrome, congenital adrenal hyperplasia, non-suppurative thyroiditis, hypercalcemia associated with cancer, severe erythema multiforme, seasonal or perennial allergic rhinitis, drug allergic reaction, allergic conjunctivitis Inflammation, keratitis, herpetic ophthalmitis, iridocyclitis, chorioretinitis, symptomatic sarcoidosis, chemotherapy for fulminant or disseminated pulmonary tuberculosis, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenic purpura in adults, acquired autoimmune hemolytic anemia, leukemia and lymphoma in adults, acute leukemia in children, regional enteritis, chronic obstructive pulmonary disease, sepsis, asthma, inflammatory bowel disease, systemic lupus erythematosus, chronic lung disease and inflammation associated with infectious conditions; The neurodegenerative disease is selected from Huntington's disease, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS); The cell proliferation is selected from the group consisting of arthritis and restenosis; fibrotic disorders; mesangial cell proliferative disorders; and metabolic disorders, and / or The infectious disease results from a bacterial infection, a parasitic protozoan infection, or a DNA or RNA viral infection.

20. The use according to claim 18, in: The autoimmune disease is selected from insulin-dependent diabetes mellitus (IDDM), cutaneous vasculitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, primary central nervous system vasculitis, and microscopic polyangiitis; The inflammation has one or more of the following inflammatory features: ANCA-associated vasculitis, Kawasaki disease, microscopic polyarteritis, temporal arteritis, contact dermatitis, hay fever, allergic rhinitis, organ transplant rejection, serum sickness, graft-versus-host disease, acute pancreatitis, chronic pancreatitis, bullous dermatitis herpetiformis, exfoliative dermatitis, seborrheic dermatitis, bronchial asthma, atopic dermatitis, and autoimmune vasculitis; and / or The cell proliferation is selected from the group consisting of rheumatoid arthritis, liver cirrhosis, atherosclerosis, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, proliferative retinopathy, organ transplant rejection and glomerular disease, diabetes and chronic wound healing.

21. The use according to claim 20, in: The contact dermatitis is caused by poison ivy; and / or The organ rejected by the organ transplant is selected from the group consisting of kidney, liver, heart, lung, pancreas, bone marrow, cornea, small intestine, skin allograft, skin homograft and heart valve xenograft.

22. The use according to claim 20, in: The organ transplant rejection is solid organ transplant rejection.

23. The use according to claim 21, in: The organ rejected by the organ transplant is a pancreatic islet cell.

24. The use according to claim 18, in: The disease, disorder or condition is selected from one or more of the following: Aicardi Goutieres syndrome (AGS), retinal vasculopathy with leukodystrophy (RCVL), STING-associated vasculitis of infancy (SAVI), Henoch-Schönlein purpura, scleroderma, Behcet's disease, ataxia telangiectasia, Louis-Barr syndrome, autoimmune hepatitis, myasthenia gravis, rheumatoid arthritis, Sjögren's syndrome (SS), psoriatic arthritis, psoriasis, dermatomyositis, type 1 diabetes, multiple sclerosis, giant cell arteritis, polyarteritis nodosa and Wegener's granulomatosis.